WO2013082417A1 - Traitement à l'aide de cellules souches du placenta - Google Patents

Traitement à l'aide de cellules souches du placenta Download PDF

Info

Publication number
WO2013082417A1
WO2013082417A1 PCT/US2012/067276 US2012067276W WO2013082417A1 WO 2013082417 A1 WO2013082417 A1 WO 2013082417A1 US 2012067276 W US2012067276 W US 2012067276W WO 2013082417 A1 WO2013082417 A1 WO 2013082417A1
Authority
WO
WIPO (PCT)
Prior art keywords
stem cells
placental stem
cells
isolated
disease
Prior art date
Application number
PCT/US2012/067276
Other languages
English (en)
Inventor
Uri Herzberg
Robert J. Hariri
Jodi P. GURNEY
Original Assignee
Anthrogenesis Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anthrogenesis Corporation filed Critical Anthrogenesis Corporation
Publication of WO2013082417A1 publication Critical patent/WO2013082417A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources

Definitions

  • schizophreniform disorder Alzheimer's disease or Alzheimer's-type dementia, or Huntington's disease using isolated placental stem cells, e.g., tissue culture plastic-adherent placental stem cells.
  • placental stem cells and compositions comprising placental stem cells, useful in the treatment of schizophrenia, Alzheimer's disease, and Huntington's disease, and methods of using the same to treat schizophrenia, Alzheimer's disease, and Huntington's disease.
  • a method of treating schizophrenia comprising administering to an individual having schizophrenia a therapeutically effective amount of placental stem cells, e.g., tissue culture plastic-adherent placental stem cells, or culture medium conditioned by placental stem cells, e.g., tissue culture plastic-adherent placental stem cells.
  • placental stem cells e.g., tissue culture plastic-adherent placental stem cells
  • culture medium conditioned by placental stem cells e.g., tissue culture plastic-adherent placental stem cells.
  • therapeutically effective means an amount effective to reduce or ameliorate one or more symptoms of schizophrenia that manifest in the individual, e.g., sufficient to cause a detectable improvement in one or more symptoms of schizophrenia, sufficient to delay the onset or worsening of one or more symptoms of schizophrenia, sufficient to reduce the severity of one or more symptoms of schizophrenia, or sufficient to increase the duration or quality of life following onset of symptoms.
  • the therapeutically effective amount means an amount effective to improve cognition and/or mental status in the individual or induce neural repair and/or neuroregeneration in the individual.
  • said one or more symptoms comprise one or more Schneiderian First Rank symptoms, e.g., one or more of hearing thoughts audibly; hearing voices arguing; hearing voices commenting on one's actions; delusions of being controlled by others; delusions that the individual's thoughts have been withdrawn or taken by others; delusions that thoughts have been inserted or caused by others; delusions that others can read the individual's thoughts; and/or delusional perception by the individual.
  • said one or more symptoms comprise one or more of disordered thoughts and/or speech; formal thought disorder;
  • hallucinations e.g., tactile, auditory, visual, olfactory and/or gustatory hallucinations
  • flat or blunted affect and/or emotion e.g., poverty of speech (alogia); inability to experience pleasure (anhedonia); lack of desire to form relationships (asociality); and/or lack of motivation
  • the individual is diagnosed as schizophrenic according to either or both of Diagnostic and Statistical Manual of Mental Disorders (e.g., version DSM-IV- TR), or the World Health Organization's International Statistical Classification of Diseases and Related Health Problems (ICD-10) criteria.
  • Diagnostic and Statistical Manual of Mental Disorders e.g., version DSM-IV- TR
  • ICD-10 World Health Organization's International Statistical Classification of Diseases and Related Health Problems
  • said one or more symptoms of formal thought disorder comprise one or more of blocking (interrupted speech, often with no memory of the discussed topic after the block); circumstantiality (highly detailed speech that delays reaching a goal); clanging (speech emphasizing sounds, rather than meaning); derailment (speech characterized by failure to maintain ideas on a single track); distractible speech; echolalia (echoing of speech once, or in continuous in repetition); evasive interaction (expression of ideas and/or feelings about another individual evasively or in diluted form); flight of ideas (speech characterized by a sequence of unrelated ideas); illogicality (non-sequiturs or faulty inferences); incoherence (word salad); loss of goal (failure to show a train of thought to a natural conclusion); neologisms (new word formations); perseveration (repetition of words or ideas); honemic paraphasia; pressured speech (increase in the rate or amount of spontaneous speech); self-
  • a method of prophylaxis against schizophrenia in an infant comprising prenatally administering placental stem cells, e.g., an effective dose of placental stem cells, to an individual pregnant with the infant.
  • the individual's immune system has been activated during pregnancy by, e.g., bacterial infection, viral infection, rickettsial infection, spirochete infection, protozoal infection, exposure to allergens, or the like.
  • the individual who gives birth to the infant has an infection during pregnancy, e.g., a bacterial infection, viral infection, rickettsial infection, spirochete infection, or protozoal infection.
  • said viral infection is a viral infection during the first trimester.
  • said bacterial infection is a bacterial infection in the second trimester.
  • placental stem cells e.g., tissue culture plastic-adhesive placental stem cells, or culture medium conditioned by placental stem cells, for use in treating schizophrenia in an individual, wherein the
  • therapeutically effective amount means an amount effective to reduce or ameliorate one or more symptoms of schizophrenia that manifest in the individual, e.g. , sufficient to cause a detectable improvement in one or more symptoms of schizophrenia, sufficient to delay the onset or worsening of one or more symptoms of schizophrenia, sufficient to reduce the severity of one or more symptoms of schizophrenia, or sufficient to increase the duration or quality of life following onset of symptoms.
  • the therapeutically effective amount means an amount effective to improve cognition and/or mental status in the individual or induce neural repair and/or neuroregeneration in the individual.
  • said individual has been diagnosed as having schizophrenia according to criteria listed in the Diagnostic and Statistical Manual of Mental Disorders (DSM).
  • said one or more symptoms comprise one or more Schneiderian First Rank symptoms.
  • said one or more symptoms comprise one or more of hearing thoughts audibly; hearing voices arguing; hearing voices commenting on one's actions; delusions of being controlled by others; delusions that the individual's thoughts have been withdrawn or taken by others; delusions that thoughts have been inserted or caused by others; delusions that others can read the individual's thoughts; or delusional perception by said individual.
  • said one or more symptoms comprise one or more of disordered thoughts and/or speech; tactile hallucinations; auditory hallucinations; visual hallucinations; olfactory hallucinations; gustatory hallucinations); flat or blunted affect; flat or blunted emotion; poverty of speech; inability to experience pleasure; lack of desire to form relationships; or lack of motivation.
  • a method of treating an individual having schizophrenia who exhibits one or more symptoms of schizophrenia comprising administering to the individual a therapeutically effective amount of placental stem cells, wherein said therapeutically effective amount is an amount that results in reduction or amelioration of one or more of said symptoms of schizophrenia, e.g. , improvement in one or more symptoms of schizophrenia, delay of worsening of one or more symptoms of schizophrenia, reduction of severity of one or more symptoms of schizophrenia, or an increase in duration or quality of life or cognition and/or mental status following onset of symptoms; monitoring one or more of said symptoms in said patient; and administering a second dose of placental stem cells when said one or more symptoms begins to worsen.
  • a method of treating Alzheimer's disease comprising administering to an individual having Alzheimer's disease or Alzheimer's-type disorder a therapeutically effective amount of placental stem cells, e.g., tissue culture plastic- adherent placental stem cells, or culture medium conditioned by placental stem cells, e.g. , tissue culture plastic-adherent placental stem cells.
  • placental stem cells e.g., tissue culture plastic- adherent placental stem cells
  • culture medium conditioned by placental stem cells e.g. , tissue culture plastic-adherent placental stem cells.
  • therapeutically effective means an amount effective to reduce or ameliorate one or more symptoms of Alzheimer's disease that manifest in the individual, e.g., sufficient to cause a detectable improvement in one or more symptoms of Alzheimer's disease, sufficient to delay the onset or worsening of one or more symptoms of Alzheimer's disease, sufficient to reduce the severity of one or more symptoms of Alzheimer's disease, or sufficient to increase the duration or quality of life following onset of symptoms.
  • the therapeutically effective amount means an amount effective to improve cognition and/or mental status in the individual or induce neural repair and/or neuroregeneration in the individual.
  • said one or more symptoms comprise one or more of impaired memory, language or speaking ability, perceptual skills, reading, writing, understanding, attention, constructive abilities, orientation, problem solving, or functional abilities, or psychiatric symptoms such as anxiety or aggression.
  • a therapeutically effective amount of placental stem cells e.g., tissue culture plastic-adhesive placental stem cells, or culture medium conditioned by placental stem cells, for use in treating Alzheimer's disease in an individual
  • the therapeutically effective amount means an amount effective to reduce or ameliorate one or more symptoms of Alzheimer's disease that manifest in the individual, e.g., sufficient to cause a detectable improvement in one or more symptoms of Alzheimer's disease, sufficient to delay the onset or worsening of one or more symptoms of Alzheimer's disease, sufficient to reduce the severity of one or more symptoms of Alzheimer's disease, or sufficient to increase the duration or quality of life following onset of symptoms.
  • the therapeutically effective amount means an amount effective to improve cognition and/or mental status in the individual or induce neural repair and/or neuroregeneration in the individual.
  • said treatment of Alzheimer's disease is administered to an individual diagnosed as having Alzheimer' s-type dementia according to either or all of the NINCDS-ADRDA Alzheimer's Criteria (from the National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) and Alzheimer's Disease and Related
  • NINCDS-ADRDA Alzheimer's Criteria from the National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) and Alzheimer's Disease and Related
  • ADRDA Alzheimer's Association
  • DSM-IV-TR Diagnostic and Statistical Manual of Mental Disorders
  • ICD-10 World Health Organization's International Statistical Classification of Diseases and Related Health Problems
  • a method of treating an individual having Alzheimer's disease who exhibits one or more symptoms of Alzheimer's disease comprising administering to the individual a therapeutically effective amount of placental stem cells, wherein said therapeutically effective amount is an amount that results in reduction or amelioration of one or more of said symptoms of Alzheimer's disease, e.g., improvement in one or more symptoms of Alzheimer's disease, delay of worsening of one or more symptoms of Alzheimer's disease, reduction of severity of one or more symptoms of Alzheimer's disease, or an increase in duration or quality of life or cognition and/or mental status following onset of symptoms; monitoring one or more of said symptoms in said patient; and administering a second dose of placental stem cells when said one or more symptoms begins to worsen.
  • a method of treating Huntington's disease comprising administering to an individual having Huntington's disease a therapeutically effective amount of placental stem cells, e.g., tissue culture plastic-adherent placental stem cells, or culture medium conditioned by placental stem cells, e.g., tissue culture plastic-adherent placental stem cells.
  • a therapeutically effective amount means an amount effective to reduce or ameliorate one or more symptoms of Huntington's disease that manifest in the individual, e.g.
  • the therapeutically effective amount means an amount effective to improve cognition and/or mental status in the individual or induce neural repair and/or neuroregeneration in the individual.
  • said one or more symptoms comprise one or more of physical, cognitive, psychiatric, or peripheral symptoms.
  • the symptom is a physical symptom selected from the group consisting of restlessness, lack of coordination, unintentionally initiated motions, unintentionally uncompleted motions, unsteady gait, chorea, rigidity, writhing motions, abnormal posturing, instability, abnormal facial expressions, difficulty chewing, difficulty swallowing, difficulty speaking, seizure, and sleep disturbances.
  • the symptom is a cognitive symptom selected from the group consisting of impaired planning, impaired flexibility, impaired abstract thinking, impaired rule acquisition, impaired initiation of appropriate actions, impaired inhibition of inappropriate actions, impaired short-term memory, impaired long-term memory, paranoia, disorientation, confusion, hallucination and dementia.
  • the symptom is a psychiatric symptom selected from the group consisting of anxiety, depression, blunted affect, egocentrisms, aggression, compulsive behavior, irritability and suicidal ideation.
  • the symptom is a peripheral symptom selected from the group consisting of reduced brain mass, muscle atrophy, cardiac failure, impaired glucose tolerance, weight loss, osteoporosis, and testicular atrophy.
  • a therapeutically effective amount of placental stem cells e.g., tissue culture plastic-adhesive placental stem cells, or culture medium conditioned by placental stem cells, for use in treating Huntington's disease in an individual
  • the therapeutically effective amount means an amount effective to reduce or ameliorate one or more symptoms of Huntington's disease that manifest in the individual, e.g., sufficient to cause a detectable improvement in one or more symptoms of Huntington's disease, sufficient to delay the onset or worsening of one or more symptoms of Huntington's disease, sufficient to reduce the severity of one or more symptoms of Huntington's disease, or sufficient to increase the duration or quality of life following onset of symptoms.
  • the therapeutically effective amount means an amount effective to improve cognition and/or mental status in the individual or induce neural repair and/or neuroregeneration in the individual.
  • said treatment of Huntington's disease is administered to an individual diagnosed as having Huntington's disease, or dementia associated with Huntington's disease, according to either or both of Diagnostic and Statistical Manual of Mental Disorders (e.g., version DSM-IV-TR), or the World Health Organization's International Statistical
  • ICD-10 Classification of Diseases and Related Health Problems
  • a method of treating an individual having Huntington's disease who exhibits one or more symptoms of Huntington's disease comprising administering to the individual a therapeutically effective amount of placental stem cells, wherein said therapeutically effective amount is an amount that results in reduction or amelioration of one or more of said symptoms of Huntington's disease, e.g., improvement in one or more symptoms of Huntington's disease, delay of worsening of one or more symptoms of Huntington's disease, reduction of severity of one or more symptoms of Huntington's disease, or an increase in duration or quality of life or cognition and/or mental status following onset of symptoms; monitoring one or more of said symptoms in said patient; and administering a second dose of placental stem cells when said one or more symptoms begins to worsen.
  • said monitoring comprises monitoring said individual over between 1 and 7 days post-administration; monitoring over between 7 and 28 days post administration; or monitoring comprises monitoring over between 1 and 28 weeks post-administration of said placental stem cells.
  • said methods above additionally comprise administering a second therapeutic composition to the individual.
  • said placental stem cells are CD10 + , CD34 , and CD105 + , as detectable by flow cytometry.
  • said placental stem cells are additionally CD200 + , as detectable by flow cytometry.
  • said placental stem cells are additionally CD45 and CD90 + , as detectable by flow cytometry.
  • said placental stem cells are additionally CD8(T and CD86 , as detectable by flow cytometry.
  • said placental stem cells express CD200 and do not express HLA-G; or express CD73, CD 105, and CD200; or express CD73 and CD 105 and do not express HLA-G, respectively as detectable by flow cytometry.
  • said placental stem cells express CD200 and OCT-4, as detectable by flow cytometry and reverse-transcriptase polymerase chain reaction (RT-PCR), respectively.
  • said placental stem cells are HLA-A,B,C + , as detectable by flow cytometry.
  • said placental stem cells are additionally OCT- 4 + , as detectable by RT-PCR.
  • the placental stem cells are CD10 + , CD34 , CD105 + , CD45 and CD90 + .
  • the placental stem cells are CD10 + , CD34 , CD105 + , CD200 + , CD45 and CD90 + .
  • the placental stem cells are CD10 + , CD34 , CD105 + , CD45 , CD90 + , CD80 and CD86 .
  • the placental stem cells are CD10 + , CD34 , CD105 + , CD200 + , CD45 , CD90 + , and CD80 and CD86 .
  • the markers described in this paragraph as detectable by flow cytometry are detectable by any method known in the art, such as, e.g., flow cytometry or surface plasmon resonance. In certain embodiments,
  • intracellular markers are detectable by any method known in the art such as, e.g., RT-PCR.
  • said placental stem cells express higher levels of one or more of that following genes ACTG2, ADARB1, AMIG02, ARTS-1, B4GALT6, BCHE, Cl lorf9, CD200, COL4A1, COL4A2, CPA4, DMD, DSC3, DSG2, ELOVL2, F2RL1, FLJ10781, GATA6, GPR126, GPRC5B, HLA-G, ICAMl, IER3, IGFBP7, ILIA, IL6, IL18, KRT18, KRT8, LIPG, LRAP, MATN2, MEST, NFE2L3, NUAK1, PCDH7, PDLIM3, PKP2, RTN1,
  • SERPINB9 ST3GAL6, ST6GALNAC5, SLC12A8, TCF21, TGFB2, VTN, ZC3H12A, or a combination of any of the foregoing, wherein the expression of the one or more genes is higher in placental stem cells or umbilical cord stem cells than in bone marrow-derived stem cells, when the stem cells are grown under equivalent conditions.
  • said placental stem cells are isolated.
  • said placental stem cells are formulated to be administered locally.
  • the placental stem cells are formulated to be administered systemically, intravenously, parenterally, intracranially, intracerebroventricularly, intraarterially, intraperitoneally, subcutaneously, or intrathecally.
  • the placental stem cells are formulated to be administered by injections.
  • said therapeutically effective amount comprises at least 1 x 10 7 placental stem cells per administration; at least 2 x 10 7 placental stem cells per administration; at least 1 x 10 8 placental stem cells per administration; at least 2 x 10 8 placental stem cells per administration; or at least 1 x 10 9 placental stem cells per administration.
  • the therapeutically effective amount is a dose in the range of l x l 0 7 - 8 x 10 8 placental stem cells, administered as a single or repeated injections, or in two or three boluses, for example, as 1-3 injections per week with one or more or several months in between each series of injections.
  • said placental stem cells are formulated for local administration, e.g. , into the brain.
  • said placental stem cells are administered at a dose of up to or about 1 x 10 6 , 3 x 10 6 , 5 x 10 6 , 1 x 10 7 , 3 x 10 7 , 5 x 10 7 , or 1 x 10 8 placental stem cells per administration.
  • derived means isolated from or otherwise purified.
  • placental derived adherent cells are isolated from placenta.
  • the term “derived” encompasses cells that are cultured from cells isolated directly from a tissue, e.g., the placenta, and cells cultured or expanded from primary isolates.
  • immuno localization means the detection of a compound, e.g., a cellular marker, using an immune protein, e.g., an antibody or fragment thereof in, for example, flow cytometry, fluorescence-activated cell sorting, magnetic cell sorting, in situ hybridization, immunohistochemistry, or the like.
  • SH2 refers to an antibody that binds an epitope on the marker CD 105.
  • cells that are referred to as SH2 + are CD105 + .
  • SH3 and SH4 refer to antibodies that bind epitopes present on the marker CD73.
  • cells that are referred to as SH3 + and/or SH4 + are CD73 + .
  • a stem cell is "isolated” if at least 50%, 60%, 70%, 80%, 90%, 95%, or at least 99% of the other cells with which the stem cell is naturally associated are removed from the stem cell, e.g., during collection and/or culture of the stem cell.
  • a population of "isolated” cells means a population of cells that is substantially separated from other cells of the tissue, e.g., placenta, from which the population of cells is derived.
  • a population of, e.g., stem cells is "isolated” if at least 50%, 60%, 70%, 80%, 90%, 95%, or at least 99% of the cells with which the population of stem cells are naturally associated are removed from the population of stem cells, e.g., during collection and/or culture of the population of stem cells.
  • the term "placental stem cell” refers to a stem cell or progenitor cell that is derived from, e.g., isolated from, a mammalian placenta, regardless of the number of passages after a primary culture, which adheres to a tissue culture substrate ⁇ e.g., tissue culture plastic or a fibronectin-coated tissue culture plate).
  • placement stem cell does not, however, refer to a trophoblast, a cytotrophoblast, embryonic germ cell, or embryonic stem cell, as those cells are understood by persons of skill in the art.
  • a cell is considered a "stem cell” if the cell retains at least one attribute of a stem cell, e.g., a marker or gene expression profile associated with one or more types of stem cells; the ability to replicate at least 10-40 times in culture; multipotency, e.g., the ability to differentiate, either in vitro, in vivo or both, into cells of one or more of the three germ layers; the lack of adult (i.e., differentiated) cell characteristics, or the like.
  • placental stem cell and “placenta-derived stem cell” may be used interchangeably. Unless otherwise noted herein, the term “placental” includes the umbilical cord.
  • the placental stem cells disclosed herein are, in certain embodiments, multipotent in vitro (that is, the cells differentiate in vitro under differentiating conditions), multipotent in vivo (that is, the cells differentiate in vivo), or both.
  • a stem cell is "positive" for a particular marker when that marker is detectable, e.g., by flow cytometry or RT-PCR.
  • a placental stem cell is positive for, e.g., CD73 when CD73 is detectable on the placental stem cell, e.g., in flow cytometry using a labeled anti-CD73 antibody, in an amount detectably greater than background (in comparison to, e.g., an isotype control or an experimental negative control for any given assay).
  • a cell is also positive for a marker when that marker can be used to distinguish the cell from at least one other cell type, or can be used to select or isolate the cell when present or expressed by the cell.
  • immunomodulation and “immunomodulatory” mean causing, or having the capacity to cause, a detectable change in an immune response, and the ability to cause a detectable change in an immune response.
  • immunosuppression and
  • immunosuppressive mean causing, or having the capacity to cause, a detectable reduction in an immune response.
  • ANOVA Analysis of variance
  • FIG. 1 Daily water maze results in acute kainic acid model.
  • A Shown are averages ⁇ SEM for daily latency to find the platform.
  • B Shown are averages ⁇ SEM for daily latency to find the platform.
  • Figure 3 Time spent in "targeted quadrants” compared to “non-targeted quadrants” in water maze in acute kainic acid model. Shown are averages ⁇ SEM for the time difference in seconds between targeted quadrants (old + new) and the other two non-targeted quadrants.
  • FIG. 1M Shown is the distribution of RAM results + medians for day 5 of training.
  • One way ANOVA p ⁇ 0.0001.
  • a method of treating an individual having or diagnosed as having schizophrenia comprising administering to the individual a therapeutically effective amount of placental stem cells.
  • therapeutically effective means an amount effective to improve cognition and/or mental status in the individual or induce neural repair and/or neuroregeneration in the individual.
  • therapeuticically effective means an amount effective to reduce or ameliorate one or more symptoms of schizophrenia in the individual.
  • said one or more symptoms comprise one or more Schneiderian First Rank symptoms, e.g., hearing thoughts audibly; hearing voices arguing; hearing voices commenting on one's actions; delusions of being controlled by others; delusions that the individual's thoughts have been withdrawn or taken by others; delusions that thoughts have been inserted or caused by others; delusions that others can read the individual's thoughts; and/or delusional perception by the individual.
  • Schneiderian First Rank symptoms e.g., hearing thoughts audibly; hearing voices arguing; hearing voices commenting on one's actions; delusions of being controlled by others; delusions that the individual's thoughts have been withdrawn or taken by others; delusions that thoughts have been inserted or caused by others; delusions that others can read the individual's thoughts; and/or delusional perception by the individual.
  • said symptoms comprise one or more of disordered thoughts and/or speech; hallucinations (e.g., tactile, auditory, visual, olfactory and/or gustatory hallucinations); flat or blunted affect and/or emotion; poverty of speech (alogia); inability to experience pleasure (anhedonia); lack of desire to form relationships (asociality); and/or lack of motivation (avolition).
  • hallucinations e.g., tactile, auditory, visual, olfactory and/or gustatory hallucinations
  • flat or blunted affect and/or emotion e.g., alogia
  • inability to experience pleasure anhedonia
  • lack of desire to form relationships asociality
  • lack of motivation avolition
  • the individual is diagnosed as schizophrenic according to either or both of Diagnostic and Statistical Manual of Mental Disorders (version DSM-IV-TR), or the World Health
  • ICD-10 International Statistical Classification of Diseases and Related Health Problems
  • schizophreniform disorder symptoms of schizophrenia have manifested in the affected individual, but the symptoms have not been present for the six months required for a diagnosis of schizophrenia according to the DSM.
  • a method of treating an individual having or diagnosed as having a schizophreniform disorder comprising administering to the individual a therapeutically effective amount of placental stem cells, wherein said therapeutically effective amount is an amount effective to reduce or ameliorate one or more symptoms of schizophrenia in the individual or an amount effective to improve cognition and/or mental status in the individual or induce neural repair and/or neuroregeneration in the individual.
  • said one or more symptoms of schizophreniform disorder comprise one or more of delusions, hallucinations, disorganized speech (e.g., resulting from formal thought disorder), disorganized or catatonic behavior, inability to show emotion (flat affect), inability to experience pleasure (anhedonia), impaired or decreased speech (aphasia), lack of desire to form
  • terapéuticaally effective means an amount effective to reduce or ameliorate one or more symptoms of schizophrenia, e.g., described above, e.g., wherein said one or more symptoms are not accounted for by another disease, disorder or condition.
  • therapeuticically effective means an amount effective to delay the onset or worsening of one or more symptoms of schizophrenia, e.g., described above, e.g., wherein said one or more symptoms are not accounted for by another disease, disorder or condition.
  • said "therapeutically effective” amount is an amount sufficient to cause a detectable improvement in one or more symptoms of schizophrenia, sufficient to delay the onset or worsening of one or more symptoms of schizophrenia, sufficient to reduce the severity of one or more symptoms of schizophrenia, or sufficient to increase the duration or quality of life following onset of symptoms.
  • “therapeutically effective” means an amount effective to improve cognition and/or mental status in the individual or induce neural repair and/or neuroregeneration in the individual.
  • one or more treatments with placental stem cells results in extension of a treated individual's quality of life or a treated individual's improvement in cognition and/or mental status by about 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year, 13 months, 14 months, 15 months, 16 months, 18 months, 20 months, 2 years, 3 years or more (compared, e.g., to the individual's predicted quality of life or cognition and/or mental status in the absence of the placental stem cell treatment). 5.1.2 Prophylaxis against Schizophrenia
  • a method of prophylaxis against the development of schizophrenia in an infant comprising prenatally administering placental stem cells, e.g., an effective dose of placental stem cells, to an individual pregnant with the infant.
  • the individual's immune system has been activated during pregnancy by, e.g., bacterial infection, viral infection, rickettsial infection, spirochete infection, protozoal infection, exposure to allergens, or the like.
  • the individual who gives birth to the infant has an infection during pregnancy, e.g., a bacterial infection, viral infection, rickettsial infection, spirochete infection, or protozoal infection.
  • said viral infection is a viral infection during the first trimester.
  • said bacterial infection is a bacterial infection in the second trimester.
  • a method of treating an individual having or diagnosed as having Alzheimer's disease comprising administering to the individual a therapeutically effective amount of placental stem cells.
  • the term "Alzheimer's disease” includes Alzheimer' s-type dementia.
  • “therapeutically effective” means an amount effective to improve cognition and/or mental status in the individual or induce neural repair and/or neuroregeneration in the individual.
  • “therapeutically effective” means an amount effective to reduce or ameliorate one or more symptoms of Alzheimer's disease in the individual.
  • said one or more symptoms comprise one or more of impaired memory, language or speaking ability, perceptual skills, reading, writing,
  • said treatment of Alzheimer's disease is administered to an individual diagnosed as having
  • Alzheimer' s-type dementia according to either or all of the NINCDS-ADRDA Alzheimer's Criteria (from the National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) and Alzheimer's Disease and Related Disorders Association (ADRDA, now known as the Alzheimer's Association)), the Diagnostic and Statistical Manual of Mental Disorders (e.g., version DSM-IV-TR), or the World Health Organization's International Statistical
  • ICD-10 Classification of Diseases and Related Health Problems
  • the method is applicable to individuals suspected of having Alzheimer's disease or at risk for Alzheimer's disease.
  • therapeutically effective means an amount effective to reduce or ameliorate one or more symptoms of Alzheimer's disease, e.g., described above, e.g., wherein said one or more symptoms are not accounted for by another disease, disorder or condition.
  • therapeuticically effective means an amount effective to delay the onset or worsening of one or more symptoms of Alzheimer's disease, e.g., described above, e.g., wherein said one or more symptoms are not accounted for by another disease, disorder or condition.
  • said "therapeutically effective” amount is an amount sufficient to cause a detectable improvement in one or more symptoms of Alzheimer's disease, sufficient to delay the onset or worsening of one or more symptoms of Alzheimer's disease, sufficient to reduce the severity of one or more symptoms of Alzheimer's disease, or sufficient to increase the duration or quality of life following onset of symptoms.
  • “therapeutically effective” means an amount effective to improve cognition and/or mental status in the individual or induce neural repair and/or neuroregeneration in the individual.
  • one or more treatments with placental stem cells results in extension of a treated individual's quality of life or a treated individual's improvement in cognition and/or mental status by about 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year, 13 months, 14 months, 15 months, 16 months, 18 months, 20 months, 2 years, 3 years or more (compared, e.g., to the individual's predicted quality of life or cognition and/or mental status in the absence of the placental stem cell treatment).
  • a method of treating an individual having or diagnosed as having Huntington's disease comprising administering to the individual a therapeutically effective amount of placental stem cells.
  • the term “Huntington's disease” refers to dementia associated with Huntington's disease.
  • “therapeutically effective” means an amount effective to improve cognition and/or mental status in the individual or induce neural repair and/or neuroregeneration in the individual.
  • “therapeutically effective” means an amount effective to reduce or ameliorate one or more symptoms of Huntington's disease in the individual.
  • said one or more symptoms comprise one or more of physical, cognitive, psychiatric, or peripheral symptoms.
  • the symptom is a physical symptom selected from the group consisting of restlessness, lack of coordination, unintentionally initiated motions, unintentionally uncompleted motions, unsteady gait, chorea, rigidity, writhing motions, abnormal posturing, instability, abnormal facial expressions, difficulty chewing, difficulty swallowing, difficulty speaking, seizure, and sleep disturbances.
  • the symptom is a cognitive symptom selected from the group consisting of impaired planning, impaired flexibility, impaired abstract thinking, impaired rule acquisition, impaired initiation of appropriate actions, impaired inhibition of inappropriate actions, impaired short-term memory, impaired long-term memory, paranoia, disorientation, confusion, hallucination and dementia.
  • the symptom is a psychiatric symptom selected from the group consisting of anxiety, depression, blunted affect, egocentrisms, aggression, compulsive behavior, irritability and suicidal ideation.
  • the symptom is a peripheral symptom selected from the group consisting of reduced brain mass, muscle atrophy, cardiac failure, impaired glucose tolerance, weight loss, osteoporosis, and testicular atrophy.
  • said treatment of Huntington's disease is
  • the methods of treating individuals having Huntington's disease provided herein apply as well to prophylaxis against Huntington's disease, e.g., the prevention or delay of onset of Huntington's disease or a symptom thereof.
  • the method is applicable to individuals suspected of having Huntington's disease or at risk for Huntington's disease.
  • "therapeutically effective” means an amount effective to reduce or ameliorate one or more symptoms of Huntington's disease, e.g., described above, e.g., wherein said one or more symptoms are not accounted for by another disease, disorder or condition.
  • “therapeutically effective” means an amount effective to delay the onset or worsening of one or more symptoms of Huntington's disease, e.g., described above, e.g., wherein said one or more symptoms are not accounted for by another disease, disorder or condition.
  • said "therapeutically effective” amount is an amount sufficient to cause a detectable improvement in one or more symptoms of Huntington's disease, sufficient to delay the onset or worsening of one or more symptoms of Huntington's disease, sufficient to reduce the severity of one or more symptoms of Huntington's disease, or sufficient to increase the duration or quality of life following onset of symptoms.
  • "therapeutically effective” means an amount effective to improve cognition and/or mental status in the individual or induce neural repair and/or neuroregeneration in the individual.
  • one or more treatments with placental stem cells results in extension of a treated individual's lifespan or quality of life, or a treated individual's improvement in cognition and/or mental status by about 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year, 13 months, 14 months, 15 months, 16 months, 18 months, 20 months, 2 years, 3 years or more (compared, e.g., to the individual's predicted lifespan or quality of life or cognition and/or mental status in the absence of the placental stem cell treatment).
  • placental stem cells to the individual can take place once, or more than once.
  • placental stem cells are administered multiple times to an individual having schizophrenia, Alzheimer's disease, or Huntington's disease, e.g., for as long as symptoms of schizophrenia, Alzheimer's disease, or Huntington's disease in the individual persist.
  • placental stem cells are administered to an individual having schizophrenia, Alzheimer's disease, or Huntington's disease once, twice, or 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100 or more times, e.g., for as long as symptoms of schizophrenia, Alzheimer's disease, or Huntington's disease in the individual persist.
  • placental stem cells are administered to an individual having schizophrenia, Alzheimer's disease, or Huntington's disease once per day, e.g., for as long as symptoms of schizophrenia, Alzheimer's disease, or Huntington's disease in the individual persist.
  • placental stem cells are administered to an individual having schizophrenia, Alzheimer's disease, or Huntington's disease once per week, e.g., for as long as symptoms of schizophrenia, Alzheimer's disease, or Huntington's disease in the individual persist.
  • placental stem cells are administered to an individual having schizophrenia, Alzheimer's disease, or Huntington's disease once per month, e.g., for as long as symptoms of schizophrenia, Alzheimer's disease, or Huntington's disease in the individual persist.
  • placental stem cells are administered to an individual having schizophrenia, Alzheimer's disease, or Huntington's disease twice, three times, four times or more per month. In certain embodiments, placental stem cells are administered to an individual having schizophrenia, Alzheimer's disease, or Huntington's disease multiple times over the course of a month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year, 2 years, 3 years, 4 years, 5 years, or more.
  • an administration of placental stem cells is followed by a period of less than 1 day, or 1 day, 2, days, 3 days, 4 days, 5 days , 6 days, 7 days, 1 week, 2 weeks, 3 weeks, 4 weeks, 1 month, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 2 months, 3 months, or more in which stem cells are not administered before a subsequent administration.
  • administration of placental stems cells is according to a cycle in which one, two, three or more administrations is followed by one period of time ⁇ e.g., less than 1 day, or 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 1 week, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 2 weeks, 3 weeks, 4 weeks, 1 month, 5 weeks, 6 weeks, 7, weeks, 8 weeks, 2 months, 3 months or more) which is followed by one, two, three or more administrations, followed by a second period of time ⁇ e.g., less than 1 day, or 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 1 week, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 2 weeks, 3 weeks, 4 weeks, 1 month, 5 weeks, 6 weeks, 7, weeks, 8 weeks, 2 months, 3 months or more) of lesser, equal, or greater duration.
  • one period of time ⁇ e.g
  • the method comprises identifying an individual patient with schizophrenia, Alzheimer's disease, or Huntington's disease who exhibits one or more symptoms of schizophrenia, Alzheimer's disease, or
  • Huntington's disease administering to the individual a therapeutically effective amount of placental stem cells, wherein said therapeutically effective amount is an amount that results in improvement in one or more of said symptoms; monitoring one or more of said symptoms in said patient; and administering a second dose of placental stem cells when said one or more symptoms begin to worsen.
  • this method comprising monitoring and readministration of placental stem cells is repeated 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more times during the course of schizophrenia, Alzheimer's disease, or Huntington's disease in said individual.
  • said individual, or said one or more symptoms can be monitored for, e.g., 1, 2, 3, 4, 5, 6 or 7 days post-administration, for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27 or 28 weeks after administration, or for 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more years after administration, or each separate
  • the methods of treatment of an individual having or diagnosed with schizophrenia, or schizophreniform disorder, or Alzheimer's disease or Huntington's disease provided herein comprises administering to said individual between 1 x 10 5 and 1 x 10 11 placental stem cells.
  • said method comprises administering about, or at least or at most about 1 x 10 5 , 2.5 x 10 5 , 3 x 10 5 , 5 x 10 5 , 7.5 x 10 5 , 1 x 10 6 , 2.5 x 10 6 , 3 x 10 6 , 5 x
  • the method comprises administering a single unit dose of placental stem cells to said individual, wherein said single unit dose comprises about 1 x 10 5 , 2.5 x 10 5 , 3 x 10 5 , 5 x 10 5 , 7.5 x 10 5 , 1 x 10 6 , 2.5 x 10 6 , 3 x 10 6 , 5 x 10 6 , 7.5 x 10 6 , 1 x 10 7 , 2.5 x 10 7 , 3 x 10 7 , 5 x
  • the method comprises administering about 1 x 10 5 to about 1 x 10 8 placental stem cells per kilogram body weight, or about 1 x 10 6 to about 1 x 10 7 placental stem per kilogram body weight.
  • placental stem cells are administered to an individual in an amount of 1 x 10 5 - 5 x 10 5 , 5 x 10 5 - 1 x 10 6 , 1 x 10 6 - 5 x 10 6 , 5 x 10 6 - 1 x 10 7 , 1 x 10 7 - 5 x 10 7 , 5 x 10 7 - 1 x 10 8 , 1 x 10 8 - 5 x 10 8 , 5 x 10 8 - 1 x 10 9 , 1 x 10 9 - 5 x 10 9 , 5 x 10 9 - 1 x 10 10 , 1 x 10 10 - 5 x l0 10 , 5 x 10 10 - 1 x 10 11 or more placental stem cells per administration.
  • placental stem cells are administered to an individual in an amount of 1 x 10 5 , 3 x 10 5 , 5 x 10 5 , 1 x 10 6 , 3 x 10 6 , 5 x 10 6 , 1 x 10 7 , 3 x 10 7 , 5 x 10 7 , 1 x 10 8 , 2 x 10 8 , 3 x 10 8 , 4 x 10 8 , 5 x 10 8 , 6 x 10 8 , 7 x 10 8 , 8 x 10 8 , 8 x 10 8 , 1 x 10 9 , 2 x 10 9 , 3 x 10 9 , 4 x 10 9 , 5 x 10 9 , 1 x 10 10 , 5 x 10 10 , or 1 x 10 11 or more placental stem cells per day.
  • placental stem cells are administered to an individual in an amount of 1 x 10 5 - 5 x 10 5 , 5 x 10 5 - 1 x 10 6 , 1 x 10 6 - 5 x 10 6 , 5 x 10 6 - 1 x 10 7 , 1 x 10 7 - 5 x 10 7 , 5 x 10 7 - 1 x 10 8 , 1 x 10 8 - 5 x 10 8 , 5 x 10 8 - 1 x 10 9 , 1 x 10 9 - 5 x 10 9 , 5 x 10 9 - 1 x 10 10 , 1 x 10 10 - 5 x 10 10 , 5 x 10 10 - 1 x 10 11 or more placental stem cells per day.
  • placental stem cells are administered to an individual in an amount of at least 1 x 10 7 placental stem cells per administration; at least 1 x 10 8 placental stem cells per administration; at least 2 x 10 8 placental stem cells per administration; or at least 1 x 10 9 placental stem cells per administration.
  • placental stem cells are
  • x 10 7 - 8 x 10 8 placental stem cells administered as a single or repeated injections, or in two or three boluses, for example, as 1-3 injections per week with one or more or several months in between each series of injections.
  • the method of treatment additionally comprises administration to the individual with schizophrenia, Alzheimer's disease, or Huntington's disease of one or more second therapeutic modalities. In certain embodiments, the method of treatment additionally comprises administration to the individual with schizophrenia, Alzheimer's disease, or
  • the second therapeutic composition may be administered to the individual having schizophrenia,
  • Such second therapeutic compositions may comprise any compound known in the art that is used in the treatment of schizophrenia, Alzheimer's disease, or Huntington's disease.
  • the second therapeutic composition comprises a compound described in Section 5.9 below.
  • the treatment is administered to a human individual.
  • the human individual is a child.
  • the human individual is an adolescent.
  • the human individual is an adult.
  • the human individual is an elderly adult. In certain embodiments, the human individual is aged 30 years or more, 40 years or more, 50 years or more, 60 years or more, 70 years or more, 80 years or more, or 90 years or more.
  • the treatment is administered to a male individual, for example, a male human individual. In other embodiments, the treatment is administered to a female individual, for example, a female human individual. In certain embodiments, the treatment is administered to a pregnant female individual. In certain embodiments, the treatment is administered to an embryo in utero.
  • placental stem cells and/or unit doses of placental stem cells described above, useful for the methods of treating schizophrenia or schizophreniform disorder or Alzheimer's disease or Huntington's disease are formulated into pharmaceutical
  • compositions can comprise placental stem cells in a pharmaceutically-acceptable carrier, e.g., a saline solution or other accepted physiologically- acceptable solution for in vivo administration.
  • Pharmaceutical compositions comprising the isolated placental stem cells described herein can comprise any, or any combination, of the isolated placental stem cell populations, or isolated placental stem cells, described elsewhere herein.
  • the pharmaceutical compositions can comprise fetal, maternal, or both fetal and maternal isolated cells.
  • the pharmaceutical compositions provided herein can further comprise isolated placental stem cells obtained from a single individual, umbilical cord or placenta, or from a plurality of individuals, umbilical cords or placentae. Any of the placental stem cells, described elsewhere herein, can be formulated into pharmaceutical compositions, as described below.
  • the pharmaceutical compositions provided herein comprise at least 50% viable cells or more (that is, at least 50% of the cells in the population are functional or living). Preferably, at least 60%) of the cells in the population are viable. More preferably, at least 70%>, 80%>, 90%>, 95%, or 99% of the cells in the population in the pharmaceutical composition are viable.
  • the pharmaceutical compositions provided herein comprise one or more compounds that, e.g., facilitate engraftment ⁇ e.g., anti-T-cell receptor antibodies, an immunosuppressant, or the like); stabilizers such as albumin, dextran 40, gelatin, hydroxyethyl starch, plasmalyte, and the like.
  • stabilizers such as albumin, dextran 40, gelatin, hydroxyethyl starch, plasmalyte, and the like.
  • the pharmaceutical composition comprises about 1% to 1.5% HSA and about 2.5% dextran.
  • the pharmaceutical composition comprises from about 5 x 10 6 cells per mL to about 2 x 10 7 cells per mL in a solution comprising 5% HSA and 10% dextran, optionally comprising an
  • immunosuppressant e.g., cyclosporine A at, e.g., 10 mg/kg.
  • the pharmaceutical composition e.g., a solution
  • the pharmaceutical composition e.g., a solution
  • the pharmaceutical composition comprises between about 1.5 x 10 6 cells per mL to about 3.75 x 10 6 cells per mL. In other embodiments, the pharmaceutical composition comprises between about 0.1 x 10 6 cells/mL to about 1 x 10 6 cells/mL, about 1 x 10 6 cells/mL to about 50 x 10 6 cells/mL, about 1 x 10 6 cells/mL to about 40 x 10 6 cells/mL, about 1 x 10 6 cells/mL to about 30 x 10 6 cells/mL, about 1 x 10 6 cells/mL to about 20 x 10 6 cells/mL, about 1 x 10 6 cells/mL to about 15 x 10 6 cells/mL, or about 1 x 10 6 cells/mL to about 10 x 10 6 cells/mL.
  • the pharmaceutical composition comprises no visible cell clumps (i.e., no macro cell clumps), or substantially no such visible clumps.
  • macro cell clumps means an aggregation of cells visible without magnification, e.g., visible to the naked eye, and generally refers to a cell aggregation larger than about 150 microns.
  • the pharmaceutical composition comprises about 2.5%, 3.0%, 3.5%, 4.0%>, 4.5%, 5.0%, 5.5%, 6.0%, 6.5%, 7.0%, 7.5% 8.0%, 8.5%, 9.0%, 9.5% or 10% dextran, e.g., dextran-40.
  • said composition comprises about 7.5% to about 9% dextran-40.
  • said composition comprises about 5.5 % dextran-40.
  • the pharmaceutical composition comprises from about 1% to about 15% human serum albumin (HSA).
  • HSA human serum albumin
  • the pharmaceutical composition comprises about 1%, 2%, 3%, 4%, 5%, 65, 75, 8%, 9%, 10%, 11%, 12%, 13%, 14% or 15% HSA.
  • said cells have been cryopreserved and thawed.
  • said cells have been filtered through a 70 ⁇ to 100 ⁇ filter.
  • said composition comprises no visible cell clumps.
  • said composition comprises fewer than about 200 cell clumps per 10 6 cells, wherein said cell clumps are visible only under a microscope, e.g., a light microscope. In another specific embodiment, said composition comprises fewer than about 150 cell clumps per 10 6 cells, wherein said cell clumps are visible only under a microscope, e.g., a light microscope. In another specific embodiment, said composition comprises fewer than about 100 cell clumps per 10 6 cells, wherein said cell clumps are visible only under a microscope, e.g., a light microscope.
  • the pharmaceutical composition comprises about 1.0 ⁇ 0.3 x 10 6 cells per mL, about 5.5% dextran-40 (w/v), about 10% HSA (w/v), and about 5% DMSO (v/v).
  • the pharmaceutical composition comprises a plurality of cells, e.g., a plurality of isolated placental stem cells, in a solution comprising 10%> dextran-40, wherein the pharmaceutical composition comprises between about 1.0 ⁇ 0.3 x 10 6 cells per mL to about 5.0 ⁇ 1.5 x 10 6 cells per mL, and wherein said composition comprises no cell clumps visible with the unaided eye (i.e., comprises no macro cell clumps).
  • the pharmaceutical composition comprises between about 1.5 x 10 6 cells per mL to about 3.75 x 10 6 cells per mL.
  • said cells have been cryopreserved and thawed.
  • said cells have been filtered through a 70 ⁇ to 100 ⁇ filter.
  • said composition comprises fewer than about 200 micro cell clumps (that is, cell clumps visible only with magnification) per 10 6 cells.
  • the pharmaceutical composition comprises fewer than about 150 micro cell clumps per 10 6 cells.
  • the pharmaceutical composition comprises fewer than about 100 micro cell clumps per 10 6 cells.
  • composition comprises less than 15%>, 14%>, 13%>, 12%>, 11%>, 10%>, 9%>, 8%>, 7%>, 6%, 5%, 4%, 3%, or 2% DMSO, or less than 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% DMSO.
  • compositions comprising cells, wherein said compositions are produced by one of the methods disclosed herein.
  • the pharmaceutical composition comprises cells, wherein the pharmaceutical composition is produced by a method comprising filtering a solution comprising placental stem cells to form a filtered cell-containing solution; diluting the filtered cell-containing solution with a first solution to about 1 to 50 x 10 6 , 1 to 40 x 10 6 , 1 to 30 x 10 6 , 1 to 20 x 10 6 , 1 to 15 x 10 6 , or 1 to 10 x 10 6 cells per mL, e.g., prior to cryopreservation; and diluting the resulting filtered cell-containing solution with a second solution comprising dextran, but not comprising human serum albumin (HSA) to produce said composition.
  • HSA human serum albumin
  • said diluting is to no more than about 15 x 10 6 cells per mL. In certain embodiments, said diluting is to no more than about 10 ⁇ ⁇ x 10 6 cells per mL. In certain embodiments, said diluting is to no more than about 7.5 x 10 cells per mL. In other certain embodiments, if the filtered cell-containing solution, prior to the dilution, comprises less than about 15 x 10 6 cells per mL, filtration is optional. In other certain embodiments, if the filtered cell-containing solution, prior to the dilution, comprises less than about 10 ⁇ 3 x 10 6 cells per mL, filtration is optional. In other certain embodiments, if the filtered cell-containing solution, prior to the dilution, comprises less than about 7.5 x 10 6 cells per mL, filtration is optional.
  • the cells are cryopreserved between said diluting with a first dilution solution and said diluting with said second dilution solution.
  • the first dilution solution comprises dextran and HSA.
  • the dextran in the first dilution solution or second dilution solution can be dextran of any molecular weight, e.g., dextran having a molecular weight of from about 10 kDa to about 150 kDa.
  • said dextran in said first dilution solution or said second solution is about 2.5%, 3.0%, 3.5%, 4.0%, 4.5%, 5.0%, 5.5%, 6.0%, 6.5%, 7.0%, 7.5% 8.0%, 8.5%, 9.0%, 9.5% or 10% dextran.
  • the dextran in said first dilution solution or said second dilution solution is dextran-40.
  • the dextran in said first dilution solution and said second dilution solution is dextran-40.
  • said dextran-40 in said first dilution solution is 5.0% dextran-40.
  • said dextran-40 in said first dilution solution is 5.5% dextran-40.
  • said dextran-40 in said second dilution solution is 10% dextran-40.
  • said HSA in said solution comprising HSA is 1 to 15 % HSA.
  • said HSA in said solution comprising HSA is about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14% or 15 % HSA.
  • said HSA in said solution comprising HSA is 10% HSA.
  • said first dilution solution comprises HSA.
  • said HSA in said first dilution solution is 10% HSA.
  • said first dilution solution comprises a cryoprotectant.
  • said cryoprotectant is DMSO.
  • said dextran-40 in said second dilution solution is about 10% dextran-40.
  • said composition comprising cells comprises about 7.5% to about 9% dextran.
  • the pharmaceutical composition comprises from about 1.0 ⁇ 0.3 x 10 6 cells per mL to about 5.0 ⁇ 1.5 x 10 6 cells per mL. In another specific embodiment, the pharmaceutical composition comprises from about 1.5 x 10 6 cells per mL to about 3.75 x 10 6 cells per mL.
  • the pharmaceutical composition is made by a method comprising (a) filtering a cell-containing solution comprising placental stem cells prior to cryopreservation to produce a filtered cell-containing solution; (b) cryopreserving the cells in the filtered cell- containing solution at about 1 to 50 x 10 6 , 1 to 40 x 10 6 , 1 to 30 x 10 6 , 1 to 20 x 10 6 , 1 to 15 x 10 6 , or 1 to 10 x 10 6 cells per mL; (c) thawing the cells; and (d) diluting the filtered cell- containing solution about 1 : 1 to about 1 : 1 1 (v/v) with a dextran-40 solution.
  • the cells in step (b) are cryopreserved at about 10 ⁇ 3 x 10 6 cells per mL. In a more specific embodiment, the cells in step (b) are cryopreserved in a solution comprising about 5% to about 10% dextran-40 and HSA. In certain embodiments, said diluting in step (b) is to no more than about 15 x 10 6 cells per mL.
  • the pharmaceutical composition is made by a method
  • said diluting in step (c) is to no more than about 15 x 10 6 cells per mL. In certain embodiments, said diluting in step (c) is to no more than about 10 ⁇ 3 x 10 6 cells/mL. In certain embodiments, said diluting in step (c) is to no more than about 7.5 x 10 6 cells/mL.
  • the composition comprising cells is made by a method comprising: (a) centrifuging placental stem cells, to collect the cells; (b) resuspending the cells in 5.5% dextran-40; (c) centrifuging the cells to collect the cells; (d) resuspending the cells in a 5.5%) dextran-40 solution that comprises 10%> HSA; (e) filtering the cells through a 70 ⁇ filter; (f) diluting the cells in 5.5% dextran-40, 10% HSA, and 5% DMSO to about 1 to 50 x 10 6 , 1 to 40 x 10 6 , 1 to 30 x 10 6 , 1 to 20 x 10 6 , 1 to 15 x 10 6 , or 1 to 10 x 10 6 cells per niL; (g) cryopreserving the cells; (h) thawing the cells; and (i) diluting the cells 1 : 1 to 1 : 1 1 (v/v) with 10% dextran-40.
  • said diluting in step (f) is to no more than about 15 x 10 6 cells per mL. In certain embodiments, said diluting in step (f) is to no more than about 10 ⁇ 3 x 10 6 cells/mL. In certain embodiments, said diluting in step (f) is to no more than about 7.5 x 10 6 cells/mL. In other certain embodiments, if the number of cells is less than about 10 ⁇ 3 x 10 6 cells per mL, filtration is optional.
  • compositions comprising the isolated placental cells described herein can comprise any of the isolated placental stem cells described herein.
  • the composition additionally comprises an antibody against tissue factor (CD142), e.g., antibody CNTO 859.
  • CD142 tissue factor
  • injectable formulations suitable for the administration of cellular products, may be used.
  • the placental stem cells can be encapsulated in, e.g., alginate, either before or after cryopreservation.
  • the placental stem cells can be combined with platelet-rich plasma, e.g., for local injection or local administration applications.
  • the platelet rich plasma is autologous platelet rich plasma, e.g., autologous to the individual to whom the placental stem cells are administered.
  • the platelet-rich plasma is allogeneic to the individual to whom the placental stem cells are administered.
  • said platelet rich plasma is derived from placental perfusate.
  • the volume to volume ratio of placental stem cells to platelet rich plasma in the composition is between about 10: 1 and 1 : 10; between about 100: 1 and 1 : 100; or is about 1 : 1.
  • the pharmaceutical composition comprises isolated placental stem cells that are substantially, or completely, non-maternal in origin, that is, have the fetal genotype; e.g., at least about 90%, 95%>, 98%>, 99%> or about 100% are non-maternal in origin.
  • the pharmaceutical composition additionally comprises stem cells that are not placental stem cells.
  • Isolated placental stem cells in the compositions can comprise placental stem cells derived from a single donor, or from multiple donors.
  • the isolated placental cells can be completely HLA-matched to an intended recipient, or partially or completely HLA-mismatched.
  • the method of treating schizophrenia, Alzheimer's disease, or Huntington's disease comprises monitoring immunosuppression by said placental stem cells in said individual, e.g., following administration of the cells.
  • monitoring can be used, e.g., as a surrogate for monitoring symptoms, or as a way of determining when additional dosing is warranted.
  • the method additionally comprises correlating said immunosuppression with reduction in one or more of said symptoms of schizophrenia,
  • the method of treatment can comprise: (1) administering to an individual having schizophrenia, Alzheimer's disease, or Huntington's disease placental stem cells such that one or more symptoms of said schizophrenia, Alzheimer's disease, or Huntington's disease are reduced; and (2) monitoring the individual to determine the level of immunosuppression due to said placental stem cells.
  • Such monitoring can comprise, for example, monitoring the activity of peripheral blood mononuclear cells, e.g., T cells, macrophages and/or dendritic cells from the individual against an antigen in, e.g., a oneway mixed lymphocyte reaction (MLR) assay, post-administration to determine the degree of immunosuppression by the placental stem cells, e.g., over time.
  • peripheral blood mononuclear cells e.g., T cells, macrophages and/or dendritic cells from the individual against an antigen in, e.g., a oneway mixed lymphocyte reaction (MLR) assay
  • MLR mixed lymphocyte reaction
  • the individual is administered an amount of placental stem cells that results in a suppression of immune cell activity by, e.g., 20%, 30%, 40%), 50%o, 60%), 70%) or 80%>, as compared to an equivalent number of said immune cells' activity before administration of placental stem cells.
  • the individual is monitored for any increase in the activity of the immune cells, e.g., within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or 21 days of said administration; if the activity of the immune cells increases to a predetermined level, e.g., 30%, 40%, 50%, 60%, 70%, 80%, of 90% pre- administration activity, placental stem cells are administered again.
  • placental stem cells can be used to reduce activation of immune cells associated with schizophrenia, Alzheimer's disease, or Huntington's disease, e.g., to reduce an immune response associated with, or causative of, schizophrenia, Alzheimer's disease, or Huntington's disease.
  • An "immune cell” in the context of this method means any cell of the immune system, particularly T cells and NK (natural killer) cells.
  • placental stem cells are contacted with a plurality of immune cells, wherein the plurality of immune cells are, or comprises, a plurality of T cells ⁇ e.g., a plurality of CD3 + T cells, CD4 + T cells and/or CD8 + T cells) and/or natural killer cells.
  • the plurality of immune cells are, or comprises, a plurality of T cells ⁇ e.g., a plurality of CD3 + T cells, CD4 + T cells and/or CD8 + T cells) and/or natural killer cells.
  • placental stem cells are brought into proximity with a plurality of immune cells, wherein the plurality of immune cells are, or comprises, a plurality of T cells ⁇ e.g., a plurality of CD3 + T cells, CD4 + T cells and/or CD8 + T cells) and/or natural killer cells, wherein the proximity is sufficient to reduce activation of immune cells associated with schizophrenia, Alzheimer's disease, or Huntington's disease, e.g., to reduce an immune response associated with, or causative of, schizophrenia, Alzheimer's disease, or Huntington's disease.
  • the term "proximity" refers to sufficient proximity to elicit the desired result.
  • an "immune response" in the context of the method can be any response by an immune cell to a stimulus normally perceived by an immune cell, e.g., a response to the presence of an antigen.
  • an immune response can be the proliferation of T cells ⁇ e.g., CD3 + T cells, CD4 + T cells and/or CD8 + T cells) in response to a foreign antigen, such as an antigen present in a transfusion or graft, or to a self-antigen, as in an autoimmune disease.
  • the immune response can also be a proliferation of T cells contained within a graft.
  • the immune response can also be any activity of a natural killer (NK) cell, the maturation of a dendritic cell, or the like.
  • NK natural killer
  • Placental stem cells can be tested, e.g., prior to administration to an individual having schizophrenia, Alzheimer's disease, or Huntington's disease, e.g., in an MLR comprising combining CD4 + or CD8 + T cells, dendritic cells (DC) and placental stem cells in a ratio of about 10: 1 :2, wherein the T cells are stained with a dye such as, e.g., CFSE that partitions into daughter cells, and wherein the T cells are allowed to proliferate for about 6 days.
  • the T cells and/or DC cells can be obtained from the individual to be treated, e.g., can be autologous to the individual, or can be allogeneic to the individual.
  • placental stem cells are immunosuppressive if the T cell proliferation at 6 days in the presence of placental stem cells is detectably reduced compared to T cell proliferation in the presence of DC and absence of placental stem cells.
  • placental stem cells can be either thawed or harvested from culture. About 20,000 placental stem cells are resuspended in 100 ⁇ of medium (RPMI 1640, 1 mM HEPES buffer, antibiotics, and 5% pooled human serum), and allowed to attach to the bottom of a well for 2 hours.
  • CD4 + and/or CD8 + T cells are isolated from whole peripheral blood mononuclear cells using Miltenyi magnetic beads.
  • the cells are CFSE stained, and a total of 100,000 T cells (CD4 + T cells alone, CD8 + T cells alone, or equal amounts of CD4 + and CD8 + T cells) are added per well. The volume in the well is brought to 200 ⁇ 1, and the MLR is allowed to proceed.
  • the anti-inflammatory activity (i.e., immunosuppressive activity) of the placental stem cells is determined prior to administration to the individual having schizophrenia, Alzheimer's disease, or Huntington's disease. This can be accomplished, for example, by determining the immunosuppressive activity of a sample of the placental stem cells to be administered for treatment of schizophrenia, Alzheimer's disease, or Huntington's disease. Such an activity can be determined, for example, by testing a sample of the placental stem cells or placental stem cells in, e.g., an MLR or regression assay. In one embodiment, an MLR is performed with the sample, and a degree of immunosuppression demonstrated by the sample placental stem cells in the assay is determined. In certain embodiments, the degree of reduction of a symptom of schizophrenia, Alzheimer's disease, or Huntington's disease is expected to correlate with the immunosuppressive activity of the sampled placental stem cells.
  • the parameters of the MLR can be varied to provide more data or to best determine the capacity of a sample of a population of placental stem cells to immunosuppress. For example, because immunosuppression by placental stem cells appears to increase in proportion to the number of placental stem cells present in the assay, the MLR can be performed with, in one embodiment, two or more numbers of placental stem cells, e.g., 1 x 10 3 , 3 x 10 3 , 1 x 10 4 and/or 3 x 10 4 placental stem cells per reaction. The number of placental stem cells relative to the number of T cells in the assay can also be varied.
  • placental stem cells and T cells in the assay can be present in any ratio of, e.g. about 10: 1 to about 1 : 10, preferably about 1 :5, though a relatively greater number of placental stem cells or T cells can be used.
  • Placental stem cells can be administered to an individual in a ratio, with respect to a known or expected number of immune cells, e.g., T cells, in the individual, of from about 10:1 to about 1 :10, preferably in some embodiments about 1 :5.
  • placental stem cells can be administered to an individual in a ratio of, in non- limiting examples, about 10,000:1, about 1,000: 1, about 100: 1, about 10: 1, about 1 : 1, about 1 : 10, about 1 : 100, about 1 : 1,000 or about 1 : 10,000.
  • placental stem cells administered to an individual or subject comprise at least, about, or no more than, 1 x 10 5 , 3 x 10 5 , 5 x 10 5 , 1 x 10 6 , 3 x 10 6 , 5 x 10 6 , 1 x 10 7 , 3 x 10 7 , 5 x 10 7 , 1 x 10 8 , 2 x 10 8 , 3 x 10 8 , 4 x 10 8 , 5 x 10 8 , 6 x 10 8 , 7 x 10 8 , 8 x 10 8 , 8 x 10 8 , 1 x 10 9 , 2 x 10 9 , 3 x 10 9 , 4 x 10 9 , 5 x 10 9 , 1 x 10 10 , 5 x 10 10 , 5 x 10 10 , 5 x 10 10 , 5 x 10 10 , 5 x 10 10 , 5 x 10 9 , 1 x 10 10 , 5 x 10 9 , 1 x 10 10 , 5
  • placental stem cells administered to an individual or subject comprise at least, about, or no more than, 1 x 10 5 - 5 x 10 5 , 5 x 10 5 - 1 x 10 6 , 1 x 10 6 - 5 x 10 6 , 5 x 10 6 - 1 x 10 7 , 1 x 10 7 - 5 x 10 7 , 5 x 10 7 - 1 x 10 8 , 1 x 10 8 - 5 x 10 8 , 5 x 10 8 - 1 x 10 9 , 1 x 10 9 - 5 x 10 9 , 5 x 10 9 - 1 x 10 10 , 1 x 10 10 - 5 x 10 10 , 5 x 10 9 - 1 x 10 10 , 1 x 10 10 - 5 x 10 10 , 5 x 10 10 - 1 x 10 11 or more placental stem cells.
  • the placental stem cells can also be administered with one or more second types of stem cells, e.g., mesenchymal stem cells from bone marrow, neural stem cells from brain or spinal cord, or stem cells from fat tissue.
  • second stem cells can be administered to an individual with said placental stem cells in a ratio of, e.g., between about 1 : 10 to about 10: 1.
  • the placental stem cells can be administered to an individual by any route sufficient to bring the placental stem cells and immune cells into contact with or proximity to each other.
  • the placental stem cells can be administered to the individual, e.g., intravenously,
  • intramuscularly intraperitoneally, intraocularly, parenterally, intrathecally, intraarterially, intracerebroventricularly, intracranially, subcutaneously, or directly into an organ, e.g., pancreas or brain.
  • the placental stem cells are administered in a dose in the range of 1 x 10 7 - 8 x 10 8 placental stem cells, administered as a single or repeated injections, or in two or three boluses, for example, as 1-3 injections per week with one or more or several months in between each series of injections.
  • said placental stem cells are formulated for local administration, e.g. , into the brain.
  • said placental stem cells are administered at a dose of up to or about 1 x 10 6 , 3 x 10 6 , 5 x 10 6 , 1 x 10 7 , 3 x 10 7 , 5 x 10 7 , or 1 x 10 8 placental stem cells per administration
  • the placental stem cells are formulated as a pharmaceutical composition as described in 5.8.1.2, below.
  • the placental stem cells administered to the individual having schizophrenia, Alzheimer's disease, or Huntington's disease have been genetically engineered to express one or more anti-inflammatory cytokines.
  • said antiinflammatory cytokine is IL-10.
  • the methods of treating an individual having schizophrenia, Alzheimer's disease, or Huntington's disease comprise administering placental stem cells, e.g., tissue culture plastic-adherent placental stem cells, to the individual, e.g., a therapeutically effective amount of said placental stem cells.
  • placental stem cells also have, in sufficient numbers, the capacity to detectably suppress an immune function, e.g., proliferation of CD4 + and/or CD8 + T cells in a mixed lymphocyte reaction assay or regression assay.
  • Huntington's disease can be derived from, e.g., isolated from and/or expanded from, a single species, e.g., the species of the intended recipient or the species of the immune cells the function of which is to be reduced or suppressed, or can be derived from multiple species.
  • the placental stem cells can be derived from one or more individuals of the same species as the intended recipient.
  • the placental stem cells can be derived from one or more individuals of the same sex as the intended recipient.
  • the placental stem cells are maternal in origin and are derived from the same individual for whom the treatment is intended.
  • Placental stem cells can be either fetal or maternal in origin (that is, can have the genotype of either the mother or fetus).
  • Populations of placental stem cells, or populations of cells comprising placental stem cells can comprise placental stem cells that are solely fetal or maternal in origin, or can comprise a mixed population of placental stem cells of both fetal and maternal origin.
  • the placental stem cells are fetal in origin and are derived from the fetus of the same individual for whom the treatment is intended.
  • the placental stem cells are both maternal and fetal in origin and comprise cells derived from the same individual for whom the treatment is intended.
  • the placental stem cells are obtained from a placental stem cell bank or other type of cell bank.
  • the placental stem cells disclosed herein are, in certain embodiments, multipotent in vitro (that is, the cells differentiate in vitro under differentiating conditions), multipotent in vivo (that is, the cells differentiate in vivo), or both. In certain embodiments, the placental stem cells disclosed herein do not engraft in vivo.
  • placental stem cells and populations of cells comprising the placental stem cells, can be identified and selected by the morphological, marker, and culture characteristics discussed below.
  • placental stem cells used as described herein when cultured in primary cultures or in cell culture, adhere to the tissue culture substrate, e.g., tissue culture container surface ⁇ e.g., tissue culture plastic).
  • tissue culture substrate e.g., tissue culture container surface ⁇ e.g., tissue culture plastic.
  • Placental stem cells in culture assume a generally fibroblastoid, stellate appearance, with a number of cytoplasmic processes extending from the central cell body.
  • the placental stem cells are, however, morphologically differentiable from fibroblasts cultured under the same conditions, as the placental stem cells exhibit a greater number of such processes than do fibroblasts. Morphologically, placental stem cells are also distinguishable from
  • hematopoietic stem cells which generally assume a more rounded, or cobblestone, morphology in culture.
  • the isolated placental stem cells e.g., isolated multipotent placental stem cells, and populations of such isolated placental stem cells, useful in the methods disclosed herein, e.g., the methods of treatment of schizophrenia or a schizophreniform disorder or Alzheimer's disease or Huntington's disease, are tissue culture surface-adherent human placental stem cells that have characteristics of multipotent cells or stem cells, and express a plurality of markers that can be used to identify and/or isolate the cells, or populations of cells that comprise the stem cells.
  • the isolated placental stem cells, and placental cell populations ⁇ e.g., two or more isolated placental stem cells) described herein include placental stem cells and placental cell-containing cell populations obtained directly from the placenta, or any part thereof (e.g., chorion, placental cotyledons, or the like), or that are cultured from such cells.
  • Isolated placental cell populations also include populations of (that is, two or more) isolated placental stem cells in culture, and a population in a container, e.g., a bag.
  • the isolated placental stem cells described herein are not bone marrow-derived mesenchymal cells, adipose-derived mesenchymal stem cells, or mesenchymal cells obtained from umbilical cord blood, placental blood, or peripheral blood.
  • Placental cells e.g., placental multipotent cells and placental stem cells, useful in the methods and compositions described herein are described herein and, e.g., in U.S. Patent Nos. 7,311,904; 7,311,905; 7,468,276; and 8,057,788, the disclosures of which are hereby incorporated by reference in their entireties.
  • the isolated placental stem cells express markers as detectable by, e.g., flow cytometry.
  • the isolated placental stem cells are CD34 , CD10 + and CD105 + , as detectable by flow cytometry.
  • the isolated CD34 , CD10 + , CD105 + placental stem cells have the potential to differentiate into cells of a neural phenotype, cells of an osteogenic phenotype, and/or cells of a chondrogenic phenotype.
  • the isolated CD34 , CD10 + , CD105 + placental stem cells are additionally CD200 + , as detectable by flow cytometry.
  • the isolated CD34 , CD10 + , CD105 + placental stem cells are additionally CD45 or CD90 + , as detectable by flow cytometry. In another specific embodiment, the isolated CD34 , CD10 + , CD105 + placental stem cells are additionally CD45 and CD90 + , as detectable by flow
  • the isolated CD34 , CD10 + , CD105 + , CD200 + placental stem cells are additionally CD90 + or CD45 , as detectable by flow cytometry.
  • the isolated CD34 , CD10 + , CD105 + , CD200 + placental stem cells are additionally CD90 + and CD45 , as detectable by flow cytometry, i.e., the cells are CD34 , CD10 + , CD45 , CD90 + , CD105 + and CD200 + .
  • said CD34 , CD10 + , CD45 , CD90 + , CD105 + , CD200 + placental stem cells are additionally CD80 and CD86 as detectable by flow cytometry.
  • said placental stem cells are CD34 , CD10 + , CD105 + and CD200 + , and one or more of CD38 , CD45 , CD80 , CD86 , CD133 , HLA-DR,DP,DQ , SSEA3 , SSEA4 , CD29 + , CD44 + , CD73 + , CD90 + , CD105 + , HLA-A,B,C + , PDL1 + , and/or ABC- p + , as detectable by flow cytometry, and/or OCT-4 + , as detectable by RT-PCR.
  • any of the CD34 , CD 10 , CD 105 placental stem cells described above are additionally one or more of CD29 + , CD38 , CD44 + , CD54 + , SH3 + or SH4 + , as detectable by flow cytometry.
  • the placental stem cells are additionally CD44 + , as detectable by flow cytometry.
  • the cells are additionally one or more of CD117 ⁇ , CD133 , KDR (VEGFR2 ), HLA-A,B,C + , HLA-DP,DQ,DR , or Programmed Death-1 Ligand (PDL1) + , as detectable by flow cytometry, or any combination thereof.
  • VEGFR2 KDR
  • HLA-A,B,C + HLA-DP,DQ,DR
  • PDL1 + Programmed Death-1 Ligand
  • the CD34 , CD10 + , CD105 + placental stem cells are additionally one or more of CD13 + , CD29 + , CD33 + , CD38 , CD44 + , CD45 , CD54 + , CD62E , CD62L , CD62P , SH3 + (CD73 + ), SH4 + (CD73 + ), CD80 , CD86 , CD90 + , SH2 + (CD105 + ),
  • CD106/VCAM + CD117 " CD144/VE-cadherin low , CD184/CXCR4 , CD200 + , CD133 , SSEA3 , SSEA4 , ABC-p + , KDR (VEGFR2 ), HLA-A,B,C + , HLA-DP,DQ,DR , HLA-G , or
  • the CD34 , CD10 + , CD105 + placental stem cells are additionally CD13 + , CD29 + , CD33 + , CD38 , CD44 + , CD45 , CD54/ICAM + , CD62E , CD62L , CD62P , SH3 + (CD73 + ), SH4 + (CD73 + ), CD80 , CD86 , CD90 + , SH2 + (CD105 + ), CD106/VCAM + , CD117 " CD144/VE-cadherin low , CD184/CXCR4 , CD200 + , CD 133 ,SSEA3 , SSEA4 , ABC-p + , KDR (VEGFR2 ), HLA-A,B,C + , HLA- DP,DQ,DR , HLA-G , and
  • the placental stem cells are additionally OCT-4 + , as detectable by, e.g. , RT-PCR.
  • Isolated placental stem cells generally do not express alpha smooth muscle actin (aSMA), e.g., as detectable by
  • Isolated placental stem cells generally express MHC Class I molecules, e.g., HLA-A,B,C, as detectable by flow cytometry.
  • any of the placental stem cells described herein are additionally ABC-p + , as detectable by flow cytometry, or OCT-4 + (POU5Fl + ) (detectable by RT-PCR), wherein ABC-p is a placenta-specific ABC transporter protein (also known as breast cancer resistance protein (BCRP) or as mitoxantrone resistance protein (MXR)), and OCT-4 is the Octamer-4 protein (POU5F1).
  • ABC-p is a placenta-specific ABC transporter protein (also known as breast cancer resistance protein (BCRP) or as mitoxantrone resistance protein (MXR))
  • OCT-4 is the Octamer-4 protein (POU5F1).
  • any of the placental stem cells described herein are additionally SSEA3 ⁇ or SSEA4 ⁇ , as detectable by flow cytometry, wherein SSEA3 is Stage Specific Embryonic Antigen 3, and SSEA4 is Stage Specific Embryonic Antigen 4.
  • any of the placental stem cells described herein are additionally SSEA3 and SSEA4 ⁇ , as detectable by flow cytometry.
  • any of the placental stem cells described herein are, or are additionally, one or more of MHC-I + (e.g., HLA-A,B,C + ), MHC-II (e.g., HLA- DP,DQ,DR ) or HLA-G , as detectable by flow cytometry.
  • MHC-I + e.g., HLA-A,B,C
  • MHC- II e.g., HLA-DP,DQ,DR
  • HLA-G HLA-G
  • the markers described above as detectable by flow cytometry may be detectable by any method known in the art, such as, e.g. , flow cytometry or surface plasmon resonance.
  • intracellular markers may be detectable by any method known in the art such as, e.g., RT-PCR.
  • populations of the isolated placental stem cells or populations of cells, e.g., populations of placental cells, comprising, e.g., that are enriched for, the isolated placental stem cells, that are useful in the methods and compositions disclosed herein.
  • Preferred populations of cells are those comprising the isolated placental stem cells, wherein the populations of cells comprise, e.g., at least 10%, 15%, 20%>, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% isolated CD10 + , CD105 + and CD34 placental stem cells; that is, at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% of cells in said population are isolated CD10 + , CD105 + and CD34 placental stem cells.
  • the isolated CD34 , CD10 + , CD105 + placental stem cells are additionally CD200 + , as detectable by flow cytometry.
  • the isolated CD34 , CD10 + , CD105 + , CD200 + placental stem cells are additionally CD90 + or CD45 , as detectable by flow cytometry.
  • the isolated CD34 , CD10 + , CD105 + , CD200 + placental stem cells are additionally CD90 + and CD45 , as detectable by flow cytometry.
  • any of the isolated CD34 , CD10 + , CD105 + placental stem cells described above are additionally one or more of CD29 + , CD38 , CD44 + , CD54 + , SH3 + or SH4 + , as detectable by flow cytometry.
  • the isolated CD34 , CD10 + , CD105 + placental stem cells, or isolated CD34 , CD10 + , CD105 + , CD200 + placental stem cells are additionally CD44 + , as detectable by flow cytometry.
  • the isolated placental stem cells are additionally one or more of CD13 + , CD29 + , CD33 + , CD38 , CD44 + , CD45 , CD54 + , CD62E , CD62L , CD62P , SH3 + (CD73 + ), SH4 + (CD73 + ), CD80 , CD86 , CD90 + , SH2 + (CD105 + ), CD106/VCAM + , CD117 " CD144/VE-cadherin low , CD184/CXCR4 , CD200 + , CD 133 ,SSEA3 , SSEA4 , ABC-p + , KDR (VEGFR2 ), HLA-A,B,C + , HLA- DP,DQ,DR , HLA-G , or Programmed Death- 1 Ligand (PDL1) + , as detectable by flow cytometry, or
  • the CD34 , CD10 + , CD105 + placental stem cells are additionally CD13 + , CD29 + , CD33 + , CD38 , CD44 + , CD45 , CD54/ICAM + , CD62E , CD62L , CD62P , SH3 + (CD73 + ), SH4 + (CD73 + ), CD80 , CD86 , CD90 + , SH2 + (CD105 + ), CD106/VCAM + , CD117 , CD144/VE- cadherin low , CD184/CXCR4 , CD200 + , CD 133 ,SSEA3 , SSEA4 , ABC-p + , KDR (VEGFR2 ), HLA-A,B,C + , HLA-DP,DQ,DR , HLA-G , and Programmed Death- 1 Ligand (PDL1) + , as detectable by flow cytometry, or OCT-4 + as detectable by RT-PCR,.
  • PDL1 Programmed Death
  • the isolated placental stem cells in said population of cells are one or more, or all, of CD10 + , CD29 + , CD34 , CD38 , CD44 + , CD45 , CD54 + , CD90 + , SH2 + , SH3 + , SH4 + , SSEA3 SSEA4 " ,and ABC-p + , as detectable by flow cytometry, and OCT- 4 + , as detectable by RT-PCR, wherein said isolated placental stem cells are obtained, or are obtainable, by physical and/or enzymatic disruption of placental tissue.
  • CD10 + , CD29 + , CD34 , CD38 , CD44 + , CD45 , CD54 + , CD90 + , SH2 + , SH3 + , SH4 + , SSEA3 SSEA4 " ,and ABC-p + , as detectable by flow cytometry, and OCT- 4 + , as detectable by RT-PCR wherein said isolated placental stem cells are obtained
  • the isolated placental stem cells are OCT-4 , as detectable by RT-PCR, and ABC- p + , as detectable by flow cytometry.
  • the isolated placental stem cells are OCT-4 + , as detectable by RT-PCR, and CD34 , as detectable by flow cytometry, wherein said isolated placental stem cells have at least one of the following characteristics:
  • the isolated placental stem cells are OCT-4 + , as detectable by RT-PCR, and CD34 , CD10 + , CD29 + , CD44 + , CD45 , CD54 + , CD90 + , SH3 + , SH4 + , SSEA3 , and SSEA4 ⁇ as detectable by flow cytometry.
  • the isolated placental stem cells are OCT-4 + , as detectable by RT-PCR, and CD34 , CD10 + , CD29 + , CD44 + , CD45 , CD54 + , CD90 + , SH3 + , SH4 + , SSEA3 and SSEA4 ⁇ as detectable by flow cytometry.
  • the isolated placental stem cells are OCT-4 + , as detectable by RT-PCR, and CD34 , SSEA3 ⁇ , and SSEA4 , as detectable by flow cytometry.
  • the isolated placental stem cells are OCT-4 + , as detectable by RT-PCR, and CD34 , and are either SH2 + or SH3 + , as detectable by flow cytometry.
  • the isolated placental stem cells are OCT-4 , as detectable by RT-PCR, and CD34 , SH2 , and SH3 , as detectable by flow cytometry.
  • the isolated placental stem cells are OCT-4 + , as detectable by RT-PCR, and CD34 , SSEA3 " , and SSEA4 " , as detectable by flow cytometry, and are either SH2 + or SH3 + , as detectable by flow cytometry.
  • the isolated placental stem cells are OCT-4 + , as detectable by RT-PCR, and CD34 , and either SH2 + or SH3 + , and are at least one of CD10 + , CD29 + , CD44 + , CD45 , CD54 + , CD90 + , SSEA3 ⁇ , or SSEA4 , as detectable by flow cytometry.
  • the isolated placental stem cells are OCT-4 + , as detectable by RT-PCR, and CD34 , CD10 + , CD29 + , CD44 + , CD45 , CD54 + , CD90 + , SSEA3 ⁇ , and SSEA4 ⁇ , as detectable by flow cytometry, and are either SH2 + or SH3 + , as detectable by flow cytometry.
  • the isolated placental stem cells are SH2 + , SH3 + , SH4 +
  • the isolated placental stem cells are CD10 + , CD29 + , CD44 + , CD54 + , CD90 + , CD34 , CD45 , SSEA3 or SSEA4 ⁇ (e.g., detectable by flow cytometry).
  • the isolated placental stem cells are SH2 + , SH3 + , SH4 + , SSEA3 and SSEA4 ⁇ (e.g., detectable by flow cytometry).
  • the isolated placental stem cells are SH2 + , SH3 + , SH4 + , SSEA3 and SSEA4 ⁇ , CD10 + , CD29 + , CD44 + , CD54 + , CD90 + , CD34 or CD45 " (e.g., detectable by flow cytometry) or OCT-4 + (e.g., detectable by RT-PCR).
  • the isolated placental stem cells useful in the methods and compositions disclosed herein are CD 10 + , CD29 + , CD34 , CD44 + , CD45 , CD54 + , CD90 + , SH2 + , SH3 + , and SH4 + (e.g., detectable by flow cytometry); wherein said isolated placental stem cells are additionally one or more of OCT-4 + (e.g., detectable by RT-PCR), SSEA3 or SSEA4 ⁇ (e.g., detectable by flow cytometry).
  • OCT-4 + e.g., detectable by RT-PCR
  • SSEA3 or SSEA4 ⁇ e.g., detectable by flow cytometry
  • the isolated placental stem cells are SH2+, SH3+, SH4+, SSEA3-, SSEA4- , CD 10+, CD29+, CD44+, CD54+, CD90+, OCT-4+, CD34- and CD45-.
  • isolated placental stem cells are CD200 + or HLA-G , as detectable by flow cytometry.
  • the isolated placental stem cells are CD200 + and HLA-G , as detectable by flow cytometry.
  • the isolated placental stem cells are additionally CD73 + and CD105 + , as detectable by flow cytometry.
  • the isolated placental stem cells are additionally CD34 , CD38 or CD45 , as detectable by flow cytometry.
  • the isolated placental stem cells are additionally CD34 , CD38 and CD45 , as detectable by flow cytometry.
  • said placental stem cells are CD34 , CD38 , CD45 , CD73 + and CD105 + , as detectable by flow cytometry.
  • said isolated CD200 + or HLA-G- placental stem cells facilitate the formation of embryoid-like bodies in a population of placental cells comprising the isolated placental stem cells, under conditions that allow the formation of embryoid-like bodies.
  • the isolated placental stem cells are isolated away from placental cells that are not said placental stem cells.
  • said isolated placental stem cells are isolated away from placental cells that do not display this combination of markers.
  • a cell population useful in the methods and compositions described herein is a population of cells comprising, e.g., that is enriched for, CD200 + , HLA-G- placental stem cells.
  • said population is a population of placental cells.
  • at least about 10%, at least about 20%, at least about 30%, at least about 40%), at least about 50%>, at least about 60%>, at least about 70%>, at least about 80%>, at least about 90%), at least about 95%>, or at least about 99%> of cells in said cell population are isolated CD200+, HLA-G- placental stem cells.
  • At least about 10%, at least about 20%), at least about 30%>, at least about 40%>, at least about 50%>, or at least about 60%> of cells in said cell population are isolated CD200 + , HLA-G- placental stem cells.
  • at least about 70% of cells in said cell population are isolated CD200 , HLA-G placental stem cells.
  • at least about 90%>, 95%>, or 99%> of said cells are isolated CD200 + , HLA-G- placental stem cells.
  • said isolated CD200 , HLA-G- placental stem cells are also CD73 and CD 105 .
  • said isolated CD200 + , HLA-G- placental stem cells are also CD34 , CD38 or CD45 .
  • said isolated CD200 + , HLA-G- placental stem cells are also CD34 , CD38 , CD45 , CD73 + and CD105 + .
  • said cell population produces one or more embryoid-like bodies when cultured under conditions that allow the formation of embryoid-like bodies.
  • said cell population is isolated away from placental cells that are not placental stem cells.
  • said isolated CD200 + , HLA-G- placental stem cells are isolated away from placental cells that do not display these markers.
  • the isolated placental stem cells useful in the methods and compositions described herein are CD73 + , CD105 + , and CD200 + , as detectable by flow cytometry.
  • the isolated placental stem cells are HLA-G , as detectable by flow cytometry.
  • the isolated placental stem cells are CD34 , CD38 or CD45 , as detectable by flow cytometry.
  • the isolated placental stem cells are CD34 , CD38 and CD45 , as detectable by flow cytometry.
  • the isolated placental stem cells are CD34 , CD38 , CD45 , and HLA-G , as detectable by flow cytometry.
  • the isolated CD73 + , CD105 + , and CD200 + placental stem cells facilitate the formation of one or more embryoid-like bodies in a population of placental cells comprising the isolated placental stem cells, when the population is cultured under conditions that allow the formation of embryoid-like bodies.
  • the isolated placental stem cells are isolated away from placental cells that are not the isolated placental stem cells.
  • the isolated placental stem cells are isolated away from placental cells that do not display these markers.
  • a cell population useful in the methods and compositions described herein is a population of cells comprising, e.g., that is enriched for, isolated CD73 + , CD105 + , CD200 + placental stem cells.
  • at least about 10%, at least about 20%), at least about 30%>, at least about 40%>, at least about 50%>, or at least about 60%> of cells, at least about 70%>, at least about 80%>, at least about 90%>, at least about 95%>, or at least about 99%> of cells in said cell population are isolated CD73+, CD105+, CD200+ placental stem cells.
  • At least about 10%, at least about 20%, at least about 30%, at least about 40%), at least about 50%>, or at least about 60%> of cells in said cell population are isolated CD73 + , CD105 + , CD200 + placental stem cells.
  • at least about 70% of said cells in said population of cells are isolated CD73 + , CD105 + , CD200 + placental stem cells.
  • at least about 80%>, 90%>, 95%> or 99%> of cells in said population of cells are isolated CD73 + , CD105 + , CD200 + placental stem cells.
  • the isolated placental stem cells are HLA-G .
  • the isolated placental stem cells are additionally CD34 , CD38 or CD45 . In another specific embodiment, the isolated placental stem cells are additionally CD34 , CD38 and CD45 . In another specific embodiment, the isolated placental stem cells are additionally CD34 , CD38 , CD45 , and HLA-G . In another specific embodiment, said population of cells produces one or more embryoid-like bodies when cultured under conditions that allow the formation of embryoid-like bodies. In another specific embodiment, said population of placental stem cells is isolated away from placental cells that are not placental stem cells. In another specific embodiment, said population of placental stem cells is isolated away from placental cells that do not display these characteristics.
  • the isolated placental stem cells are one or more of
  • the isolated placental stem cells are CD10 + , CD29 + , CD34 , CD38 , CD44 + , CD45 , CD54 + , CD90 + , SH2 + , SH3 + , SH4 + , SSEA3-, and SSEA4 ⁇ , as detectable by flow cytometry, and OCT-4 + , as detectable by RT-PCR.
  • the isolated placental stem cells are CD10 + , CD29 + , CD34 , CD38 , CD45 , CD54 + , SH2 + , SH3 + , and SH4 + , as detectable by flow cytometry.
  • the isolated placental stem cells are CD10 + , CD29 + , CD34 , CD38 , CD45 , CD54 + , SH2 + , SH3 + , and SH4 + , as detectable by flow cytometry, and OCT-4 + , as detectable by RT-PCR.
  • the isolated placental stem cells are CD10 + , CD29 + , CD34 , CD38 , CD44 + , CD45 , CD54 + , CD90 + , HLA-G , SH2 + , SH3 + , and SH4 + , as detectable by flow cytometry.
  • the isolated placental stem cells are OCT-4 + , as detectable by RT-PCR, and ABC-p + , as detectable by flow cytometry.
  • the isolated placental stem cells are SH2 + , SH3 + , and SH4 + , as detectable by flow cytometry, and OCT-4 + , as detectable by RT-PCR.
  • the isolated placental stem cells are OCT-4 + , as detectable by RT-PCR, and CD34 , SSEA3 ⁇ and SSEA4 ⁇ as detectable by flow cytometry.
  • said isolated OCT-4 + , CD34 , SSEA3 , and SSEA4 ⁇ placental stem cells are additionally CD10 + , CD29 + , CD34 , CD44 + , CD45 , CD54 + , CD90 + , SH2 + , SH3 + , and SH4 + , as detectable by flow cytometry.
  • the isolated placental stem cells are OCT-4 + , as detectable by RT-PCR, and CD34 , and either SH3 + or SH4 + , as detectable by flow cytometry.
  • the isolated placental stem cells are CD34 and either CD10 + , CD29 + , CD44 + , CD54 + , or CD90 + , as detectable by flow cytometry, or OCT-4 + , as detectable by RT-PCR.
  • isolated placental stem cells are CD200 + , as detectable by flow cytometry, and OCT-4 + , as detectable by RT-PCR.
  • the isolated placental stem cells are CD73 and CD 105 , as detectable by flow cytometry.
  • said isolated placental stem cells are HLA-G , as detectable by flow cytometry.
  • said isolated CD200 + , OCT-4 + placental stem cells are CD34 , CD38 or CD45 , as detectable by flow cytometry.
  • said isolated CD200 + , OCT-4 + placental stem cells are CD34 , CD38 and CD45 , as detectable by flow cytometry.
  • said isolated CD200 + , OCT-4 + placental stem cells are CD34 , CD38 , CD45 , CD73 + , CD105 + and HLA-G , as detectable by flow cytometry.
  • the isolated CD200 + , OCT-4 + placental stem cells facilitate the production of one or more embryoid-like bodies by a population of placental cells that comprises the placental stem cells, when the population is cultured under conditions that allow the formation of embryoid-like bodies.
  • said isolated CD200 + , OCT-4 + placental stem cells are isolated away from placental cells that are not said placental stem cells.
  • said isolated CD200 + , OCT-4 + placental stem cells are isolated away from placental cells that do not display these characteristics.
  • a cell population useful in the methods and compositions described herein is a population of cells comprising, e.g., that is enriched for, CD200 + , OCT-4 + placental stem cells.
  • at least about 80%>, at least about 90%>, at least about 95%>, or at least about 99%> of cells in said cell population are isolated CD200+, OCT-4+ placental stem cells.
  • At least about 10%), at least about 20%>, at least about 30%>, at least about 40%>, at least about 50%>, or at least about 60% of cells in said cell population are isolated CD200 + , OCT-4 + placental stem cells.
  • at least about 70% of said cells are said isolated CD200 , OCT-4 + placental stem cells.
  • at least about 80%>, 90%>, 95%>, or 99%> of cells in said cell population are said isolated CD200 + , OCT-4 + placental stem cells.
  • said isolated CD200 + , OCT-4 + placental stem cells are additionally CD73 + and CD105 + .
  • said isolated CD200 + , OCT- 4 + placental stem cells are additionally HLA-G .
  • said isolated CD200 + , OCT-4 + placental stem cells are additionally CD34 , CD38 and CD45 .
  • said isolated CD200 + , OCT-4 + placental stem cells are additionally CD34 , CD38 , CD45 , CD73 + , CD105 + and HLA-G .
  • the cell population produces one or more embryoid-like bodies when cultured under conditions that allow the formation of embryoid-like bodies.
  • said cell population is isolated away from placental cells that are not isolated CD200 + , OCT-4 + placental cells.
  • said cell population is isolated away from placental cells that do not display these markers.
  • the isolated placental stem cells useful in the methods and compositions described herein are CD73 + , CD105 + and HLA-G , as detectable by flow cytometry.
  • the isolated CD73 + , CD105 + and HLA-G- placental stem cells are additionally CD34 , CD38 or CD45 , as detectable by flow cytometry.
  • the isolated CD73 + , CD105 + , HLA-G- placental stem cells are additionally CD34 , CD38 and CD45 , as detectable by flow cytometry.
  • the isolated CD73 + , CD105 + , HLA-G- placental stem cells are additionally OCT-4 + , as detectable by RT-PCR.
  • the isolated CD73 + , CD105 + , HLA-G placental stem cells are additionally CD200 + , as detectable by flow cytometry.
  • the isolated CD73 + , CD105 + , HLA-G- placental stem cells are additionally CD34 , CD38 , CD45 , and CD200 + , as detectable by flow cytometry, and OCT-4 + , as detectable by RT- PCR.
  • the isolated CD73 + , CD105 + , HLA-G- placental stem cells facilitate the formation of embryoid-like bodies in a population of placental cells comprising said placental stem cells, when the population is cultured under conditions that allow the formation of embryoid-like bodies.
  • said the isolated CD73 + , CD105 + , HLA-G- placental stem cells are isolated away from placental cells that are not the isolated CD73 + , CD105 + , HLA-G- placental stem cells. In another specific embodiment, said the isolated CD73 , CD 105 , HLA-G- placental stem cells are isolated away from placental cells that do not display these markers.
  • a cell population useful in the methods and compositions described herein is a population of cells comprising, e.g., that is enriched for, isolated CD73 + , CD105 + and HLA-G- placental stem cells.
  • at least about 80%>, at least about 90%>, at least about 95%>, or at least about 99%> of cells in said cell population are isolated CD73+, CD105+, HLA-G- placental stem cells.
  • At least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, or at least about 60%> of cells in said population of cells are isolated CD73 + , CD105 + , HLA-G placental stem cells.
  • at least about 70% of cells in said population of cells are isolated CD73 + , CD105 + , HLA-G placental stem cells.
  • at least about 90%>, 95% or 99% of cells in said population of cells are isolated CD73 + , CD105 + , HLA-G placental stem cells.
  • said isolated CD73 + , CD105 + , HLA-G placental stem cells are additionally CD34 , CD38 or CD45 .
  • said isolated CD73 + , CD105 + , HLA-G placental stem cells are additionally CD34 , CD38 and CD45 .
  • said isolated CD73 + , CD105 + , HLA-G- placental stem cells are additionally OCT-4 + .
  • said isolated CD73 + , CD105 + , HLA-G- placental stem cells are
  • said isolated CD73 + , CD105 + , HLA-G placental stem cells are additionally CD34 , CD38 , CD45 , OCT-4 + and CD200 + .
  • said cell population is isolated away from placental cells that are not CD73 + , CD105 + , HLA-G- placental stem cells. In another specific embodiment, said cell population is isolated away from placental cells that do not display these markers.
  • the isolated placental stem cells are CD73 and CD 105 , as detectable by flow cytometry and facilitate the formation of one or more embryoid-like bodies in a population of isolated placental cells comprising said CD73 + , CD105 + cells when said population is cultured under conditions that allow formation of embryoid-like bodies.
  • said isolated CD73 + , CD105 + placental stem cells are additionally CD34 , CD38- or CD45 , as detectable by flow cytometry.
  • said isolated CD73 + , CD105 + placental stem cells are additionally CD34 , CD38- and CD45 , as detectable by flow cytometry.
  • said isolated CD73 + , CD105 + placental stem cells are additionally OCT-4 + , as detectable by RT-PCR.
  • said isolated CD73 + , CD105 + placental stem cells are additionally CD34 , CD38- and CD45 , as detectable by flow cytometry, and OCT-4 + , as detectable by RT-PCR.
  • said isolated CD73 + , CD105 + placental stem cells are isolated away from placental cells that are not said cells.
  • said isolated CD73 + , CD105 + placental stem cells are isolated away from placental cells that do not display these
  • a cell population useful in the methods and compositions described herein is a population of cells comprising, e.g., that is enriched for, isolated placental stem cells that are CD73 + , CD105 + , as detectable by flow cytometry, and facilitate the formation of one or more embryoid-like bodies in a population of isolated placental cells comprising said cells when said population is cultured under conditions that allow formation of embryoid-like bodies.
  • at least about 10%, at least about 20%>, at least about 30%>, at least about 40%>, at least about 50%>, or at least about 60%> of cells in said population of cells are said isolated CD73 + , CD105 + placental stem cells.
  • At least about 70% of cells in said population of cells are said isolated CD73 + , CD105 + placental stem cells.
  • at least about 80%>, 90%>, 95% or 99% of cells in said population of cells are said isolated CD73 + , CD105 + placental stem cells.
  • said isolated CD73 + , CD105 + placental stem cells are additionally CD34 , CD38 or CD45 .
  • said isolated CD73 + , CD105 + placental stem cells are additionally CD34 , CD38 and CD45 .
  • said isolated CD73 + , CD105 + placental stem cells are additionally OCT-4 + .
  • said isolated CD73 + , CD105 + placental stem cells are additionally CD200 + .
  • said isolated CD73 + , CD105 + placental stem cells are additionally CD34 , CD38 , CD45 , OCT-4 + and CD200 + .
  • said cell population is isolated away from placental cells that are not said isolated CD73 + , CD105 + placental stem cells.
  • said cell population is isolated away from placental cells that do not display these markers.
  • the isolated placental stem cells are OCT-4 + , as detectable by RT-PCR, and facilitate formation of one or more embryoid-like bodies in a population of isolated placental cells comprising said placental stem cells when said population of cells is cultured under conditions that allow formation of embryoid-like bodies.
  • said isolated OCT-4 + placental stem cells are additionally CD73 + and CD105 + , as detectable by flow cytometry.
  • said isolated OCT-4 + placental stem cells are additionally CD34 , CD38 , or CD45 , as detectable by flow cytometry.
  • said isolated OCT-4 + placental stem cells are additionally CD200 + , as detectable by flow cytometry.
  • said isolated OCT-4 + placental stem cells are additionally CD73 + , CD105 + , CD200 + , CD34 , CD38 , and CD45 , as detectable by flow cytometry.
  • said isolated OCT-4 placental stem cells are isolated away from placental cells that are not OCT-4 + placental cells.
  • said isolated OCT-4 + placental stem cells are isolated away from placental cells that do not display these characteristics.
  • a cell population useful in the methods and compositions described herein is a population of cells comprising, e.g., that is enriched for, isolated placental stem cells that are OCT-4 + and facilitate the formation of one or more embryoid-like bodies in a population of isolated placental cells comprising said cells when said population is cultured under conditions that allow formation of embryoid-like bodies.
  • at least about 10%, at least about 20%, at least about 30%>, at least about 40%>, at least about 50%>, or at least about 60%> of cells in said population of cells are said isolated OCT-4 + placental stem cells.
  • at least about 70% of cells in said population of cells are said isolated OCT-4 + placental stem cells.
  • At least about 80%>, 90%>, 95% or 99% of cells in said population of cells are said isolated OCT-4 + placental stem cells.
  • said isolated OCT-4 + placental stem cells are additionally CD34 , CD38 or CD45 .
  • said isolated OCT-4 + placental stem cells are additionally CD34 , CD38 and CD45 .
  • said isolated OCT-4 + placental stem cells are additionally CD73 + and CD105 + .
  • said isolated OCT-4 + placental stem cells are additionally CD200 + .
  • said isolated OCT-4 + placental stem cells are additionally CD73 + , CD105 + , CD200 + , CD34 , CD38 , and CD45 .
  • said cell population is isolated away from placental cells that are not said placental stem cells.
  • said cell population is isolated away from placental cells that do not display these markers.
  • the isolated placental stem cells useful in the methods and compositions described herein are isolated HLA-A,B,C + , CD45 , CD 133 and CD34 placental stem cells, as detectable by flow cytometry.
  • a cell population useful in the methods and compositions described herein is a population of cells comprising isolated placental stem cells, wherein at least about 70%, at least about 80%, at least about 90%, at least about 95% or at least about 99% of cells in said population of cells are isolated HLA- A,B,C + , CD45 , CD 133 and CD34 placental stem cells.
  • said isolated placental cell or population of isolated placental cells is isolated away from placental cells that are not HLA-A,B,C + , CD45 , CD 133 and CD34 placental stem cells.
  • said isolated placental stem cells are non-maternal in origin.
  • said population of isolated placental stem cells are substantially free of maternal components; e.g., at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%), 98%o or 99% of said cells in said population of isolated placental stem cells are non- maternal in origin.
  • the isolated placental stem cells useful in the methods and compositions described herein are isolated CD10 + , CD13 + , CD33 + , CD45 , CDl 17 " and CD 133 placental stem cells, as detectable by flow cytometry.
  • a cell population useful in the methods and compositions described herein is a population of cells comprising isolated placental stem cells, wherein at least about 70%>, at least about 80%>, at least about 90%), at least about 95% or at least about 99% of cells in said population of cells are isolated CD10 + , CD13 + , CD33 + , CD45 , CDl IT and CD 133 placental stem cells.
  • said isolated placental stem cells or population of isolated placental stem cells is isolated away from placental cells that are not said isolated placental stem cells.
  • said isolated CD10 + , CD13 + , CD33 + , CD45 , CDl 17 " and CD 133 placental stem cells are non-maternal in origin, i.e., have the fetal genotype.
  • at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99% of said cells in said population of isolated placental stem cells are non-maternal in origin.
  • said isolated placental stem cells or population of isolated placental stem cells are isolated away from placental cells that do not display these characteristics.
  • the isolated placental stem cells are isolated CD10 +
  • a cell population useful for the in the methods and compositions described herein is a population of cells comprising, e.g., enriched for, isolated placental cells, wherein at least about 70%), at least about 80%, at least about 90%, at least about 95% or at least about 99% of cells in said population of cells are isolated CD10 + CD33 , CD44 + , CD45 , and CDl IT placental cells.
  • said isolated placental cell or population of isolated placental cells is isolated away from placental cells that are not said cells.
  • said isolated placental cells are non-maternal in origin. In another specific embodiment, at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99% of said placental stem cells in said cell population are non-maternal in origin. In another specific embodiment, said isolated placental stem cells or population of isolated placental stem cells is isolated away from placental cells that do not display these markers.
  • the isolated placental stem cells useful in the methods and compositions described herein are isolated CD10 + CD 13 , CD33 , CD45 , and CD117 " placental stem cells, as detectable by flow cytometry.
  • a cell population useful in the methods and compositions described herein is a population of cells comprising, e.g., enriched for, isolated CD10 + , CD 13 , CD33 , CD45 , and CD117 " placental stem cells, wherein at least about 70%, at least about 80%, at least about 90%, at least about 95% or at least about 99% of cells in said population are CD 10+ CD 13 , CD33 , CD45 , and CD1 IT placental stem cells.
  • said isolated placental stem cells or population of isolated placental stem cells are isolated away from placental cells that are not said placental stem cells.
  • said isolated placental cells are non-maternal in origin.
  • at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%o, 90%), 95%), 98%o or 99%> of said cells in said cell population are non-maternal in origin.
  • said isolated placental stem cells or population of isolated placental stem cells is isolated away from placental cells that do not display these characteristics.
  • the isolated placental stem cells useful in the methods and compositions described herein are HLA A,B,C + , CD45 , CD34 , and CD 133 , and are additionally CD10 + , CD13 + , CD38 + , CD44 + , CD90 + , CD105 + , CD200 + and/or HLA-G , and/or negative for CD117, as detectable by flow cytometry.
  • a cell population useful in the methods described herein is a population of cells comprising isolated placental stem cells, wherein at least about 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or about 99% of the cells in said population are isolated placental stem cells that are HLA A,B,C , CD45 , CD34 , CD 133 , and that are additionally positive for CD10, CD13, CD38, CD44, CD90, CD105, CD200, and/or negative for CD117 and/or HLA-G, as detectable by flow cytometry.
  • said isolated placental stem cells or population of isolated placental stem cells are isolated away from placental cells that are not said placental stem cells.
  • said isolated placental stem cells are non-maternal in origin.
  • at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99% of said placental stem cells in said cell population are non-maternal in origin.
  • said isolated placental stem cells or population of isolated placental stem cells are isolated away from placental cells that do not display these characteristics.
  • the isolated placental stem cells are isolated placental stem cells that are CD200 + and CD10 + , as determined by antibody binding, and CD117 ⁇ , as determined by both antibody binding and RT-PCR.
  • the isolated placental stem cells are isolated placental stem cells that are CD10 + , CD29 , CD54 + , CD200 + , HLA-G , MHC class I + and ⁇ -2 -microglobulin .
  • isolated placental stem cells useful in the methods and compositions described herein are placental stem cells wherein the expression of at least one cellular marker is at least two-fold higher than in an equivalent number of mesenchymal stem cells, e.g., bone marrow-derived mesenchymal stem cells.
  • said isolated placental stem cells are non-maternal in origin.
  • at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%o, 90%), 95%), 98%) or 99%> of said cells in said cell population are non-maternal in origin.
  • the isolated placental stem cells are isolated placental stem cells that are one or more of CD10 + , CD29 + , CD44 + , CD45 , CD54/ICAM + , CD62E , CD62L , CD62P , CD80 , CD86 , CD 103 , CD 104 , CD105 + , CD106/VCAM + , CD144/VE- cadherin low , CD184/CXCR4 , p2-microglobulin low , MHC-I low , MHC- ⁇ , HLA-G low , and/or PDLl low , as detectable by flow cytometry.
  • the isolated placental stem cells are at least CD29 + and CD54 + , as detectable by flow cytometry. In another specific embodiment, the isolated placental stem cells are at least CD44 + and CD106 + , as detectable by flow cytometry. In another specific embodiment, the isolated placental stem cells are at least CD29 + .
  • a cell population useful in the methods and compositions described herein comprises isolated placental stem cells, and at least 50%>, 60%>, 70%>, 80%>, 90%>, 95%, 98% or 99% of the cells in said cell population are isolated placental stem cells that are one or more of CD10 + , CD29 + , CD44 + , CD45 , CD54/ICAM + , CD62-E , CD62-L , CD62-P , CD80 , CD86 , CD 103 , CD 104 , CD105 + , CD106/VCAM + , CD144/VE-cadherin dim , CD184/CXCR4 , P2-microglobulin dim , HLA-I dim , HLA-II , HLA-G dim , and/or PDLl dim placental stem cells, as detectable by flow cytometry.
  • At least 50%, 60%>, 70%>, 80%>, 90%, 95%, 98% or 99% of cells in said cell population are CD10 + , CD29 + , CD44 + , CD45 , CD54/ICAM + , CD62-E , CD62-L , CD62-P , CD80 , CD86 , CD 103 , CD 104 , CD105 + , CD106/VCAM + , CD144/VE-cadherin dim , CD184/CXCR4 , p2-microglobulin dim , MHC-I dim , MHC-ir, HLA-G dim , and PDLl dim placental stem cells, as detectable by flow cytometry.
  • the placental stem cells express HLA-II markers when induced by interferon gamma (IFN- ⁇ ).
  • the isolated placental stem cells useful in the methods and compositions described herein are isolated placental stem cells that are one or more, or all, of CD10 + , CD29 + , CD34 , CD38 , CD44 + , CD45 , CD54 + , CD90 + , SH2 + , SH3 + , SH4 + , SSEA3 , SSEA4 ⁇ , and ABC-p + , as detectable by flow cytometry, where ABC-p is a placenta-specific ABC transporter protein (also known as breast cancer resistance protein (BCRP) or as mitoxantrone resistance protein (MXR)), and OCT-4 + , as detectable by RT-PCR, wherein said isolated placental stem cells are obtained by perfusion of a mammalian, e.g., human, placenta that has been drained of cord blood and perfused to remove residual blood.
  • BCRP breast cancer resistance protein
  • MXR mitoxantrone resistance protein
  • expression of the recited cellular marker(s) is determined by flow cytometry.
  • expression of the marker(s) is determined by RT-PCR.
  • the markers described as detectable by flow cytometry are detectable by any method known in the art, such as, e.g., flow cytometry or surface plasmon resonance.
  • intracellular markers are detectable by any method known in the art such as, e.g., RT-PCR.
  • Gene profiling can be used to confirm that isolated placental stem cells, and populations of isolated placental stem cells, are distinguishable from other cells, e.g.,
  • mesenchymal stem cells e.g., bone marrow-derived mesenchymal stem cells.
  • the isolated placental stem cells described herein can be distinguished from, e.g., bone marrow-derived mesenchymal stem cells on the basis of the expression of one or more genes, the expression of which is specific to placental stem cells or umbilical cord stem cells in comparison to bone marrow-derived mesenchymal stem cells, e.g., the expression of which is significantly higher in the isolated placental stem cells in comparison to bone marrow-derived mesenchymal stem cells.
  • the isolated placental stem cells useful in the methods of treatment provided herein, can be distinguished from bone marrow-derived mesenchymal stem cells on the basis of the expression of one or more genes, the expression of which is detectably higher (e.g. , at least twofold higher, threefold higher, fourfold higher, fivefold higher, or more) in the isolated placental stem cells than in an equivalent number of bone marrow-derived mesenchymal stem cells, wherein the one or more genes are ACTG2, ADARB1, AMIG02, ARTS-1, B4GALT6, BCHE, Cl lorf9, CD200, COL4A1, COL4A2, CPA4, DMD, DSC3, DSG2, ELOVL2, F2RL1, FLJ10781, GATA6, GPR126, GPRC5B, HLA-G, ICAM1, IER3, IGFBP7, ILIA, IL6, IL18, KRT18, KRT8, LIPG, LRAP, MATN2, MEST, NFE2
  • the isolated placental stem cells useful in the methods of treatment provided herein, express genes at a detectably higher level than an equivalent number of bone marrow-derived mesenchymal stem cells; wherein said genes comprise ELOVL2, ST3GAL6, ST6GALNAC5, or SLC12A8.
  • said genes comprise ARTS-1, IER3, IL6, KRT18, LRAP, MEST, NFE2L3, or TGFB2.
  • said genes comprise CPA4, TCF21, VTN, FLJ10781, or NUAK1.
  • said genes comprise CD200.
  • said expression of said one or more genes is determined, e.g., by RT-PCR or microarray analysis, e.g., using a U133-A microarray (Affymetrix).
  • said isolated placental stem cells express said genes at a level detectably higher level than an equivalent number of bone marrow-derived mesenchymal stem cells over about 3 to about 35 population doublings. In a specific embodiment, said isolated placental stem cells express said genes at a level detectably higher level than an equivalent number of bone marrow-derived mesenchymal stem cells over 3 population doublings. In a specific embodiment, said isolated placental stem cells express said genes at a level detectably higher level than an equivalent number of bone marrow-derived mesenchymal stem cells over 11-14 population doublings.
  • said isolated placental stem cells express said genes at a level detectably higher level than an equivalent number of bone marrow-derived mesenchymal stem cells over 24-38 population doublings.
  • said isolated placental stem cells can express said one or more genes when cultured for a number of population doublings, e.g., anywhere from about 3 to about 35 population doublings, in a medium comprising DMEM-LG ⁇ e.g., from Gibco); 2% fetal calf serum ⁇ e.g., from Hyclone Labs.); lx insulin-transferrin-selenium (ITS); lx linoleic acid-bovine serum albumin (LA-BSA); 10 ⁇ 9 M dexamethasone ⁇ e.g., from Sigma); 10 ⁇ 4 M ascorbic acid 2-phosphate ⁇ e.g., from Sigma); epidermal growth factor 10 ng/mL ⁇ e.g., from R
  • NM 018215 FLJ10781
  • AY416799 GATA6
  • BC075798 GPR126
  • NM 016235 GPRC5B
  • AF340038 IGFBP7
  • BC013142 IGFBP7
  • BC007461 IL18
  • BC072017 KRT18
  • BC075839 KRT8
  • BC060825 LIPG
  • BC065240 (LRAP), BC010444 (MATN2), BC011908 (MEST), BC068455 (NFE2L3),
  • NM 014840 NUAK1
  • PCDH7 AB006755
  • NM 014476 PDLIM3
  • BC126199 PDP-2
  • BC090862 RNN1
  • BC002538 SERPINB9
  • BC023312 ST3GAL6
  • said isolated placental stem cells express one or more of ACTG2, ADARBl, AMIG02, ARTS-1, B4GALT6, BCHE, CI lorf9, CD200,
  • said isolated placental stem cells express each of
  • ACTG2 ADARB1, AMIG02, ARTS-1, B4GALT6, BCHE, CI lor®, CD200, COL4A1, COL4A2, CPA4, DMD, DSC3, DSG2, ELOVL2, F2RL1, FLJ10781, GATA6, GPR126, GPRC5B, ICAM1, IER3, IGFBP7, ILIA, IL6, IL18, KRT18, KRT8, LIPG, LRAP, MATN2, MEST, NFE2L3, NUAK1, PCDH7, PDLIM3, PKP2, RTN1, SERPINB9, ST3GAL6,
  • ST6GALNAC5 SLC12A8, TCF21, TGFB2, VTN, and ZC3H12A at a detectably higher level than an equivalent number of bone marrow-derived mesenchymal stem cells, when the cells are grown under equivalent conditions.
  • a population of isolated placental stem cells useful in the methods and compositions described herein express one or more genes at a detectably higher level than a population of bone marrow-derived mesenchymal stem cells, wherein said one or more genes are selected from the group consisting of ACTG2, ADARBl, AMIG02, ARTS-1, B4GALT6, BCHE, Cl lorf9, CD200, COL4A1, COL4A2, CPA4, DMD, DSC3, DSG2, ELOVL2, F2RL1, FLJ10781, GATA6, GPR126, GPRC5B, HLA-G, ICAM1, IER3, IGFBP7, ILIA, IL6, IL18, KRT18, KRT8, LIPG, LRAP, MATN2, MEST, NFE2L3, NUAK1, PCDH7, PDLIM3, PKP2, RTN1, SERPINB9, ST3GAL6, ST6GALNAC5, SLC12A8, TCF21
  • the population of isolated placental stem cells expresses ACTG2, ADARBl, AMIG02, ARTS-1, B4GALT6, BCHE, Cl lorf9, CD200, COL4A1, COL4A2, CPA4, DMD, DSC3, DSG2, ELOVL2, F2RL1, FLJ10781, GATA6, GPR126, GPRC5B, HLA- G, ICAM1, IER3, IGFBP7, ILIA, IL6, IL18, KRT18, KRT8, LIPG, LRAP, MATN2, MEST, NFE2L3, NUAK1, PCDH7, PDLIM3, PKP2, RTN1, SERPINB9, ST3GAL6, ST6GALNAC5, SLC12A8, TCF21, TGFB2, VTN, and ZC3H12A at a detectably higher level than said population of isolated bone marrow-derived mesenchymal stem cells.
  • the placental stem cells express CD200 and ARTS1
  • ARTS-1 and LRAP leukocyte- derived arginine aminopeptidase
  • IL6 interleukin-6
  • TGFB2 transforming growth factor, beta 2
  • IL6 and KRT18 keratin 18
  • IER3 immediate early response 3
  • MEST mesoderm specific transcript homolog
  • TGFB2 CD200 and IER3
  • CD200 and IL6 CD200 and KRT18
  • CD200 and LRAP CD200 and MEST
  • CD200 and NFE2L3 nuclear factor (erythroid- derived 2)-like 3
  • CD200 and TGFB2 at a detectably higher level than an equivalent number of bone marrow-derived mesenchymal stem cells wherein said bone marrow-derived
  • mesenchymal stem cells have undergone a number of passages in culture equivalent to the number of passages said isolated placental stem cells have undergone.
  • the placental stem cells express ARTS-1, CD200, IL6 and LRAP; ARTS-1, IL6, TGFB2, IER3, KRT18 and MEST; CD200, IER3, IL6, KRT18, LRAP, MEST, NFE2L3, and TGFB2; ARTS-1, CD200, IER3, IL6, KRT18, LRAP, MEST, NFE2L3, and TGFB2; or IER3, MEST and TGFB2 at a detectably higher level than an equivalent number of bone marrow- derived mesenchymal stem cells, wherein said bone marrow-derived mesenchymal stem cells have undergone a number of passages in culture equivalent to the number of passages said isolated placental stem cells have undergone.
  • Expression of the above-referenced genes can be assessed by standard techniques. For example, probes based on the sequence of the gene(s) can be individually selected and constructed by conventional techniques. Expression of the genes can be assessed, e.g., on a microarray comprising probes to one or more of the genes, e.g., an Affymetrix GENECHIP® Human Genome U133A 2.0 array, or an Affymetrix GENECHIP® Human Genome U133 Plus 2.0 (Santa Clara, California). Expression of these genes can be assessed even if the sequence for a particular GenBank accession number is amended because probes specific for the amended sequence can readily be generated using well-known standard techniques.
  • the level of expression of these genes can be used to confirm the identity of a population of isolated placental stem cells, to identify a population of cells as comprising at least a plurality of isolated placental stem cells, or the like.
  • Populations of isolated placental stem cells, the identity of which is confirmed can be clonal, e.g., populations of isolated placental stem cells expanded from a single isolated placental stem cells, or a mixed population of placental stem cells, e.g., a population of cells comprising isolated placental stem cells that are expanded from multiple isolated placental stem cells, or a population of cells comprising isolated placental stem cells, as described herein, and at least one other type of cell.
  • the level of expression of these genes can be used to select populations of isolated placental stem cells. For example, a population of cells, e.g., clonally-expanded placental stem cells, may be selected if the expression of one or more of the genes listed above is significantly higher in a sample from the population of cells than in an equivalent population of bone marrow-derived mesenchymal stem cells. Such selecting can be of a population from a plurality of isolated placental stem cell populations, from a plurality of cell populations, the identity of which is not known, etc.
  • Isolated placental stem cells can be selected on the basis of the level of expression of one or more such genes as compared to the level of expression in said one or more genes in, e.g., a bone marrow-derived mesenchymal stem cell control.
  • the level of expression of said one or more genes in a sample comprising an equivalent number of bone marrow-derived mesenchymal stem cells is used as a control.
  • the control, for isolated placental stem cells tested under certain conditions is a numeric value representing the level of expression of said one or more genes in bone marrow-derived mesenchymal stem cells under said conditions.
  • a method for selecting isolated placental stem cells or populations of isolated placental stem cells on the basis of gene expression of one or more genes comprises selecting cells that express one or more genes at a detectably higher level than a bone marrow-derived mesenchymal stem cell, wherein said one or more genes are selected from the group consisting of ACTG2, ADARB1, AMIG02, ARTS-1, B4GALT6, BCHE, Cl lorf9, CD200, COL4A1, COL4A2, CPA4, DMD, DSC3, DSG2, ELOVL2, F2RL1, FLJ10781, GATA6, GPR126, GPRC5B, HLA-G, ICAM1, IER3, IGFBP7, ILIA, IL6, IL18, KRT18, KRT8, LIPG, LRAP, MATN2, MEST, NFE2L3, NUAK1, PCDH7, PDLIM3, PKP2, RTN1, SERPINB9, ST3GAL6,
  • said selecting comprises selecting cells that express ACTG2, ADARB1, AMIG02, ARTS-1, B4GALT6, BCHE, Cl lorf9, CD200, COL4A1, COL4A2, CPA4, DMD, DSC3, DSG2, ELOVL2, F2RL1, FLJ10781, GATA6, GPR126, GPRC5B, HLA- G, ICAM1, IER3, IGFBP7, ILIA, IL6, IL18, KRT18, KRT8, LIPG, LRAP, MATN2, MEST, NFE2L3, NUAK1, PCDH7, PDLIM3, PKP2, RTN1, SERPINB9, ST3GAL6, ST6GALNAC5, SLC12A8, TCF21, TGFB2, VTN and ZC3H12A at
  • the isolated placental stem cells described herein can display the above characteristics (e.g., combinations of cell surface markers and/or gene expression profiles) in primary culture, or during culture in medium comprising, e.g., DMEM-LG (Gibco), 2% fetal calf serum (FCS) (Hyclone Laboratories), lx insulin-transferrin-selenium (ITS), lx linoleic-acid- bovine-serum-albumin (LA-BSA), 10 ⁇ 9 M dexamethasone (Sigma), 10 ⁇ 4 M ascorbic acid 2- phosphate (Sigma), epidermal growth factor (EGF) 10 ng/ml (R&D Systems), platelet derived- growth factor (PDGF-BB) 10 ng/ml (R&D Systems), and 100U penicillin/ 1000U streptomycin.
  • DMEM-LG Gibco
  • FCS 2% fetal calf serum
  • ITS insulin-transferrin-
  • the cells are human.
  • the cellular marker characteristics or gene expression characteristics are human markers or human genes.
  • the isolated placental stem cells or populations of cells comprising the isolated placental stem cells said cells or population have been expanded, for example, passaged at least, about, or no more than, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 times, or proliferated for at least, about, or no more than, 1, 2, 3, 4, 5, 6,
  • the isolated placental stem cells or populations of cells comprising the isolated placental stem cells said cells or population have been passaged at least, about, or no more than 3 times, 4 times, 5 times, or 6 times. In a specific embodiment of the isolated placental stem cells or populations of cells comprising the isolated placental stem cells, said cells or population have been passaged at least, about, or no more than 3-10 times, 4-8 times, or 5-7 times.
  • the isolated placental stem cells or populations of cells comprising the isolated placental stem cells said cells or population have been proliferated for at least, about, or no more than, 2, 3, 4, 5, or 6 population doublings. In a specific embodiment of the isolated placental stem cells or populations of cells comprising the isolated placental stem cells, said cells or population have been proliferated for at least, about, or no more than, 3-10, 4-
  • the isolated placental stem cells or populations of cells comprising the isolated placental stem cells said cells or population have been proliferated for at least, about, or no more than, 6-10, 11-14, 15-30, 30-45, or 18-26, or 24- 38 population doublings.
  • said isolated placental stem cells or populations of cells comprising the isolated placental stem cells said cells or population are primary isolates.
  • said isolated placental stem cells are fetal in origin (that is, have the fetal genotype).
  • said isolated placental stem cells do not differentiate during culturing in growth medium, i.e., medium formulated to promote proliferation, e.g., during proliferation in growth medium.
  • said isolated placental stem cells do not require a feeder layer in order to proliferate.
  • said isolated placental stem cells do not differentiate in culture in the absence of a feeder layer, solely because of the lack of a feeder cell layer.
  • the isolated placental cells are positive for aldehyde dehydrogenase (ALDH), as assessed by an aldehyde dehydrogenase activity assay.
  • ALDH aldehyde dehydrogenase
  • said ALDH assay uses ALDEFLUOR® (Aldagen, Inc., Ashland, Oregon) as a marker of aldehyde dehydrogenase activity.
  • ALDEFLUOR® Aldagen, Inc., Ashland, Oregon
  • placental stem cells are positive for ALDH.
  • said isolated placental stem cells show at least three-fold, or at least five-fold, higher ALDH activity than a population of bone marrow-derived mesenchymal stem cells having about the same number of cells and cultured under the same conditions.
  • the placental stem cells in said populations of cells are substantially free of cells having a maternal genotype; e.g., at least 40%, 45%, 50%>, 55%, 60%>, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% of the placental stem cells in said population have a fetal genotype.
  • the populations of cells comprising said placental stem cells are substantially free of cells having a maternal genotype; e.g., at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99% of the cells in said population have a fetal genotype.
  • the karyotype of the cells e.g., all of the cells, or at least about 95% or about 99% of the cells in said population, is normal.
  • the placental stem cells are non-maternal in origin.
  • the placental cells are genetically stable, displaying a normal diploid chromosome count and a normal karyotype.
  • Isolated placental stem cells or populations of isolated placental stem cells, bearing any of the above combinations of markers, can be combined in any ratio. Any two or more of the above isolated placental stem cell populations can be combined to form an isolated placental stem cell population.
  • a population of isolated placental stem cells can comprise a first population of isolated placental stem cells defined by one of the marker combinations described above, and a second population of isolated placental stem cells defined by another of the marker combinations described above, wherein said first and second populations are combined in a ratio of about 1 :99, 2:98, 3:97, 4:96, 5:95, 10:90, 20:80, 30:70, 40:60, 50:50, 60:40, 70:30, 80:20, 90: 10, 95:5, 96:4, 97:3, 98:2, or about 99: 1.
  • any three, four, five or more of the above-described isolated placental stem cells or isolated placental stem cell populations can be combined.
  • Isolated placental stem cells useful in the methods and compositions described herein can be obtained, e.g., by disruption of placental tissue, with or without enzymatic digestion ⁇ see Section 5.5.3) or perfusion ⁇ see Section 5.5.4).
  • populations of isolated placental stem cells can be produced according to a method comprising perfusing a mammalian placenta that has been drained of cord blood and perfused to remove residual blood; perfusing said placenta with a perfusion solution; and collecting said perfusion solution, wherein said perfusion solution after perfusion comprises a population of placental cells that comprises isolated placental stem cells; and isolating said placental stem cells from said population of cells.
  • the perfusion solution is passed through both the umbilical vein and umbilical arteries and collected after it exudes from the placenta.
  • the perfusion solution is passed through the umbilical vein and collected from the umbilical arteries, or passed through the umbilical arteries and collected from the umbilical vein.
  • the isolated placental stem cells contained within a population of cells obtained from perfusion of a placenta, are at least 50%, 60%, 70%>, 80%>, 90%), 95%o, 99%), or at least 99.5% of said population of placental stem cells.
  • the isolated placental stem cells collected by perfusion comprise fetal and maternal cells.
  • the isolated placental stem cells collected by perfusion are at least 50%, 60%, 70%, 80%, 90%, 95%, 99%, or at least 99.5% fetal cells.
  • composition comprising a population of the isolated placental stem cells, as described herein, collected (isolated) by perfusion, wherein said composition comprises at least a portion of the perfusion solution used to isolate the placental stem cells.
  • Populations of the isolated placental stem cells described herein can be produced by digesting placental tissue with a tissue-disrupting enzyme to obtain a population of placental cells comprising the placental stem cells, and isolating, or substantially isolating, a plurality of the placental stem cells from the remainder of said placental cells.
  • the whole, or any part of, the placenta can be digested to obtain the isolated placental stem cells described herein.
  • said placental tissue can be a whole placenta (e.g., including an umbilical cord), an amniotic membrane, chorion, a combination of amnion and chorion, or a combination of any of the foregoing.
  • the tissue-disrupting enzyme is trypsin or collagenase.
  • the isolated placental stem cells, contained within a population of cells obtained from digesting a placenta are at least 50%, 60%, 70%, 80%, 90%, 95%, 99%, or at least 99.5% of said population of placental cells.
  • the populations of isolated placental stem cells described above, and populations of isolated placental stem cells generally, can comprise about, at least, or no more than, 1 x 10 5 , 5 x 10 5 , 1 x 10 6 , 5 x 10 6 , 1 x 10 7 , 5 x 10 7 , 1 x 10 8 , 5 x 10 8 , 1 x 10 9 , 5 x 10 9 , 1 x 10 10 , 5 x 10 10 , 1 x 10 11 or more of the isolated placental stem cells.
  • Populations of isolated placental stem cells useful in the methods of treatment described herein comprise at least 50%>, 55%, 60%>, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% viable isolated placental stem cells, e.g., as determined by, e.g., trypan blue exclusion.
  • the cells or population of placental stem cells are, or can comprise, cells that have been passaged at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, or 20 times, or more, or expanded for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, or 40 population doublings, or more.
  • the karyotype of the cells, or at least about 95% or about 99% of the cells in said population is normal.
  • the cells, or cells in the population of cells are non- maternal in origin.
  • Isolated placental stem cells, or populations of isolated placental stem cells, bearing any of the above combinations of markers, can be combined in any ratio. Any two or more of the above placental stem cell populations can be isolated, or enriched, to form a placental stem cell population.
  • a population of isolated placental stem cells comprising a first population of placental stem cells defined by one of the marker combinations described above can be combined with a second population of placental stem cells defined by another of the marker combinations described above, wherein said first and second populations are combined in a ratio of about 1 :99, 2:98, 3:97, 4:96, 5:95, 10:90, 20:80, 30:70, 40:60, 50:50, 60:40, 70:30, 80:20, 90: 10, 95:5, 96:4, 97:3, 98:2, or about 99: 1.
  • any three, four, five or more of the above-described placental stem cells or placental stem cell populations can be combined.
  • the placental stem cells constitutively secrete IL-6, IL-8 and monocyte chemoattractant protein (MCP-1).
  • the populations of placental cells described above can comprise about, at least, or no more than, 1 x 10 5 , 5 x 10 5 , 1 x 10 6 , 5 x 10 6 , 1 x 10 7 , 5 x 10 7 , 1 x 10 8 , 5 x 10 8 , 1 x 10 9 , 5 x 10 9 , 1 x 10 10 , 5 x 10 10 , 1 x 10 11 or more placental stem cells.
  • the placental stem cells useful in the methods provided herein do not express CD34, as detected by immuno localization, after exposure to 1 to 100 ng/mL VEGF for 4 to 21 days.
  • said placental stem cells are adherent to tissue culture plastic.
  • said placental stem cells induce endothelial cells to form sprouts or tube-like structures, e.g., when cultured in the presence of an angiogenic factor such as vascular endothelial growth factor (VEGF), epithelial growth factor (EGF), platelet derived growth factor (PDGF) or basic fibroblast growth factor (bFGF), e.g., on a substrate such as MATRIGELTM.
  • VEGF vascular endothelial growth factor
  • EGF epithelial growth factor
  • PDGF platelet derived growth factor
  • bFGF basic fibroblast growth factor
  • the placental stem cells provided herein, or a population of cells e.g., a population of placental stem cells, or a population of cells wherein at least about 50%, 60%, 70%, 80%, 90%, 95% or 98% of cells in said population of cells are placental stem cells, secrete one or more, or all, of VEGF, HGF, IL-8, MCP-3, FGF2, follistatin, G-CSF, EGF, ENA-78, GRO, IL-6, MCP-1 , PDGF-BB, TIMP-2, uPAR, or galectin-1 , e.g., into culture medium in which the cell, or cells, are grown.
  • the placental stem cells express increased levels of CD202b, IL-8 and/or VEGF under hypoxic conditions (e.g., less than about 5% 0 2 ) compared to normoxic conditions (e.g., about 20%> or about 21 > 02).
  • any of the placental stem cells or populations of cells comprising placental stem cells described herein can cause the formation of sprouts or tube-like structures in a population of endothelial cells in contact with or proximity to said placental stem cells.
  • the placental stem cells are co-cultured with human endothelial cells, which form sprouts or tube-like structures, or support the formation of endothelial cell sprouts, e.g., when cultured in the presence of extracellular matrix proteins such as collagen type I and IV, and/or angiogenic factors such as vascular endothelial growth factor (VEGF), epithelial growth factor (EGF), platelet derived growth factor (PDGF) or basic fibroblast growth factor (bFGF), e.g., in or on a substrate such as placental collagen or MATRIGELTM for at least 4 days.
  • VEGF vascular endothelial growth factor
  • EGF epithelial growth factor
  • PDGF platelet derived growth factor
  • bFGF basic fibroblast growth factor
  • any of the populations of cells comprising placental stem cells, described herein secrete angiogenic factors such as vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), platelet derived growth factor (PDGF), basic fibroblast growth factor (bFGF), or Interleukin-8 (IL-8) and thereby can induce human endothelial cells to form sprouts or tube-like structures when cultured in the presence of extracellular matrix proteins such as collagen type I and IV e.g., in or on a substrate such as placental collagen or MATRIGELTM.
  • VEGF vascular endothelial growth factor
  • HGF hepatocyte growth factor
  • PDGF platelet derived growth factor
  • bFGF basic fibroblast growth factor
  • IL-8 Interleukin-8
  • any of the above populations of cells comprising placental stem cells secretes angiogenic factors.
  • the population of cells secretes vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), platelet derived growth factor (PDGF), basic fibroblast growth factor (bFGF), and/or interleukin-8 (IL- 8).
  • VEGF vascular endothelial growth factor
  • HGF hepatocyte growth factor
  • PDGF platelet derived growth factor
  • bFGF basic fibroblast growth factor
  • IL-8 interleukin-8
  • the population of cells comprising placental stem cells secretes one or more angiogenic factors and thereby induces human endothelial cells to migrate in an in vitro wound healing assay.
  • the population of cells comprising placental stem cells induces maturation, differentiation or proliferation of human endothelial cells, endothelial progenitors, myocytes or myoblasts.
  • populations of placental stem cells can be selected, wherein the population is immunosuppressive.
  • the population is immunosuppressive.
  • immunosuppressive placental stem cells can be selected from a plurality of placental cells, comprising selecting a population of placental cells wherein at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95% of said cells are CD10 + , CD34 , CD105 + placental stem cells, CD10 + , CD34 , CD200 + placental stem cells, or CD10 + , CD34 , CD105 + , CD200 + placental stem cells, and wherein said placental stem cells detectably suppress T cell proliferation in a mixed lymphocyte reaction (MLR) assay.
  • said selecting comprises selecting placental stem cells that are also CD45 and CD90 + .
  • a method of selecting a plurality of immunosuppressive placental stem cells from a plurality of placental cells comprising selecting a population of placental stem cells wherein at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95% of said cells are CD200 + , HLA-G- placental stem cells, and wherein said placental stem cells detectably suppress T cell proliferation in a mixed lymphocyte reaction (MLR) assay.
  • said selecting comprises selecting placental stem cells that are also CD73 + and CD105 + .
  • said selecting comprises selecting placental stem cells that are also CD34 , CD38 or CD45 . In another specific embodiment, said selecting comprises selecting placental stem cells that are also CD34 , CD38 , CD45 , CD73 + and CD105 + . In another specific embodiment, said selecting also comprises selecting a plurality of placental cells, e.g., the placental stem cells described above, that forms one or more embryoid-like bodies when cultured under conditions that allow the formation of embryoid-like bodies.
  • a method of selecting a plurality of immunosuppressive placental stem cells from a plurality of placental cells comprising selecting a plurality of placental cells wherein at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95% of said cells are CD73 , CD 105 , CD200 placental stem cells, and wherein said placental cells detectably suppress T cell proliferation in a mixed lymphocyte reaction (MLR) assay.
  • said selecting comprises selecting placental stem cells that are also HLA-G .
  • said selecting comprises selecting placental stem cells that are also CD34 , CD38 or CD45 . In another specific embodiment, said selecting comprises selecting placental stem cells that are also CD34 , CD38 and CD45 . In another specific embodiment, said selecting comprises selecting placental stem cells that are also CD34 , CD38 , CD45 , and HLA-G . In another specific embodiment, said selecting additionally comprises selecting a population of placental stem cells that produces one or more embryoid-like bodies when the population is cultured under conditions that allow the formation of embryoid-like bodies.
  • a method of selecting a plurality of immunosuppressive placental stem cells from a plurality of placental cells comprising selecting a plurality of placental cells wherein at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95% of said cells are CD200 + , OCT-4 + placental stem cells, and wherein said placental cells detectably suppress T cell proliferation in a mixed lymphocyte reaction (MLR) assay.
  • said selecting comprises selecting placental stem cells that are also CD73 + and CD105 + .
  • said selecting comprises selecting placental stem cells that are also HLA-G . In another specific embodiment, said selecting comprises selecting placental stem cells that are also CD34 , CD38 and CD45 . In another specific embodiment, said selecting comprises selecting placental stem cells that are also CD34 , CD38 , CD45 , CD73 + , CD105 + and HLA-G .
  • a method of selecting a plurality of immunosuppressive placental stem cells from a plurality of placental cells comprising selecting a plurality of placental cells wherein at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95% of said cells are CD73 + , CD105 + and HLA-G- placental stem cells, and wherein said placental cells detectably suppress T cell proliferation in a mixed lymphocyte reaction (MLR) assay.
  • said selecting comprises selecting placental stem cells that are also CD34 , CD38 or CD45 .
  • said selecting comprises selecting placental stem cells that are also CD34 , CD38 and CD45 . In another specific embodiment, said selecting comprises selecting placental stem cells that are also CD200 . In another specific embodiment, said selecting comprises selecting placental stem cells that are also CD34 , CD38 , CD45 , OCT- 4 + and CD200 + .
  • a method of selecting a plurality of immunosuppressive placental stem cells from a plurality of placental cells comprising selecting a plurality of placental cells wherein at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95% of said cells are CD73 + , CD105 + placental stem cells, and wherein said plurality forms one or more embryoid-like bodies under conditions that allow formation of embryoid-like bodies.
  • said selecting comprises selecting placental stem cells that are also CD34 , CD38 or CD45 .
  • said selecting comprises selecting placental stem cells that are also CD34 , CD38 and CD45 . In another specific embodiment, said selecting comprises selecting placental stem cells that are also OCT-4 + . In a more specific embodiment, said selecting comprises selecting placental stem cells that are also OCT-4 + , CD34 , CD38 and CD45 .
  • a method of selecting a plurality of immunosuppressive placental stem cells from a plurality of placental cells comprising selecting a plurality of placental stem cells wherein at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95% of said isolated placental cells are OCT4 + placental stem cells, and wherein said plurality forms one or more embryoid-like bodies under conditions that allow formation of embryoid-like bodies.
  • said selecting comprises selecting placental stem cells that are also CD73 + and CD105 + .
  • said selecting comprises selecting placental stem cells that are also CD34 , CD38 , or CD45 . In another specific embodiment, said selecting comprises selecting placental stem cells that are also CD200 . In a more specific embodiment, said selecting comprises selecting placental stem cells that are also CD73 + , CD105 + , CD200 + , CD34 , CD38 , and CD45 .
  • Immunosuppressive populations, or pluralities, of placental cells can be produced according to the methods provided herein.
  • method of producing a cell population comprising selecting any of the pluralities of placental stem cells described above, and isolating the plurality of placental cells from other cells, e.g., other placental cells.
  • a method of producing a cell population comprising selecting placental stem cells, wherein said placental stem cells (a) adhere to a substrate; (b) express CD200 and do not express HLA-G; or express CD73, CD 105, and CD200; or express CD200 and OCT-4; or express CD73, CD 105, and do not express HLA-G; or express CD73 and CD 105 and facilitate the formation of one or more embryoid-like bodies in a population of placental cells that comprise the placental stem cells, when said population is cultured under conditions that allow formation of embryoid-like bodies; or express OCT-4 and facilitate the formation of one or more embryoid-like bodies in a population of placental cells that comprise the placental stem cells, when said population is cultured under conditions that allow formation of embryoid-like bodies; and (c) detectably suppress CD4 + or CD8 + T cell proliferation in an MLR (mixed lymphocyte reaction) or regression assay; and selecting said placental stem cells (a) adhere to a
  • immunosuppressive placental stem cell populations can be produced by a method comprising selecting placental stem cells that (a) adhere to a substrate, (b) express CD200 and do not express HLA-G, and (c) detectably suppress CD4 + or CD8 T cell proliferation in an MLR (mixed lymphocyte reaction); and isolating said placental stem cells from other cells to form a cell population.
  • the method comprises selecting placental stem cells that (a) adhere to a substrate, (b) express CD73, CD 105, and CD200, and (c) detectably suppress CD4 + or CD8 + T cell proliferation in an MLR; and isolating said placental stem cells from other cells to form a cell population.
  • a method of producing a cell population comprising selecting placental stem cells that (a) adhere to a substrate, (b) express CD200 and OCT-4, and (c) detectably suppress CD4 + or CD8 + T cell proliferation in an MLR; and isolating said placental stem cells from other cells to form a cell population.
  • a method of producing a cell population comprising selecting placental stem cells that (a) adhere to a substrate, (b) express CD73 and CD 105, (c) form embryoid-like bodies when cultured under conditions allowing the formation of embryoid-like bodies, and (d) detectably suppress CD4 + or CD8 + T cell proliferation in an MLR; and isolating said placental stem cells from other cells to form a cell population.
  • the method comprises selecting placental stem cells that (a) adhere to a substrate, (b) express CD73 and CD 105, and do not express HLA-G, and (c) detectably suppress CD4 + or CD8 T cell proliferation in an MLR; and isolating said placental stem cells from other cells to form a cell population.
  • the method comprises selecting placental stem cells that (a) adhere to a substrate, (b) express OCT-4, (c) form embryoid-like bodies when cultured under conditions allowing the formation of embryoid-like bodies, and (d) detectably suppress CD4 + or CD8 + T cell proliferation in an MLR; and isolating said placental cells from other cells to form a cell population.
  • said T cells and said placental stem cells are present in said MLR at a ratio of about 5: 1.
  • the placental stem cells used in the method can be derived from the whole placenta, or primarily from amnion, or amnion and chorion.
  • the placental stem cells suppress CD4 + or CD8 + T cell proliferation by at least 50%, at least 75%, at least 90%, or at least 95% in said MLR compared to an amount of T cell proliferation in said MLR in the absence of said placental stem cells.
  • the method can additionally comprise the selection and/or production of a placental stem cell population capable of immunomodulation, e.g., suppression of the activity of, other immune cells, e.g., an activity of a natural killer (NK) cell.
  • NK natural killer
  • placental stem cells e.g., the placental stem cells described herein, as for any mammalian cell
  • placental stem cells typically double in number in 3-5 days.
  • the placental stem cells provided herein adhere to a substrate in culture, e.g. the surface of a tissue culture container ⁇ e.g., tissue culture dish plastic, fibronectin-coated plastic, and the like) and form a monolayer.
  • Mesenchymal stem cells e.g., bone marrow-derived mesenchymal stem cells, do not develop embryoid-like bodies in culture. 5.3.5 Differentiation
  • the placental cells useful in the methods of treatment provided herein, in certain embodiments are differentiable into different committed cell lineages.
  • the placental cells can be differentiated into cells of an adipogenic, chondrogenic, neurogenic, or osteogenic lineage.
  • Such differentiation can be accomplished, e.g., by any method known in the art for differentiating, e.g., bone marrow-derived mesenchymal stem cells into similar cell lineages, or by methods described elsewhere herein.
  • Specific methods of differentiating placental cells into particular cell lineages are disclosed in, e.g., U.S. Patent Nos. 7,311,905 and 8,057,788, the disclosures of which are hereby incorporated by reference in their entireties.
  • the placental stem cells provided herein can exhibit the capacity to differentiate into a particular cell lineage in vitro, in vivo, or in vitro and in vivo.
  • the placental stem cells provided herein can be differentiated in vitro when placed in conditions that cause or promote differentiation into a particular cell lineage, but do not detectably differentiate in vivo, e.g., in a NOD-SCID mouse model.
  • placental stem cells can be used to ameliorate inflammation associated with, or causative of, schizophrenia, Alzheimer's disease, or
  • Huntington's disease Provided herein is a method for the treatment of schizophrenia
  • Alzheimer's disease, or Huntington's disease in an individual comprising contacting immune cell(s) in the individual with an effective amount of placental stem cells, wherein said effective amount is an amount that (1) detectably suppresses an immune response in said individual, and
  • said placental stem cells detectably suppress T cell proliferation in a mixed lymphocyte reaction (MLR) assay or a regression assay.
  • MLR mixed lymphocyte reaction
  • the contacting can be accomplished by, e.g., administering the placental stem cells to the individual, e.g., locally, systemically, or both.
  • a method for the treatment of schizophrenia, Alzheimer's disease, or Huntington's disease in an individual comprising contacting immune cell(s) in the individual with an effective amount of placental stem cells, wherein said effective amount is an amount that (1) detectably suppresses an immune response in said individual, and (2) detectably reduces one or more symptoms of schizophrenia, Alzheimer's disease, or Huntington's disease in said individual.
  • an "immune cell” in the context of this method means any cell of the immune system, particularly T cells and NK (natural killer) cells.
  • placental stem cells are contacted with a plurality of immune cells, wherein the plurality of immune cells are, or comprises, a plurality of T cells (e.g., a plurality of CD3 + T cells, CD4 + T cells and/or CD8 + T cells) and/or natural killer cells.
  • An "immune response" in the context of the method can be any response by an immune cell to a stimulus normally perceived by an immune cell, e.g., a response to the presence of an antigen.
  • an immune response can be the proliferation of T cells (e.g., CD3 + T cells, CD4 + T cells and/or CD8 + T cells) in response to a foreign antigen, such as an antigen present in a transfusion or graft, or to a self-antigen, as in an autoimmune disease.
  • the immune response can also be a proliferation of T cells contained within a graft.
  • the immune response can also be any activity of a natural killer (NK) cell, the maturation of a dendritic cell, or the like.
  • NK natural killer
  • Huntington's disease e.g., by reduction of inflammation
  • said contacting is sufficient to suppress an immune function (e.g., T cell proliferation in response to an antigen) or inflammation in an individual having schizophrenia, Alzheimer's disease, or Huntington's disease by at least 50%, 60%>, 70%>, 80%, 90% or 95%, compared to the immune function in the absence of the placental stem cells.
  • an immune function e.g., T cell proliferation in response to an antigen
  • Such suppression in an in vivo context can be determined in an in vitro assay (see below) using, e.g., a sample of T cells from the individual; that is, the degree of suppression in the in vitro assay can be extrapolated, for a particular number of placental stem cells and a number of immune cells in a recipient individual, to a degree of suppression in the individual.
  • Placental stem cells can be tested, e.g., in an MLR comprising combining CD4 + or CD8 + T cells, dendritic cells (DC) and placental stem cells in a ratio of about 10: 1 :2, wherein the T cells are stained with a dye such as, e.g., CFSE that partitions into daughter cells, and wherein the T cells are allowed to proliferate for about 6 days.
  • the T cells and/or DC cells can be obtained from the individual to be treated, e.g., can be autologous to the individual, or can be allogeneic to the individual.
  • placental stem cells are immunosuppressive if the T cell proliferation at 6 days in the presence of placental stem cells is detectably reduced compared to T cell proliferation in the presence of DC and absence of placental stem cells.
  • placental stem cells can be either thawed or harvested from culture. About 20,000 placental stem cells are resuspended in 100 ⁇ of medium (RPMI 1640, 1 mM HEPES buffer, antibiotics, and 5% pooled human serum), and allowed to attach to the bottom of a well for 2 hours.
  • CD4 + and/or CD8 T cells are isolated from whole peripheral blood mononuclear cells Miltenyi magnetic beads.
  • the cells are CFSE stained, and a total of 100,000 T cells (CD4 + T cells alone, CD8 + T cells alone, or equal amounts of CD4 + and CD8 + T cells) are added per well. The volume in the well is brought to 200 ⁇ 1, and the MLR is allowed to proceed.
  • the anti-inflammatory activity (i.e., immunosuppressive activity) of the placental stem cells is determined prior to administration to the individual having schizophrenia, Alzheimer's disease, or Huntington's disease. This can be accomplished, for example, by determining the immunosuppressive activity of a sample of the placental stem cells to be administered for treatment of schizophrenia, Alzheimer's disease, or Huntington's disease. Such an activity can be determined, for example, by testing a sample of the placental stem cells or placental stem cells in, e.g., an MLR or regression assay. In one embodiment, an MLR is performed with the sample, and a degree of immunosuppression demonstrated by the sample placental stem cells in the assay is determined.
  • the degree of reduction of a symptom of schizophrenia, Alzheimer's disease, or Huntington's disease is expected to correlate with the immunosuppressive activity of the sampled placental stem cells.
  • the MLR can be used as a method of determining the absolute and relative ability of a particular population of placental stem cells to treat schizophrenia, Alzheimer's disease, or Huntington's disease.
  • the parameters of the MLR can be varied to provide more data or to best determine the capacity of a sample of a population of placental stem cells to immunosuppress, and therefore the capacity of the population of placental stem cells to treat schizophrenia, Alzheimer's disease, or Huntington's disease.
  • the MLR can be performed with, in one embodiment, two or more numbers of placental stem cells, e.g., 1 x 10 3 , 3 x 10 3 , 1 x 10 4 and/or 3 x 10 4 placental stem cells per reaction.
  • placental stem cells and T cells in the assay can be present in any ratio of, e.g. about 10: 1 to about 1 : 10, preferably about 1 :5, though a relatively greater number of placental stem cells or T cells can be used.
  • regression assay or BTR assay can be used in similar fashion.
  • Placental stem cells can be administered to an individual in a ratio, with respect to a known or expected number of immune cells, e.g., T cells, in the individual, of from about 10: 1 to about 1 : 10, preferably about 1 :5.
  • placental stem cells can be administered to an individual in a ratio of, in non- limiting examples, about 10,000: 1, about 1,000: 1, about 100: 1, about 10: 1, about 1 : 1, about 1 : 10, about 1 : 100, about 1 :1 ,000 or about 1 : 10,000.
  • placental stem cells administered to an individual or subject comprise at least, about, or no more than, 1 x 10 5 , 3 x 10 5 , 1 x 10 6 , 3 x 10 6 , 1 x 10 7 , 3 x 10 7 , 1 x 10 8 , 3 x 10 8 , 1 x 10 9 , 3 x 10 9 placental stem cells, or more.
  • the placental stem cells can also be administered with one or more second types of stem cells, e.g., mesenchymal stem cells from bone marrow.
  • Such second stem cells can be administered to an individual with said placental stem cells in a ratio of, e.g., between about 1 : 10 to about 10: 1.
  • the placental stem cells can be administered to an individual by any route sufficient to bring the placental stem cells and immune cells into contact with each other.
  • the placental stem cells can be administered to the individual, e.g., intravenously, intramuscularly, intraperitoneally, intraocularly, parenterally, intrathecally, or directly into an organ, e.g., pancreas.
  • the placental stem cells can be formulated as a pharmaceutical composition as described below.
  • the placental stem cells administered to the individual having schizophrenia, Alzheimer's disease, or Huntington's disease have been genetically engineered to express one or more anti-inflammatory cytokines.
  • said antiinflammatory cytokines comprise IL-10.
  • Placental stem cells can be collected and isolated according to the methods provided herein or in any other method known in the art. Generally, placental stem cells are obtained from a mammalian placenta using a physiologically-acceptable solution, e.g., a stem cell collection composition.
  • a stem cell collection composition is described in detail in related U.S. Provisional Application No. 60/754,969, entitled "Improved Composition for Collecting and Preserving Placental cells and Methods of Using the Composition” filed on December 29, 2005.
  • the stem cell collection composition can comprise any physiologically-acceptable solution suitable for the collection and/or culture of stem cells, for example, a saline solution (e.g., phosphate-buffered saline, Kreb's solution, modified Kreb's solution, Eagle's solution, 0.9% NaCl, etc.), a culture medium (e.g., DMEM, HDMEM, etc.), and the like.
  • a saline solution e.g., phosphate-buffered saline, Kreb's solution, modified Kreb's solution, Eagle's solution, 0.9% NaCl, etc.
  • a culture medium e.g., DMEM, HDMEM, etc.
  • the stem cell collection composition can comprise one or more components that tend to preserve placental stem cells, that is, prevent the placental stem cells from dying, or delay the death of the placental stem cells, reduce the number of placental stem cells in a population of cells that die, or the like, from the time of collection to the time of culturing.
  • Such components can be, e.g., an apoptosis inhibitor (e.g., a caspase inhibitor or JNK inhibitor); a vasodilator (e.g., magnesium sulfate, an antihypertensive drug, atrial natriuretic peptide (ANP),
  • adrenocorticotropin corticotropin-releasing hormone, sodium nitroprusside, hydralazine, adenosine triphosphate, adenosine, indomethacin or magnesium sulfate, a phosphodiesterase inhibitor, etc.
  • a necrosis inhibitor e.g., 2-(lH-Indol-3-yl)-3-pentylamino-maleimide, pyrrolidine dithiocarbamate, or clonazepam
  • a TNF-a inhibitor e.g., perfluorooctyl bromide, perfluorodecyl bromide, etc.
  • the stem cell collection composition can comprise one or more tissue-degrading enzymes, e.g., a metalloprotease, a serine protease, a neutral protease, an RNase, or a DNase, or the like.
  • tissue-degrading enzymes include, but are not limited to, collagenases (e.g., collagenase I, II, III or IV, a collagenase from Clostridium histolyticum, etc), dispase, thermolysin, elastase, trypsin, LIB ERASE, hyaluronidase, and the like.
  • the stem cell collection composition can comprise a bacteriocidally or bacteriostatically effective amount of an antibiotic.
  • the antibiotic is a macro lide (e.g., tobramycin), a cephalosporin (e.g., cephalexin, cephradine, cefuroxime, cefprozil, cefaclor, cefixime or cefadroxil), a clarithromycin, an erythromycin, a penicillin (e.g., penicillin V) or a quinolone (e.g., ofloxacin, ciprofloxacin or norfloxacin), a tetracycline, a streptomycin, etc.
  • the antibiotic is active against Gram(+) and/or Gram(-) bacteria, e.g., Pseudomonas aeruginosa, Staphylococcus aureus, and the like.
  • the stem cell collection composition can also comprise one or more of the following compounds: adenosine (about 1 mM to about 50 mM); D-glucose (about 20 mM to about 100 mM); magnesium ions (about 1 mM to about 50 mM); a macromolecule of molecular weight greater than 20,000 daltons, in one embodiment, present in an amount sufficient to maintain endothelial integrity and cellular viability (e.g., a synthetic or naturally occurring colloid, a polysaccharide such as dextran or a polyethylene glycol present at about 25 g/1 to about 100 g/1, or about 40 g/1 to about 60 g/1); an antioxidant (e.g., butylated hydroxyanisole, butylated hydroxytoluene, glutathione, vitamin C or vitamin E present at about 25 ⁇ to about 100 ⁇ ); a reducing agent (e.g., N-acetylcysteine present at about 0.1 mM to
  • nitroglycerin e.g., about 0.05 g/L to about 0.2 g/L
  • an anticoagulant in one embodiment, present in an amount sufficient to help prevent clotting of residual blood (e.g., heparin or hirudin present at a concentration of about 1000 units/1 to about 100,000 units/1); or an amiloride containing compound (e.g., amiloride, ethyl isopropyl amiloride, hexamethylene amiloride, dimethyl amiloride or isobutyl amiloride present at about 1.0 ⁇ to about 5 ⁇ ).
  • an amiloride containing compound e.g., amiloride, ethyl isopropyl amiloride, hexamethylene amiloride, dimethyl amiloride or isobutyl amiloride present at about 1.0 ⁇ to about 5 ⁇ ).
  • a human placenta is recovered shortly after its expulsion after birth.
  • the placenta is recovered from a patient after informed consent and after a complete medical history of the patient is taken and is associated with the placenta.
  • the medical history continues after delivery.
  • Such a medical history can be used to coordinate subsequent use of the placenta or the stem cells harvested therefrom.
  • human placental cells can be used, in light of the medical history, for personalized medicine for the infant associated with the placenta, or for parents, siblings or other relatives of the infant.
  • the umbilical cord blood and placental blood Prior to recovery of placental stem cells, the umbilical cord blood and placental blood are removed. In certain embodiments, after delivery, the cord blood in the placenta is recovered. The placenta can be subjected to a conventional cord blood recovery process.
  • a needle or cannula is used, with the aid of gravity, to exsanguinate the placenta (see, e.g., Anderson, U.S. Patent No. 5,372,581; Hessel et al, U.S. Patent No. 5,415,665).
  • the needle or cannula is usually placed in the umbilical vein and the placenta can be gently massaged to aid in draining cord blood from the placenta.
  • cord blood recovery may be performed commercially, e.g., LifeBank Inc., Cedar Knolls, N.J., ViaCord, Cord Blood Registry and Cryocell.
  • the placenta is gravity drained without further manipulation so as to minimize tissue disruption during cord blood recovery.
  • a placenta is transported from the delivery or birthing room to another location, e.g., a laboratory, for recovery of cord blood and collection of stem cells by, e.g., perfusion or tissue dissociation.
  • the placenta is preferably transported in a sterile, thermally insulated transport device (maintaining the temperature of the placenta between 20-28°C), for example, by placing the placenta, with clamped proximal umbilical cord, in a sterile zip-lock plastic bag, which is then placed in an insulated container.
  • the placenta is transported in a cord blood collection kit substantially as described in U.S. Patent No.
  • the placenta is delivered to the laboratory four to twenty-four hours following delivery.
  • the proximal umbilical cord is clamped, preferably within 4-5 cm (centimeter) of the insertion into the placental disc prior to cord blood recovery.
  • the proximal umbilical cord is clamped after cord blood recovery but prior to further processing of the placenta.
  • the placenta prior to placental stem cell collection, can be stored under sterile conditions and at either room temperature or at a temperature of 5 to 25°C (centigrade).
  • the placenta may be stored for a period of longer than forty eight hours, and preferably for a period of four to twenty-four hours prior to perfusing the placenta to remove any residual cord blood.
  • the placenta is preferably stored in an anticoagulant solution at a temperature of 5 to 25°C (centigrade). Suitable anticoagulant solutions are well known in the art. For example, a solution of heparin or warfarin sodium can be used.
  • the anticoagulant solution comprises a solution of heparin (e.g., 1% w/w in 1 : 1000 solution).
  • the exsanguinated placenta is preferably stored for no more than 36 hours before placental cells are collected.
  • the mammalian placenta or a part thereof, once collected and prepared generally as above, can be treated in any art-known manner, e.g., can be perfused or disrupted, e.g., digested with one or more tissue-disrupting enzymes, to obtain stem cells.
  • placental stem cells are collected from a mammalian placenta by physical disruption, e.g., enzymatic digestion, of the organ, e.g., using the stem cell collection composition described in Section 5.5.1, above.
  • the placenta, or a portion thereof may be, e.g., crushed, sheared, minced, diced, chopped, macerated or the like, while in contact with, e.g., a buffer, medium or a stem cell collection composition, and the tissue subsequently digested with one or more enzymes.
  • the placenta, or a portion thereof, may also be physically disrupted and digested with one or more enzymes, and the resulting material then immersed in, or mixed into, a buffer, medium or a stem cell collection composition.
  • Any method of physical disruption can be used, provided that the method of disruption leaves a plurality, more preferably a majority, and more preferably at least 60%, 70%, 80%, 90%, 95%, 98%, or 99% of the cells in said organ viable, as determined by, e.g., trypan blue exclusion.
  • placental cells can be obtained by disruption of a small block of placental tissue, e.g., a block of placental tissue that is about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, or about 1000 cubic millimeters in volume.
  • a block of placental tissue that is about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, or about 1000 cubic millimeters in volume.
  • Enzymatic digestion can be performed using single enzymes or combinations of enzymes.
  • enzymatic digestion of placental tissue uses a combination of a matrix metalloprotease, a neutral protease, and a mucolytic enzyme for digestion of hyaluronic acid, such as a combination of collagenase, dispase, and hyaluronidase or a combination of LIBERASE (Boehringer Mannheim Corp., Indianapolis, Ind.) and hyaluronidase.
  • Other enzymes that can be used to disrupt placenta tissue include papain, deoxyribonucleases, serine proteases, such as trypsin, chymotrypsin, or elastase.
  • Serine proteases may be inhibited by alpha 2 microglobulin in serum and therefore the medium used for digestion is usually serum-free. EDTA and DNase are commonly used in enzyme digestion procedures to increase the efficiency of cell recovery.
  • the digestate is preferably diluted so as to avoid trapping stem cells within the viscous digest.
  • Typical concentrations for tissue digestion enzymes include, e.g., 50-200 U/mL for collagenase I and collagenase IV, 1-10 U/mL for dispase, and 10-100 U/mL for elastase.
  • Proteases can be used in combination, that is, two or more proteases in the same digestion reaction, or can be used sequentially in order to liberate placental cells.
  • a placenta is digested first with an appropriate amount of collagenase I at 2 mg/ml for 30 minutes, followed by digestion with trypsin, 0.25%, for 10 minutes, at 37°C.
  • Serine proteases are preferably used consecutively following use of other enzymes.
  • the tissue can further be disrupted by the addition of a chelator, e.g., ethylene glycol bis(2-aminoethyl ether)-N,N,N'N'-tetraacetic acid (EGTA) or ethylenediaminetetraacetic acid (EDTA) to the stem cell collection composition comprising the stem cells, or to a solution in which the tissue is disrupted and/or digested prior to isolation of the placental stem cells with the stem cell collection composition.
  • a chelator e.g., ethylene glycol bis(2-aminoethyl ether)-N,N,N'N'-tetraacetic acid (EGTA) or ethylenediaminetetraacetic acid (EDTA)
  • placental stem cells collected will comprise a mix of placental cells derived from both fetal and maternal sources.
  • placental stem cells collected will comprise almost exclusively fetal placental stem cells.
  • Placental stem cells can also be obtained by perfusion of the mammalian placenta.
  • Placental stem cells can be collected by perfusion, e.g., through the placental vasculature, using, e.g., a stem cell collection composition as a perfusion solution.
  • a mammalian placenta is perfused by passage of perfusion solution through either or both of the umbilical artery and umbilical vein.
  • the flow of perfusion solution through the placenta may be accomplished using, e.g., gravity flow into the placenta.
  • the perfusion solution is forced through the placenta using a pump, e.g., a peristaltic pump.
  • the umbilical vein can be, e.g., cannulated with a cannula, e.g., a TEFLON® or plastic cannula, that is connected to a sterile connection apparatus, such as sterile tubing.
  • a sterile connection apparatus such as sterile tubing.
  • the sterile connection apparatus is connected to a perfusion manifold.
  • the placenta is preferably oriented (e.g. , suspended) in such a manner that the umbilical artery and umbilical vein are located at the highest point of the placenta.
  • the placenta can be perfused by passage of a perfusion fluid, e.g., the stem cell collection composition provided herein, through the placental vasculature, or through the placental vasculature and surrounding tissue.
  • a perfusion fluid e.g., the stem cell collection composition provided herein
  • the umbilical artery and the umbilical vein are connected simultaneously to a pipette that is connected via a flexible connector to a reservoir of the perfusion solution.
  • the perfusion solution is passed into the umbilical vein and artery.
  • the perfusion solution exudes from and/or passes through the walls of the blood vessels into the surrounding tissues of the placenta, and is collected in a suitable open vessel from the surface of the placenta that was attached to the uterus of the mother during gestation.
  • the perfusion solution may also be introduced through the umbilical cord opening and allowed to flow or percolate out of openings in the wall of the placenta which interfaced with the maternal uterine wall.
  • the perfusion solution is passed through the umbilical veins and collected from the umbilical artery, or is passed through the umbilical artery and collected from the umbilical veins.
  • the proximal umbilical cord is clamped during perfusion, and more preferably, is clamped within 4-5 cm (centimeter) of the cord's insertion into the placental disc.
  • the first collection of perfusion fluid from a mammalian placenta during the exsanguination process is generally colored with residual red blood cells of the cord blood and/or placental blood; this portion of the perfusion can be discarded.
  • the perfusion fluid becomes more colorless as perfusion proceeds and the residual cord blood cells are washed out of the placenta.
  • the volume of perfusion liquid used to collect placental stem cells may vary depending upon the number of placental stem cells to be collected, the size of the placenta, the number of collections to be made from a single placenta, etc.
  • the volume of perfusion liquid may be from 50 mL to 5000 mL, 50 mL to 4000 mL, 50 mL to 3000 niL, 100 niL to 2000 niL, 250 mL to 2000 mL, 500 niL to 2000 niL, or 750 niL to 2000 mL.
  • the placenta is perfused with 700-800 mL of perfusion liquid following
  • the placenta can be perfused a plurality of times over the course of several hours or several days. Where the placenta is to be perfused a plurality of times, it may be maintained or cultured under aseptic conditions in a container or other suitable vessel, and perfused with the stem cell collection composition, or a standard perfusion solution (e.g., a normal saline solution such as phosphate buffered saline ("PBS”)) with or without an anticoagulant (e.g., heparin, warfarin sodium, coumarin, bishydroxycoumarin), and/or with or without an antimicrobial agent (e.g., ⁇ -mercaptoethanol (0.1 mM); or antibiotics such as streptomycin (e.g., at 40-100 ⁇ g/ml) or penicillin (e.g., at 40U/ml); or amphotericin B (e.g., at 0.5 ⁇ g/ml)).
  • PBS phosphate buffered s
  • an isolated placenta is maintained or cultured for a period of time without collecting the perfusate, such that the placenta is maintained or cultured for 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, or 24 hours, or 2 or 3 or more days before perfusion and collection of perfusate.
  • the perfused placenta can be maintained for one or more additional time(s), e.g., 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24 or more hours, and perfused a second time with, e.g., 700-800 mL perfusion fluid.
  • the placenta can be perfused 1 , 2, 3, 4, 5 or more times, for example, once every 1 , 2, 3, 4, 5 or 6 hours.
  • perfusion of the placenta and collection of perfusion solution e.g., stem cell collection composition, is repeated until the number of recovered nucleated cells falls below 100 cells/ml.
  • the perfusates at different time points can be further processed individually to recover time-dependent populations of placental stem cells. Perfusates from different time points can also be pooled.
  • placental stem cells are believed to migrate into the placenta
  • Stem cells can be isolated from placenta by perfusion with a solution comprising one or more proteases or other tissue-disruptive enzymes.
  • a placenta or portion thereof is brought to 25-37°C, and is incubated with one or more tissue-disruptive enzymes in 200 mL of a culture medium for 30 minutes. Cells from the perfusate are collected, brought to 4°C, and washed with a cold inhibitor mix comprising 5 mM EDTA, 2 mM
  • the placental stem cells are washed after several minutes with a cold (e.g., 4°C) stem cell collection composition described elsewhere herein.
  • Perfusion using the pan method that is, whereby perfusate is collected after it has exuded from the maternal side of the placenta, results in a mix of fetal and maternal cells.
  • the cells collected by this method comprise a mixed population of placental stem cells of both fetal and maternal origin.
  • perfusion solely through the placental vasculature whereby perfusion fluid is passed through one or two placental vessels and is collected solely through the remaining vessel(s), results in the collection of a population of placental stem cells almost exclusively of fetal origin.
  • Stem cells from mammalian placenta can initially be purified from (i.e., be isolated from) other cells by Ficoll gradient centrifugation. Such centrifugation can follow any standard protocol for centrifugation speed, etc. In one embodiment, for example, cells collected from the placenta are recovered from perfusate by centrifugation at 5000 x g for 15 minutes at room temperature, which separates cells from, e.g., contaminating debris and platelets.
  • placental perfusate is concentrated to about 200 ml, gently layered over Ficoll, and centrifuged at about 1100 x g for 20 minutes at 22°C, and the low-density interface layer of cells is collected for further processing.
  • Cell pellets can be resuspended in fresh stem cell collection composition, or a medium suitable for stem cell maintenance, e.g., IMDM serum- free medium containing 2U/ml heparin and 2mM EDTA (GibcoBRL, NY).
  • the total mononuclear cell fraction can be isolated, e.g., using Lymphoprep (Nycomed Pharma, Oslo, Norway) according to the manufacturer's recommended procedure.
  • "isolating" placental stem cells means removing at least 20%,
  • Placental stem cells obtained by perfusion or digestion can, for example, be further, or initially, isolated by differential trypsinization using, e.g., a solution of 0.05%> trypsin with 0.2%) EDTA (Sigma, St. Louis MO). Differential trypsinization is possible because placental stem cells typically detach from plastic surfaces within about five minutes whereas other adherent populations typically require more than 20-30 minutes incubation.
  • the detached placental stem cells can be harvested following trypsinization and trypsin neutralization, using, e.g., Trypsin Neutralizing Solution (TNS, Cambrex).
  • aliquots of, for example, about 5-10 x 10 6 placental cells are placed in each of several T-75 flasks, preferably fibronectin- coated T75 flasks.
  • the cells can be cultured with commercially available Mesenchymal Stem Cell Growth Medium (MSCGM) (Cambrex), and placed in a tissue culture incubator (37°C, 5% C0 2 ). After 10 to 15 days, non-adherent cells are removed from the flasks by washing with PBS. The PBS is then replaced by MSCGM. Flasks are preferably examined daily for the presence of various adherent cell types and in particular, for identification and expansion of clusters of fibroblastoid cells.
  • MSCGM Mesenchymal Stem Cell Growth Medium
  • the number and type of cells collected from a mammalian placenta can be monitored, for example, by measuring changes in morphology and cell surface markers using standard cell detection techniques such as flow cytometry, cell sorting, immunocytochemistry ⁇ e.g. , staining with tissue specific or cell-marker specific antibodies) fluorescence activated cell sorting (FACS), magnetic activated cell sorting (MACS), by examination of the morphology of cells using light or confocal microscopy, and/or by measuring changes in gene expression using techniques well known in the art, such as PCR and gene expression profiling. These techniques can be used, too, to identify cells that are positive for one or more particular markers.
  • FACS fluorescence activated cell sorting
  • MCS magnetic activated cell sorting
  • a cell comprises a detectable amount of CD34 as compared to, for example, an isotype control; if so, the cell is CD34 + .
  • the cell is OCT-4 + .
  • Antibodies to cell surface markers e.g., CD markers such as CD34
  • the sequence of stem cell-specific genes such as OCT-4, are well-known in the art.
  • Placental cells may be sorted, e.g., further isolated, using a fluorescence activated cell sorter (FACS).
  • Fluorescence activated cell sorting is a well- known method for separating particles, including cells, based on the fluorescent properties of the particles (Kamarch, 1987, Methods Enzymol, 151 :150-165). Laser excitation of fluorescent moieties in the individual particles results in a small electrical charge allowing electromagnetic separation of positive and negative particles from a mixture.
  • cell surface marker-specific antibodies or ligands are labeled with distinct fluorescent labels. Cells are processed through the cell sorter, allowing separation of cells based on their ability to bind to the antibodies used.
  • FACS sorted particles may be directly deposited into individual wells of 96- well or 384-well plates to facilitate separation and cloning.
  • placental stem cells can be sorted on the basis of expression of the markers CD34, CD38, CD44, CD45, CD73, CD105, OCT-4 and/or HLA-G, or any of the other markers listed elsewhere herein. This can be accomplished in connection with procedures to select stem cells on the basis of their adherence properties in culture. For example, adherence selection of placental stem cells can be accomplished before or after sorting on the basis of marker expression. In one embodiment, for example, placental stem cells can be sorted first on the basis of their expression of CD34; CD34 cells are retained, and cells that are
  • CD200 + or HLA-G + are separated from all other CD34 cells.
  • placental stem cells can be sorted based on their expression of CD200 and/or HLA-G, or lack thereof; for example, cells displaying either of these markers can be isolated for further use.
  • Cells that express, e.g., CD200 and/or HLA-G can, in a specific embodiment, be further sorted based on their expression of CD73 and/or CD 105, or epitopes recognized by antibodies SH2, SH3 or SH4, or lack of expression of CD34, CD38 or CD45.
  • placental stem cells are sorted by expression, or lack thereof, of CD200, HLA-G, CD73, CD105, CD34, CD38 and CD45, and placental stem cells that are CD200 + , HLA-G , CD73 + , CD105 + , CD34 , CD38 and CD45 are isolated from other placental cells for further use.
  • magnetic beads can be used to separate cells, e.g., separate placental stem cells from other placental cells.
  • the cells may be sorted using a magnetic activated cell sorting (MACS) technique, a method for separating particles based on their ability to bind magnetic beads (0.5-100 ⁇ diameter).
  • a variety of useful modifications can be performed on the magnetic microspheres, including covalent addition of antibody that specifically recognizes a particular cell surface molecule or hapten.
  • the beads are then mixed with the cells to allow binding. Cells are then passed through a magnetic field to separate out cells having the specific cell surface marker. In one embodiment, these cells can then isolated and re-mixed with magnetic beads coupled to an antibody against additional cell surface markers. The cells are again passed through a magnetic field, isolating cells that bound both the antibodies. Such cells can then be diluted into separate dishes, such as microtiter dishes for clonal isolation.
  • Placental stem cells can also be characterized and/or sorted based on cell morphology and growth characteristics. For example, placental stem cells can be characterized as having, and/or selected on the basis of, e.g., a fibroblastoid appearance in culture. Placental stem cells can also be characterized as having, and/or be selected, on the basis of their ability to form embryoid-like bodies. In one embodiment, for example, placental cells that are
  • fibroblastoid in shape express CD73 and CD 105, and produce one or more embryoid-like bodies in culture can be isolated from other placental cells.
  • OCT-4 + placental cells that produce one or more embryoid-like bodies in culture are isolated from other placental cells.
  • placental stem cells can be identified and characterized by a colony forming unit assay.
  • Colony forming unit assays are commonly known in the art, such as MESENCULTTM medium (Stem Cell Technologies, Inc., Vancouver British Columbia).
  • Placental stem cells can be assessed for viability, proliferation potential, and longevity using standard techniques known in the art, such as trypan blue exclusion assay, fluorescein diacetate uptake assay, propidium iodide uptake assay (to assess viability); and thymidine uptake assay, MTT cell proliferation assay (to assess proliferation). Longevity may be determined by methods well known in the art, such as by determining the maximum number of population doubling in an extended culture.
  • Placental stem cells can also be separated from other placental cells using other techniques known in the art, e.g., selective growth of desired cells (positive selection), selective destruction of unwanted cells (negative selection); separation based upon differential cell agglutinability in the mixed population as, for example, with soybean agglutinin; freeze-thaw procedures; filtration; conventional and zonal centrifugation; centrifugal elutriation (counter- streaming centrifugation); unit gravity separation; countercurrent distribution; electrophoresis; and the like.
  • other techniques known in the art e.g., selective growth of desired cells (positive selection), selective destruction of unwanted cells (negative selection); separation based upon differential cell agglutinability in the mixed population as, for example, with soybean agglutinin; freeze-thaw procedures; filtration; conventional and zonal centrifugation; centrifugal elutriation (counter- streaming centrifugation); unit gravity separation; countercurrent distribution; electrophoresis; and the like.
  • Isolated placental stem cells or placental cell populations, or cells or placental tissue from which placental cells grow, can be used to initiate, or seed, cell cultures.
  • Cells are generally transferred to sterile tissue culture vessels either uncoated or coated with extracellular matrix or ligands such as laminin, collagen (e.g., native or denatured), gelatin, fibronectin, ornithine, vitronectin, and extracellular membrane protein (e.g., MATRIGEL (BD Discovery Labware, Bedford, Mass.)).
  • extracellular matrix or ligands such as laminin, collagen (e.g., native or denatured), gelatin, fibronectin, ornithine, vitronectin, and extracellular membrane protein (e.g., MATRIGEL (BD Discovery Labware, Bedford, Mass.)).
  • Placental stem cells can be cultured in any medium, and under any conditions, recognized in the art as acceptable for the culture of stem cells.
  • the culture medium comprises serum.
  • Placental stem cells can be cultured in, for example, DMEM-LG (Dulbecco's Modified Essential Medium, low glucose)/MCDB 201 (chick fibroblast basal medium) containing ITS (insulin-transferrin-selenium), LA+BSA (linoleic acid-bovine serum albumin), dextrose, L-ascorbic acid, PDGF, EGF, IGF-1, and penicillin/streptomycin; DMEM-HG (high glucose) comprising 10% fetal bovine serum (FBS); DMEM-HG comprising 15% FBS; IMDM (Iscove's modified Dulbecco's medium) comprising 10% FBS, 10% horse serum, and hydrocortisone; Ml 99 comprising 10% FBS, EGF, and heparin; a
  • the culture medium can be supplemented with one or more components including, for example, serum (e.g., fetal bovine serum (FBS), preferably about 2-15% (v/v); equine (horse) serum (ES); human serum (HS)); beta-mercaptoethanol (BME), preferably about 0.001 ) (v/v); one or more growth factors, for example, platelet-derived growth factor (PDGF), epidermal growth factor (EGF), basic fibroblast growth factor (bFGF), insulin-like growth factor- 1 (IGF-1), leukemia inhibitory factor (LIF), vascular endothelial growth factor (VEGF), and erythropoietin (EPO); amino acids, including L-valine; and one or more growth factors, for example, platelet-derived growth factor (PDGF), epidermal growth factor (EGF), basic fibroblast growth factor (bFGF), insulin-like growth factor- 1 (IGF-1), leukemia inhibitory factor (LIF), vascular endotheli
  • placental stem cells are isolated (e.g., separated from at least 50%> of the placental cells with which the stem cell or population of stem cells is normally associated in vivo), the stem cell or population of stem cells can be proliferated and expanded in vitro.
  • placental stem cells can also be proliferated and expanded in vitro.
  • placental stem cells can be cultured in tissue culture containers, e.g., dishes, flasks, multiwell plates, or the like, for a sufficient time for the placental stem cells to proliferate to 70-90% confluence, that is, until the placental stem cells and their progeny occupy 70-90%) of the culturing surface area of the tissue culture container.
  • Placental stem cells can be seeded in culture vessels at a density that allows cell growth.
  • the placental stem cells may be seeded at low density (e.g., about 1,000 to about 5,000 cells/cm 2 ) to high density (e.g., about 50,000 or more cells/cm 2 ).
  • the placental stem cells are cultured at about 0 to about 5 percent by volume C0 2 in air.
  • the placental stem cells are cultured at about 2 to about 25 percent 0 2 in air, preferably about 5 to about 20 percent 0 2 in air.
  • the placental stem cells preferably are cultured at about 25°C to about 40°C, preferably 37°C.
  • the placental stem cells are preferably cultured in an incubator.
  • the culture medium can be static or agitated, for example, using a bioreactor.
  • Placental stem cells are preferably are grown under low oxidative stress (e.g., with addition of glutathione, ascorbic acid, catalase, tocopherol, N-acetylcysteine, or the like).
  • the placental stem cells may be passaged.
  • the cells can be enzymatically treated, e.g., trypsinized, using techniques well- known in the art, to separate them from the tissue culture surface.
  • about 20,000-100,000 stem cells preferably about 50,000 placental stem cells, are passaged to a new culture container containing fresh culture medium.
  • the new medium is the same type of medium from which the stem cells were removed.
  • populations of placental stem cells that have been passaged at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, or 20 times, or more, and combinations of the same.
  • the population of placental stem cells has been passaged at least 3- 10 times, 3-8 times, or 5-7 times.
  • Placental stem cells useful in the treatment of schizophrenia, Alzheimer's disease, or Huntington's disease can be preserved, that is, placed under conditions that allow for long- term storage, or conditions that inhibit cell death by, e.g., apoptosis or necrosis.
  • Placental stem cells can be preserved using, e.g., a composition comprising an apoptosis inhibitor, necrosis inhibitor and/or an oxygen-carrying perfluorocarbon, as described in related International Patent Application Publication No. WO 2007/079185.
  • a method of preserving placental stem cells comprising contacting said placental stem cells with or bringing said placental stem cells into proximity to a stem cell collection composition comprising an inhibitor of apoptosis and an oxygen-carrying perfluorocarbon, wherein said inhibitor of apoptosis is present in an amount and for a time sufficient to reduce or prevent apoptosis in the population of placental stem cells, as compared to a population of placental stem cells not contacted with or brought into proximity to the inhibitor of apoptosis.
  • said inhibitor of apoptosis is a caspase inhibitor.
  • said inhibitor of apoptosis is a JNK inhibitor.
  • said JNK inhibitor does not modulate differentiation or proliferation of said placental stem cells.
  • said stem cell collection composition comprises said inhibitor of apoptosis and said oxygen-carrying perfluorocarbon in separate phases.
  • said stem cell collection composition comprises said inhibitor of apoptosis and said oxygen-carrying perfluorocarbon in an emulsion.
  • the stem cell collection composition additionally comprises an emulsifier, e.g., lecithin.
  • said apoptosis inhibitor and said perfluorocarbon are between about 0°C and about 25°C at the time of contacting or bringing into proximity the stem cells. In another more specific embodiment, said apoptosis inhibitor and said perfluorocarbon are between about 2°C and 10°C, or between about 2°C and about 5°C, at the time of contacting or bringing into proximity the stem cells. In another more specific embodiment, said contacting or bringing into proximity is performed during transport of said placental stem cells. In another more specific embodiment, said contacting or bringing into proximity is performed during freezing and thawing of said population of stem cells.
  • placental stem cells can be preserved by a method comprising contacting said placental stem cells with or bringing said placental stem cells into proximity to an inhibitor of apoptosis and an organ-preserving compound, wherein said inhibitor of apoptosis is present in an amount and for a time sufficient to reduce or prevent apoptosis of the placental stem cells, as compared to placental stem cells not contacted with or brought into proximity to the inhibitor of apoptosis.
  • the organ-preserving compound is UW solution (described in U.S. Patent No.
  • said organ-preserving compound is hydroxyethyl starch, lactobionic acid, raffinose, or a combination thereof.
  • placental stem cells to be used to produce placental stem cells, are contacted with or brought into proximity to a stem cell collection composition comprising an apoptosis inhibitor and oxygen-carrying perfluorocarbon, organ-preserving compound, or combination thereof, during perfusion.
  • said placental stem cells, to be used to produce placental stem cells are contacted or brought into proximity during a process of tissue disruption, e.g., enzymatic digestion.
  • placental cells are contacted with or brought into proximity to said stem cell collection compound after collection by perfusion, or after collection by tissue disruption, e.g., enzymatic digestion.
  • placental stem cells to be used to produce placental stem cells, are exposed to a hypoxic condition during collection, enrichment or isolation for less than six hours during said preservation, wherein a hypoxic condition is a concentration of oxygen that is less than normal blood oxygen concentration.
  • a hypoxic condition is a concentration of oxygen that is less than normal blood oxygen concentration.
  • said placental stem cells are exposed to said hypoxic condition for less than two hours during said preservation.
  • said placental stem cells are exposed to said hypoxic condition for less than one hour, or less than thirty minutes, or is not exposed to a hypoxic condition, during collection, enrichment or isolation. In another specific embodiment, said placental stem cells are not exposed to shear stress during collection, enrichment or isolation.
  • the placental stem cells, as well as the placental stem cells to be used to produce placental stem cells, described herein can be cryopreserved, e.g., in cryopreservation medium in small containers, e.g., ampoules.
  • Suitable cryopreservation medium includes, but is not limited to, culture medium including, e.g., growth medium, or cell freezing medium, for example commercially available cell freezing medium, e.g., C2695, C2639 or C6039 (Sigma).
  • Cryopreservation medium preferably comprises DMSO (dimethylsulfoxide), at a concentration of, e.g., about 10% (v/v).
  • Cryopreservation medium may comprise additional agents, for example, Plasmalyte, methylcellulose with or without glycerol.
  • the stem cells are preferably cooled at about l°C/min during cryopreservation.
  • a preferred cryopreservation temperature is about -80°C to about -180°C, preferably about -125°C to about -140°C.
  • Cryopreserved cells can be transferred to liquid nitrogen prior to thawing for use. In some embodiments, for example, once the ampoules have reached about -90°C, they are transferred to a liquid nitrogen storage area.
  • Cryopreserved cells preferably are thawed at a temperature of about 25°C to about 40°C, preferably to a temperature of about 37°C.
  • compositions comprising the placental stem cells, or biomolecules therefrom.
  • populations of placental stem cells provided herein can be combined with any physiologically-acceptable or medically-acceptable compound, composition or device for use in, e.g., research or therapeutics. 5.8.1.1 Cryopreserved Placental Cells
  • placental stem cells can be preserved, for example, cryopreserved for later use.
  • Methods for cryopreservation of cells, such as stem cells are well known in the art.
  • Placental stem cells can be prepared in a form that is easily administrable to an individual.
  • placental stem cells described herein can be contained within a container that is suitable for medical use.
  • a container can be, for example, a sterile plastic bag, flask, jar, vial, or other container from which the placental cell population can be easily dispensed.
  • the container can be a blood bag or other plastic, medically-acceptable bag suitable for the intravenous administration of a liquid to a recipient.
  • the container is preferably one that allows for cryopreservation of the placental stem cells.
  • Cryopreserved placental stem cells can comprise placental stem cells derived from a single donor, or from multiple donors.
  • the placental stem cells can be completely HLA- matched to an intended recipient, or partially or completely HLA-mismatched.
  • a composition comprising placental stem cells in a container.
  • the placental stem cells are, or have been, cryopreserved.
  • the container is a bag, flask, vial or jar.
  • said bag is a sterile plastic bag.
  • said bag is suitable for, allows or facilitates intravenous administration of said placental stem cells.
  • the bag can comprise multiple lumens or compartments that are interconnected to allow mixing of the placental stem cells and one or more other solutions, e.g., a drug, prior to, or during, administration.
  • the composition comprises one or more compounds that facilitate cryopreservation of the combined stem cell population.
  • said placental stem cells are contained within a physiologically-acceptable aqueous solution.
  • said physiologically-acceptable aqueous solution is a 0.9% NaCl solution.
  • said placental stem cells are HLA-matched to a recipient of said placental stem cells.
  • said placental stem cells are at least partially HLA-mismatched to a recipient of said placental stem cells.
  • said placental stem cells are from a plurality of donors.
  • Populations of isolated placental stem cells, or populations of cells comprising the isolated placental stem cells can be formulated into pharmaceutical compositions for use in vivo, e.g., in the methods of treatment provided herein.
  • Such pharmaceutical compositions comprise placental stem cells, or a population of cells comprising isolated placental stem cells, in a pharmaceutically-acceptable carrier, e.g., a saline solution or other accepted physiologically- acceptable solution for in vivo administration.
  • Pharmaceutical compositions comprising the isolated placental stem cells described herein can comprise any, or any combination, of the isolated placental stem cell populations, or isolated placental stem cells, described elsewhere herein.
  • the pharmaceutical compositions can comprise fetal, maternal, or both fetal and maternal isolated cells.
  • compositions provided herein can further comprise isolated placental stem cells obtained from a single individual, umbilical cord or placenta, or from a plurality of individuals, umbilical cords or placentae. Any of the placental stem cells, described elsewhere herein, can be formulated into a pharmaceutical composition, as described below.
  • compositions provided herein can comprise any number of isolated placental stem cells.
  • a single unit dose of isolated placental stem cells can comprise, in various embodiments, about, at least, or no more than 1 x 10 5 , 3 x 10 5 , 5 x 10 5 , 1 x 10 6 , 3 x 10 6 , 5 x 10 6 , 1 x 10 7 , 3 x 10 7 , 5 x 10 7 , 1 x 10 8 , 2 x 10 8 , 3 x 10 8 , 4 x 10 8 , 5 x 10 8 , 6 x 10 8 , 7 x 10 8 , 8 x 10 8 , 8 x 10 8 , 1 x 10 9 , 2 x 10 9 , 3 x 10 9 , 4 x 10 9 , 5 x 10 9 , 1 x 10 10 , 5 x 10 10 , 1 x 10 10 , 5 x 10 10 , 1 x 10 11 or more isolated cells.
  • a single unit dose of isolated placental stem cells can comprise, in various embodiments, about, at least, or no more than 1 x 10 4 - 5 x 10 4 , 5 x 10 4 - 1 x 10 5 , 1 x 10 5 - 5 x 10 5 , 5 x 10 5 - 1 x 10 6 , 1 x 10 6 - 5 x 10 6 , 5 x 10 6 - 1 x 10 7 , 1 x 10 7 - 5 x 10 7 , 5 x 10 7 - 1 x 10 8 , 1 x 10 8 - 5 x 10 8 , 5 x 10 8 - 1 x 10 9 , 1 x 10 9 - 5 x 10 9 , 5 x 10 9 - 1 x 10 10 , 1 x 10 10 - 5 x 10 10 , 5 x 10 10 - 1 x 10 11 or more isolated cells.
  • a single unit dose comprises about 1 x 10 7 placental stem cells. In a specific embodiment, a single unit dose comprises about 2 x 10 7 placental stem cells. In a specific embodiment, a single unit dose comprises about 3 x 10 7 placental stem cells. In a specific embodiment, a single unit dose comprises about 1 x 10 8 placental stem cells. In a specific embodiment, a single unit dose comprises about 2 x 10 8 placental stem cells. In a specific embodiment, a single unit dose comprises about 3 x 10 8 placental stem cells. In this context, "about” means plus or minus 5%.
  • a single unit dose is administered all at once, or may be administered in multiple (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, or more) smaller units.
  • the multiple smaller units are administered at the same time, or within 10 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 3, hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 18 hours, 24 hours, 36 hours, 48 hours, 3 days, 4 days, 5 days, 6 days, a week, 2 weeks, 3 weeks, 4 weeks, a month, or more of one another.
  • more than one single unit dose is administered at a time, e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, or more times to achieve the desired administration.
  • the more than one single unit dose (delivered at, e.g., the same time) is delivered in one infusion or injection. In certain embodiments, the more than one single unit dose (delivered at, e.g., the same time) is delivered in more than one, e.g., 2, 3, 4, 5, 5-10, 15, 10-20, 20, or 30, infusion or injection.
  • compositions provided herein comprise populations of cells that comprise 50% viable cells or more (that is, at least 50% of the cells in the population are functional or living). Preferably, at least 60% of the cells in the population are viable. More preferably, at least 70%, 80%, 90%, 95%, or 99% of the cells in the population in the
  • compositions are viable.
  • compositions provided herein can comprise one or more compounds that, e.g., facilitate engraftment ⁇ e.g., anti-T-cell receptor antibodies, an
  • immunosuppressant or the like
  • stabilizers such as albumin, dextran 40, gelatin,
  • the pharmaceutical composition comprises about 1% to 1.5% HSA and about 2.5% dextran.
  • the pharmaceutical composition comprises from about 5 x 10 6 cells per milliliter to about 2 x 10 7 cells per milliliter in a solution comprising 5% HSA and 10% dextran, optionally comprising an immunosuppressant, e.g., cyclosporine A at, e.g., 10 mg/kg body weight.
  • an immunosuppressant e.g., cyclosporine A at, e.g., 10 mg/kg body weight.
  • the pharmaceutical composition e.g., a solution
  • the pharmaceutical composition comprises between about 1.5 x 10 6 cells per milliliter to about 3.75 x 10 6 cells per milliliter.
  • the pharmaceutical composition comprises between about 1 x 10 6 cells/mL to about 50 x 10 6 cells/mL, about 1 x 10 6 cells/mL to about 40 x 10 6 cells/mL, about 1 x 10 6 cells/mL to about 30 x 10 6 cells/mL, about 1 x 10 6 cells/mL to about 20 x 10 6 cells/mL, about 1 x 10 6 cells/mL to about 15 x 10 6 cells/mL, or about 1 x 10 6 cells/mL to about 10 x 10 6 cells/mL.
  • the pharmaceutical composition comprises no visible cell clumps (i.e., no macro cell clumps), or substantially no such visible clumps.
  • the pharmaceutical composition comprises about 2.5%, 3.0%>, 3.5%, 4.0%, 4.5%, 5.0%>, 5.5%, 6.0%>, 6.5%, 7.0%, 7.5%, 8.0%, 8.5%, 9.0%, 9.5%, or 10% dextran, e.g., dextran-40.
  • said composition comprises about 7.5% to about 9% dextran-40.
  • said composition comprises about 5.5 % dextran-40.
  • the pharmaceutical composition comprises from about 1% to about 15% human serum albumin (HSA). In specific embodiments, the pharmaceutical composition comprises about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14% or 15% HSA.
  • said cells have been cryopreserved and thawed. In another specific embodiment, said cells have been filtered through a 70 ⁇ to 100 ⁇ filter. In another specific embodiment, said
  • composition comprises no visible cell clumps. In another specific embodiment, said composition comprises fewer than about 200 cell clumps per 10 6 cells, wherein said cell clumps are visible only under a microscope, e.g., a light microscope. In another specific embodiment, said composition comprises fewer than about 150 cell clumps per 10 6 cells, wherein said cell clumps are visible only under a microscope, e.g., a light microscope. In another specific embodiment, said composition comprises fewer than about 100 cell clumps per 10 6 cells, wherein said cell clumps are visible only under a microscope, e.g., a light microscope.
  • the pharmaceutical composition comprises about 1.0
  • the pharmaceutical composition comprises a plurality of cells, e.g., a plurality of isolated placental stem cells in a solution comprising 10% dextran-40, wherein the pharmaceutical composition comprises between about 1.0 ⁇ 0.3 x 10 6 cells per milliliter to about 5.0 ⁇ 1.5 x 10 6 cells per milliliter, and wherein said composition comprises no cell clumps visible with the unaided eye (i.e., comprises no macro cell clumps). In some embodiments, the pharmaceutical composition comprises between about 1.5 x 10 6 cells per milliliter to about 3.75 x 10 6 cells per milliliter. In a specific embodiment, said cells have been cryopreserved and thawed.
  • said cells have been filtered through a 70 ⁇ to 100 ⁇ filter.
  • said composition comprises fewer than about 200 micro cell clumps (that is, cell clumps visible only with magnification) per 10 6 cells.
  • the pharmaceutical composition comprises fewer than about 150 micro cell clumps per 10 6 cells.
  • the pharmaceutical composition comprises fewer than about 100 micro cell clumps per 10 6 cells.
  • the pharmaceutical composition comprises less than 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, or 2% DMSO, or less than 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% DMSO.
  • compositions comprising cells, wherein said compositions are produced by one of the methods disclosed herein.
  • the pharmaceutical composition comprises cells, wherein the pharmaceutical composition is produced by a method comprising filtering a solution comprising placental stem cells to form a filtered cell-containing solution; diluting the filtered cell-containing solution with a first solution to about 1 to 50 x 10 6 , 1 to 40 x 10 6 , 1 to 30 x 10 6 , 1 to 20 x 10 6 , 1 to 15 x 10 6 , or 1 to 10 x 10 6 cells per milliliter, e.g., prior to cryopreservation; and diluting the resulting filtered cell-containing solution with a second solution comprising dextran, but not comprising human serum albumin (HSA) to produce said composition.
  • HSA human serum albumin
  • said diluting is to no more than about 15 x 10 6 cells per milliliter. In certain embodiments, said diluting is to no more than about 10 ⁇ 3 x 10 6 cells per milliliter. In certain embodiments, said diluting is to no more than about 7.5 x 10 6 cells per milliliter. In other certain embodiments, if the filtered cell- containing solution, prior to the dilution, comprises less than about 15 x 10 6 cells per milliliter, filtration is optional. In other certain embodiments, if the filtered cell-containing solution, prior to the dilution, comprises less than about 10 ⁇ 3 x 10 6 cells per milliliter, filtration is optional. In other certain embodiments, if the filtered cell-containing solution, prior to the dilution, comprises less than about 7.5 x 10 6 cells per milliliter, filtration is optional.
  • the cells are cryopreserved between said diluting with a first dilution solution and said diluting with said second dilution solution.
  • the first dilution solution comprises dextran and HSA.
  • the dextran in the first dilution solution or second dilution solution can be dextran of any molecular weight, e.g., dextran having a molecular weight of from about 10 kDa to about 150 kDa.
  • said dextran in said first dilution solution or said second solution is about 2.5%, 3.0%, 3.5%, 4.0%, 4.5%, 5.0%, 5.5%, 6.0%, 6.5%, 7.0%, 7.5%, 8.0%, 8.5%, 9.0%, 9.5%, or 10% dextran.
  • the dextran in said first dilution solution or said second dilution solution is dextran-40.
  • the dextran in said first dilution solution and said second dilution solution is dextran-40.
  • said dextran-40 in said first dilution solution is 5.0% dextran-40. In another specific embodiment, said dextran-40 in said first dilution solution is 5.5% dextran-40. In another specific embodiment, said dextran-40 in said second dilution solution is 10% dextran-40.
  • said HSA in said solution comprising HSA is 1 to 15 % HSA. In another specific embodiment, said HSA in said solution comprising HSA is about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14% or 15 % HSA. In another specific embodiment, said HSA in said solution comprising HSA is 10%> HSA.
  • said first dilution solution comprises HSA. In a more specific embodiment, said HSA in said first dilution solution is 10% HSA. In another specific embodiment, said first dilution solution comprises a cryoprotectant. In a more specific embodiment, said cryoprotectant is DMSO. In another specific embodiment, said dextran-40 in said second dilution solution is about 10% dextran-40. In another specific embodiment, said composition comprising cells comprises about 7.5% to about 9% dextran. In another specific embodiment, the pharmaceutical composition comprises from about 1.0 ⁇ 0.3 x 10 6 cells per milliliter to about 5.0 ⁇ 1.5 x 10 6 cells per milliliter. In another specific embodiment, the pharmaceutical composition comprises from about 1.5 x 10 6 cells per milliliter to about 3.75 x 10 6 cells per milliliter.
  • the pharmaceutical composition is made by a method comprising (a) filtering a cell-containing solution comprising placental stem cells prior to cryopreservation to produce a filtered cell-containing solution; (b) cryopreserving the cells in the filtered cell-containing solution at about 1 to 50 x 10 6 , 1 to 40 x 10 6 , 1 to 30 x 10 6 , 1 to 20 x 10 6 , I to l5 x l0 6 , or 1 to 10 x 10 6 cells per milliliter; (c) thawing the cells; and (d) diluting the filtered cell-containing solution about 1 : 1 to about 1 : 11 (v/v) with a dextran-40 solution.
  • the cells in step (b) are cryopreserved at about 10 ⁇ 3 x 10 6 cells per milliliter. In a more specific embodiment, the cells in step (b) are cryopreserved in a solution comprising about 5% to about 10%> dextran-40 and HSA. In certain embodiments, said diluting in step (b) is to no more than about 15 x 10 6 cells per milliliter.
  • the pharmaceutical composition is made by a method comprising: (a) suspending placental stem cells in a 5.5% dextran-40 solution that comprises 10% HSA to form a cell-containing solution; (b) filtering the cell-containing solution through a 70 ⁇ filter; (c) diluting the cell-containing solution with a solution comprising 5.5% dextran- 40, 10% HSA, and 5% DMSO to about 1 to 50 x 10 6 , 1 to 40 x 10 6 , 1 to 30 x 10 6 , 1 to 20 x 10 6 , 1 to 15 x 10 6 , or 1 to 10 x 10 6 cells per milliliter; (d) cryopreservmg the cells; (e) thawing the cells; and (f) diluting the cell-containing solution 1 : 1 to 1 : 11 (v/v) with 10% dextran-40.
  • said diluting in step (c) is to no more than about 15 x 10 6 cells per milliliter. In certain embodiments, said diluting in step (c) is to no more than about 10 ⁇ 3 x 10 6 cells/mL. In certain embodiments, said diluting in step (c) is to no more than about 7.5 x 10 6 cells/mL.
  • the composition comprising cells is made by a method comprising: (a) centrifuging a plurality of placental stem cells, to collect the cells; (b) resuspending the cells in 5.5% dextran-40; (c) centrifuging the cells to collect the cells; (d) resuspending the cells in a 5.5% dextran-40 solution that comprises 10% HSA; (e) filtering the cells through a 70 ⁇ filter; (f) diluting the cells in 5.5% dextran-40, 10% HSA, and 5% DMSO to about 1 to 50 x 10 6 , 1 to 40 x 10 6 , 1 to 30 x 10 6 , 1 to 20 x 10 6 , 1 to 15 x 10 6 , or 1 to 10 x 10 6 cells per milliliter; (g) cryopreservmg the cells; (h) thawing the cells; and (i) diluting the cells 1 : 1 to 1 : 11 (v/v) with 10% dex
  • said diluting in step (f) is to no more than about 15 x 10 6 cells per milliliter. In certain embodiments, said diluting in step (f) is to no more than about 10 ⁇ 3 x 10 6 cells/mL. In certain embodiments, said diluting in step (f) is to no more than about 7.5 x 10 6 cells/mL. In other certain embodiments, if the number of cells is less than about 10 ⁇ 3 x 10 6 cells per milliliter, filtration is optional.
  • compositions e.g., pharmaceutical compositions comprising the isolated placental cells, described herein can comprise any of the isolated placental stem cells described herein.
  • injectable formulations suitable for the administration of cellular products, may be used.
  • the placental stem cells can be encapsulated in, e.g., alginate, either before or after cryopreservation.
  • the placental stem cells can be combined with platelet-rich plasma, e.g., for local injection or local administration applications.
  • the platelet rich plasma is autologous platelet rich plasma, e.g., autologous to the individual to whom the placental stem cells are administered.
  • the platelet-rich plasma is allogeneic to the individual to whom the placental stem cells are administered.
  • said platelet rich plasma is derived from placental perfusate.
  • the volume to volume ratio of placental stem cells to platelet rich plasma in the composition is between about 10: 1 and 1 : 10; between about 100: 1 and 1 : 100; or is about 1 : 1.
  • the pharmaceutical composition comprises isolated placental stem cells that are substantially, or completely, non-maternal in origin, that is, have the fetal genotype; e.g., at least about 90%, 95%, 98%>, 99% or about 100% are non-maternal in origin.
  • the pharmaceutical composition additionally comprises stem cells that are not obtained from a placenta.
  • Isolated placental stem cells in the compositions e.g., pharmaceutical
  • compositions, provided herein can comprise placental stem cells derived from a single donor, or from multiple donors.
  • the isolated placental cells can be completely HLA-matched to an intended recipient, or partially or completely HLA-mismatched.
  • the placental stem cells can be used to produce conditioned medium, e.g., for the treatment of an individual having schizophrenia, Alzheimer's disease, or Huntington's disease.
  • the conditioned medium comprises medium in which placental stem cells have grown for at least 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14 or more days.
  • the conditioned medium comprises medium in which placental stem cells have grown to at least 30%, 40%, 50%, 60%), 70%), 80%), 90%) confluence, or up to 100% confluence.
  • the conditioned medium comprises medium in which placental stem cells and non-placental, non- umbilical cord stem cells have been cultured.
  • a pharmaceutical composition comprising the conditioned medium described herein. Also provided herein is a method of treating schizophrenia, Alzheimer's disease, or Huntington's disease comprising administering to an individual having schizophrenia, Alzheimer's disease, or Huntington's disease a
  • conditioned medium or conditioned medium in combination with placental stem cells or a placental cell population described herein.
  • treatment methods may be used alone or in combination with a second therapeutic composition described herein.
  • the method can comprise the administration of a second therapeutic composition or second therapy.
  • the second therapeutic composition can be, or can comprise, one or more therapeutics for treatment of schizophrenia, e.g., a typical antipsychotic composition such as chlorpromazine (Thorazine); haloperidol (Haldol); loxapine (Loxapac, Loxitane);
  • a typical antipsychotic composition such as chlorpromazine (Thorazine); haloperidol (Haldol); loxapine (Loxapac, Loxitane);
  • the second therapeutic composition can be, or can comprise, one or more second-generation antipsychotic compositions (also referred to as atypical antipsychotics), e.g., clizapine (Clozaril); Geodon (ziprasidone); risperidone (Risperdal); olanzapine (Zyprexa); quetiapine (Seroquel); ziprasidone (Geodon); aripiprazole (Abilify); or paliperidone (Invega).
  • the second therapeutic can comprise any combination of the above typical or atypical antipsychotic compositions.
  • the second therapeutic composition can be, or can comprise, one or more therapeutics for treatment of Alzheimer's disease.
  • the second therapeutic composition can be, or can comprise, one or more therapeutics for treatment of Alzheimer's disease.
  • the second therapeutic composition can be, or can comprise, one or more therapeutics for treatment of Huntington's disease.
  • Second therapeutics for use in this aspect include any therapeutic known in the art that may be used in the treatment of these diseases, for example, one or more of antipsychotic agents, such as, e.g., haloperidol, chlorpromazine, clozapine, quetapine, and olanzapine; antidepressant agents, such as, e.g., fluoxetine, sertraline hydrochloride, venlafaxine and nortriptyline; tranquilizing agents, such as, e.g., benzodiazepines, clonazepam, paroxetine, venlafaxin, and beta-blockers; mood-stabilizing agents such as, e.g., lithium, valproate, lamotrigine, and carbamazepine; paralytic agents, such as, e.g., Botulinum toxin; other agents, such as, e.g.,
  • the second therapeutic compositions comprise, but are not limited to, antiinflammatory compounds such as non-steroidal antiinflammatory drugs (NSAIDs), cox-2 inhibitors, immunomodulatory agents, immunosuppressive agents, and pharmaceutically acceptable salts, solvates, hydrates, stereoisomers, clathrates, prodrugs and pharmacologically active metabolites thereof.
  • NSAIDs non-steroidal antiinflammatory drugs
  • cox-2 inhibitors such as cox-2 inhibitors, immunomodulatory agents, immunosuppressive agents, and pharmaceutically acceptable salts, solvates, hydrates, stereoisomers, clathrates, prodrugs and pharmacologically active metabolites thereof.
  • the antiinflammatory compounds comprise, or are, salicylic acid acetate (e.g., aspirin), ibuprofen (e.g., MOTRIN®, ADVIL®, or the like), ketoprofen (e.g., ORUVAIL®), rofecoxib (e.g., VIOXX®), naproxen sodium (e.g., ANAPROX®, NAPRELAN®, NAPROSYN®, or the like), ketorolac (e.g., ACULAR®), or other known conventional medications.
  • a specific cox-2 inhibitor is celecoxib (e.g., CELEBREX).
  • said second therapy comprises an
  • immunomodulatory compound wherein the immunomodulatory compound is 3-(4-amino-l-oxo- l ,3-dihydroisoindol-2-yl)-piperidine-2,6-dione; 3-(4'aminoisolindoline- -one)-l-piperidine-2,6- dione; 4-(Amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-l ,3-dione; or a-(3-aminophthalimido) glutarimide.
  • said immunomodulatory compound is a compound having the structure
  • said immunomodulatory compound is a compound having the structure
  • R 1 is H, (Ci-Cs )alkyl, (C 3 -C 7 )cycloalkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl, benzyl, aryl, (Co-C 4 )alkyl-(Ci-C 6 )heterocycloalkyl, (C 0 -C 4 )alkyl-(C 2 -C 5 )heteroaryl, C(0)R 3 , C(S)R 3 , C(0)OR 4 , (Ci-C 8 )alkyl-N(R 6 ) 2 , (C C 8 )alkyl-OR 5 , (C C 8 )alkyl-C(0)OR 5 , C(0)NHR 3 , C(S)NHR 3 , C(0)NR 3 R 3' , C(S)NR 3 R 3' or (Ci-C 8 )alkyl-0(CO)R 5 ;
  • R 2 is H, F, benzyl, (Ci-C 8 )alkyl, (C 2 -C 8 )alkenyl, or (C 2 -C 8 )alkynyl;
  • R 3 and R 3' are independently (Ci-C 8 )alkyl, (C 3 -C 7 )cycloalkyl, (C 2 -C 8 )alkenyl, (C 2 - C 8 )alkynyl, benzyl, aryl, (Co-C 4 )alkyl-(Ci-C6)heterocycloalkyl, (Co-C 4 )alkyl-(C 2 -C5)heteroaryl, (C 0 -C 8 )alkyl-N(R 6 ) 2 , (C C 8 )alkyl-OR 5 , (C C 8 )alkyl-C(0)OR 5 , (Ci-C 8 )alkyl-0(CO)R 5 , or C(0)OR 5 ;
  • R 4 is (Ci-C 8 )alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl, (Ci-C 4 )alkyl-OR 5 , benzyl, aryl, (C 0 - C 4 )alkyl-(Ci-C6)heterocycloalkyl, or (Co-C 4 )alkyl-(C 2 -C5)heteroaryl;
  • R 5 is (Ci-C 8 )alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl, benzyl, aryl, or (C 2 -C 5 )heteroaryl; each occurrence of R 6 is independently H, (Ci-C 8 )alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl, benzyl, aryl, (C 2 -Cs)heteroaryl, or (Co-C 8 )alkyl-C(0)0-R 5 or the R 6 groups can join to form a heterocycloalkyl group;
  • n 0 or 1 ;
  • said immunomodulatory compound is a compound having the structure
  • R is H or CH 2 OCOR'
  • each of R 1 , R 2 , R 3 , or R 4 independently of the others, is halo, alkyl of 1 to 4 carbon atoms, or alkoxy of 1 to 4 carbon atoms or (ii) one of R 1 , R 2 , R 3 , or R 4 is nitro or -NHR 5 and the remaining of R 1 , R 2 , R 3 , or R 4 are hydrogen;
  • R 5 is hydrogen or alkyl of 1 to 8 carbons
  • R 6 hydrogen, alkyl of 1 to 8 carbon atoms, benzo, chloro, or fluoro;
  • R' is R 7 -CHR 10 -N(R 8 R 9 );
  • R 7 is m-phenylene or p-phenylene or -(C n H 2n )- in which n has a value of 0 to 4;
  • each of R 8 and R 9 taken independently of the other is hydrogen or alkyl of 1 to 8 carbon atoms, or R 8 and R 9 taken together are tetramethylene, pentamethylene, hexamethylene, or -CH 2 CH 2 X 1 CH 2 CH 2 - in which Xi is -0-, -S-, or -NH-;
  • R 10 is hydrogen, alkyl of to 8 carbon atoms, or phenyl
  • the second therapeutic compound is lenalidomide or pomalidomide.
  • Any combination of the above therapeutic agents can be administered. Such therapeutic agents can be administered in any combination with the placental stem cells, at the same time or as a separate course of treatment.
  • Placental stem cells can be administered to the individual in the form of a pharmaceutical composition, e.g., a pharmaceutical composition suitable for intravenous, intrathecal, intramuscular or intraperitoneal injection.
  • Placental stem cells can be administered to the individual in a single dose, or in multiple doses. Where placental stem cells are administered in multiple doses, the doses can be part of a therapeutic regimen designed to relieve one or more symptoms of schizophrenia, Alzheimer's disease, or Huntington's disease.
  • placental stem cells and second therapeutic agent and/or second type of stem cell can be administered at the same time or different times, e.g., the administrations can take place within 1, 2, 3, 4, 5, 6, 7, 8, 9 10, 20, 30, 40, or 50 minutes of each other, or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, or 22 hours of each other, or within 1, 2, 3, 4, 5, 6, 7 8, 9 or 10 days or more of each other.
  • Patient 1 presents with self-described auditory and tactile hallucinations, and appears to have no or very reduced emotional response to questions (flat affect).
  • Patient 1 has lost his job within the last three weeks due to his mental problems, which according to him began approximately three months earlier.
  • Patient 1 reports no family history of schizophrenia.
  • After voluntarily checking into a mental health facility Patient 1 is observed for one week, during which time his self-reported symptoms are confirmed.
  • DSM-IV Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition
  • Patient 1 is administered 2.5 x 10 9 CD34 , CD10 + , CD105 + , CD200 + placental stem cells by intravenous infusion, and is observed for an additional two weeks. Patient 1 reports a reduction in the number and intensity of the hallucinations, and appears to have increased affect.
  • Patient 2 a 45-year old 75 kg male, presents with self-described auditory and tactile hallucinations, and appears to have no or very reduced emotional response to questions (flat affect).
  • Patient 2 has lost his job within the last three weeks due to his mental problems, which according to him began approximately three months earlier.
  • Patient 2 reports a second cousin who was diagnosed in the last two years with schizophrenia. After voluntarily checking into a mental health facility, Patient 2 is observed for one week, during which time his self- reported symptoms are confirmed.
  • DSM-IV Disorders, Fourth Edition
  • Patient 2 is diagnosed with schizophreniform disorder.
  • Patient 2 is administered 2.5 x 10 9 CD34 , CD10 + , CD105 + , CD200 + placental stem cells by intravenous infusion, and is observed for an additional two weeks.
  • Patient 2 reports a reduction in the number and intensity of the hallucinations, and appears to have increased affect.
  • [00281] Within two months after initial treatment, Patient 2 reports a recurrence of the auditory and tactile hallucinations, and again appears to have a reduced emotional response.
  • Patient 2 is administered a second dose of 2.5 x 10 9 CD34 , CD10 + , CD105 + , CD200 + placental stem cells, and is monitored for an additional two weeks, during which time Patient 2 reports a reduction in the number and intensity of the hallucinations, and appears, again, to have increased affect.
  • Patient 3 a 37 year old 80 kg male, presents with disordered speech, auditory hallucinations that, according to Patient 3, comment on his actions (including his initial conversation with an attending psychiatrist, and recurring delusions that family members are planning to attack him. According to family members, his symptoms first began to manifest seven months earlier, and have rapidly progressed within the last month.
  • Patient 3 is additionally characterized by family members as having lost interest in personal hygiene during that period, particularly within the last month. Family members report no known occurrence of
  • schizophrenia in the extended family After voluntarily checking into a mental health facility, Patient 3 is observed for one week, during which time his self-reported and family-reported symptoms are confirmed. Per the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), Patient 3 is diagnosed with schizophrenia. Patient 3 is determined to be mentally unable to consent to therapy; as such, consent for therapy is provided by Patient 3's spouse.
  • Patient 3 is administered 2.5 x 10 9
  • Patient 3 is determined by a psychiatrist to have significantly more ordered speech than when first admitted, and a reduction in the number and intensity of the auditory hallucinations.
  • Patient 4 a 37 year old 80 kg male, presents with disordered speech, auditory hallucinations that, according to Patient 4, comment on his actions (including his initial conversation with an attending psychiatrist, and recurring delusions that family members are planning to attack him. According to family members, his symptoms first began to manifest seven months earlier, and have rapidly progressed within the last month.
  • Patient 4 is additionally characterized by family members as having lost interest in personal hygiene during that period, particularly within the last month. Family members report no known occurrence of
  • schizophrenia in the extended family After voluntarily checking into a mental health facility, Patient 4 is observed for one week, during which time his self-reported and family-reported symptoms are confirmed. Per the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), Patient 4 is diagnosed with schizophrenia. Patient 4 is determined to be mentally unable to consent to therapy; as such, consent for therapy is provided by Patient 4's spouse.
  • Patient 4 is placed on risperidone (RISPERDAL®) at an initial dose of 2 mg/day, which is increased over four days to 4 mg/day.
  • RISPERDAL® risperidone
  • Patient 4 is administered 2.5 x 10 9 CD34 , CD10 + , CD105 + , CD200 + placental stem cells by intravenous infusion, and is observed for an additional two weeks.
  • Patient 4 is determined by a psychiatrist to have significantly more ordered speech than when first admitted, and a reduction in the number and intensity of the auditory hallucinations.
  • Patient 5 a 25 year old 80 kg male, presents with disordered speech, including pressured speech, auditory hallucinations, and delusions that he has been designated as a messianic figure. According to family members, his symptoms first began to manifest a year earlier, five months after which Patient 5 was involuntarily committed by his family. Patient 5 is additionally characterized by family members as having lost interest in personal hygiene during the period prior to commitment. Family members report no known occurrence of schizophrenia in the extended family. Patient 5 was diagnosed upon commitment with schizophrenia per the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV).
  • DSM-IV Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition
  • Patient 5 is administered 2.5 x 10 9 CD34 , CD10 + , CD105 + , CD200 + placental stem cells by intravenous infusion, and is observed for two weeks thereafter. At the end of the two weeks, Patient 5 is determined by a psychiatrist to have significantly more ordered speech than when first admitted, and a reduction in the number and intensity of the auditory hallucinations. Patient 5 is readministered placental stem cells at the same dosage during the commitment period at intervals of 3-5 weeks, or as needed based upon relapse (noticeable worsening of one or more symptoms).
  • Patient 6 a 25 year old 80 kg male, presents with disordered speech, including pressured speech, auditory hallucinations, and delusions that he has been designated as a messianic figure. According to family members, his symptoms first began to manifest a year earlier, five months after which Patient 6 was involuntarily committed by his family. Patient 6 is additionally characterized by family members as having lost interest in personal hygiene during the period prior to commitment. Family members report no known occurrence of schizophrenia in the extended family. Patient 6 was diagnosed upon commitment with schizophrenia per the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV).
  • DSM-IV Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition
  • Placenta donors were recruited from expectant mothers that enrolled in private umbilical cord blood banking programs and provided informed consent permitting the use of the exsanguinated placenta following recovery of cord blood for research purposes. These donors permitted use of blinded data generated from the normal processing of their umbilical cord blood specimens for cryopreservation. This allowed comparison between the composition of the collected cord blood and the effluent perfusate recovered using this experimental method described below.
  • placenta Following exsanguination of the umbilical cord and placenta, the placenta was placed in a sterile, insulated container at room temperature and delivered to the laboratory within 4 hours of birth. Placentas were discarded if, on inspection, they had evidence of physical damage such as fragmentation of the organ or avulsion of umbilical vessels. Placentas were maintained at room temperature (23+/-2°C) or refrigerated (4°C) in sterile containers for 2 to 20 hours. Periodically, the placentas were immersed and washed in sterile saline at 25+/-3°C to remove any visible surface blood or debris.
  • the umbilical cord was transected approximately 5 cm from its insertion into the placenta and the umbilical vessels were cannulated with Teflon or polypropylene catheters connected to a sterile fluid path allowing bidirectional perfusion of the placenta and recovery of the effluent fluid.
  • the system employed herein enabled all aspects of conditioning, perfusion and effluent collection to be performed under controlled ambient atmospheric conditions as well as real-time monitoring of intravascular pressure and flow rates, core and perfusate temperatures and recovered effluent volumes.
  • a range of conditioning protocols was evaluated over a 24 hour postpartum period and the cellular composition of the effluent fluid was analyzed by flow cytometry, light microscopy and colony forming unit assays.
  • Placental conditioning A placenta was maintained under varying conditions in an attempt to simulate and sustain a physiologically compatible environment for the proliferation and recruitment of placental stem cells.
  • a cannula was flushed with IMDM serum- free medium (GibcoBRL, NY) containing 2U/ml heparin (EJkins-Sinn, N. J.).
  • Perfusion of the placenta was performed at a rate of 50 mL per minute until approximately 150 mL of perfusate was collected. This volume of perfusate was labeled the "early fraction”.
  • the placenta was perfused at the same rate to collect a second fraction of approximately 150 mL, which was labeled the "late fraction”.
  • Placenta was gently massaged to aid in the perfusion process and assist in the recovery of cellular material. Effluent fluid was collected from the perfusion circuit by both gravity drainage and aspiration through the arterial cannula.
  • Placentas were obtained from delivery rooms along with cord blood after obtaining written parental consent, and were processed at room temperature within 12 to 24 hours after delivery. Before processing, the membranes were removed and the maternal site washed clean of residual blood. The umbilical vessels were cannulated with catheters made from 20 gauge Butterfly needles use for blood sample collection.
  • Placentas were then perfused with heparinized (2U/mL) Dulbecco's modified Eagle Medium (HDMEM) at the rate of 15 mL/minute for 10 minutes and the perfusates were collected from the maternal sites within one hour and the nucleated cells counted. The perfusion and collection procedures were repeated once or twice until the number of recovered nucleated cells fell below ⁇ / ⁇ . The perfusates were pooled and subjected to light centrifugation to remove platelets, debris and de-nucleated cell membranes. The nucleated cells were then isolated by Ficoll-Hypaque density gradient centrifugation and after washing, resuspended in HDMEM.
  • HDMEM Dulbecco's modified Eagle Medium
  • MSCGM Mesenchymal Stem Cell Growth Medium
  • Cell Recovery and Isolation Cells were recovered from the perfusates by centrifugation at about 200 x g for 15 minutes at room temperature. This procedure served to separate cells from contaminating debris and platelets. The cell pellets were resuspended in IMDM serum-free medium containing 2U/ml heparin and 2 mM EDTA (GibcoBRL, NY). The total mononuclear cell fraction was isolated using Lymphoprep (Nycomed Pharma, Oslo, Norway) according to the manufacturer's recommended procedure and the mononuclear cell fraction was resuspended. Cells were counted using a hemocytometer. Viability was evaluated by trypan blue exclusion.
  • Isolation of mesenchymal cells was achieved by differential trypsinization using a solution of 0.05% trypsin with 0.2% EDTA (Sigma). Differential trypsinization was possible because fibroblastoid cells detached from plastic surfaces within about five minutes whereas the other adherent populations required more than 20-30 minutes incubation. The detached fibroblastoid cells were harvested following trypsinization and trypsin neutralization using Trypsin Neutralyzing Solution (TNS, BioWhittaker). The cells were washed in HDMEM and resuspended in MSCGM.
  • Flow cytometry of the cells was carried out using a Becton-Dickinson FACSCalibur instrument using FITC and PE labeled monoclonal antibodies selected on the basis of known markers for bone marrow-derived MSC (mesenchymal stem cells). Antibodies were purchased from B.D. and Caltag laboratories (South San Francisco, Calif), and SH2, SH3 and SH4 antibody producing hybridomas were obtained from ATCC and reactivities of the antibodies in their cultured supematants were detected by FITC or PE labeled F(ab)' 2 goat anti-mouse antibodies. Lineage differentiation was carried out using the
  • fibroblastoid cells appearing last as clusters and appearing by visual inspection to be similar to bone marrow- derived mesenchymal stem cells, were isolated by differential trypsinization and subcultured in secondary flasks. Phase microscopy of the cells, which appeared rounded after trypsinization, showed them to be highly granulated, and similar to bone marrow-derived MSC produced in the laboratory or purchased from BioWhittaker.
  • OCT-4 the gene expression phenotype, of these adherent cells, obtained from different perfusion experiments, was characterized. The results of these experiments are shown in the following table: Characterization of placental stem cells collected from separate perfusion experiments.
  • Placental stem cells are obtained from a post-partum mammalian placenta either by perfusion or by physical disruption, e.g., enzymatic digestion.
  • the cells are cultured in a culture medium comprising 60% DMEM-LG (Gibco), 40% MCDB-201 (Sigma), 2% fetal calf serum (FCS) (Hyclone Laboratories), lx insulin-transferrin-selenium (ITS), lx linoleic-acid- bovine-serum-albumin (LA-BSA), 10 "9 M dexamethasone (Sigma), 10 "4 M ascorbic acid 2- phosphate (Sigma), epidermal growth factor (EGF)10ng/ml (R&D Systems), platelet derived- growth factor (PDGF-BB) lOng/ml (R&D Systems), and 100U penicillin/ 1000U streptomycin.
  • DMEM-LG Gibco
  • MCDB-201 Sigma
  • the culture flask in which the cells are cultured is prepared as follows. T75 flasks are coated with fibronectin (FN), by adding 5 ml PBS containing 5ng/ml human FN (Sigma F0895) to the flask. The flasks with FN solution are left at 37°C for 30 min. The FN solution is then removed prior to cell culture. There is no need to dry the flasks following treatment.
  • FN fibronectin
  • the flasks are left in contact with the FN solution at 4°C overnight or longer; prior to culture, the flasks are warmed and the FN solution is removed. 6.2.2.1 Placental Stem Cells Isolated By Perfusion
  • Cultures of placental stem cells from placental perfusate are established as follows. Cells from a Ficoll gradient are seeded in FN-coated T75 flasks, prepared as above, at 50-100xl0 6 cells/flask in 15 ml culture medium. Typically, 5 to 10 flasks are seeded. The flasks are incubated at 37°C for 12-18 hrs to allow the attachment of adherent cells. 10 ml of warm PBS is added to each flask to remove cells in suspension, and mixed gently. 15 mL of the medium is then removed and replaced with 15 ml fresh culture medium. All medium is changed 3-4 days after the start of culture. Subsequent culture medium changes are performed, during which 50% or 7.5 ml of the medium is removed.
  • the culture is checked under a microscope to examine the growth of the adherent cell colonies.
  • adherent cells are harvested by trypsin digestion. Cells harvested from these primary cultures are designated passage 0 (zero).
  • Placental stem cell cultures are established from digested placental tissue as follows. The perfused placenta is placed on a sterile paper sheet with the maternal side up. Approximately 0.5 cm of the surface layer on maternal side of placenta is scraped off with a blade, and the blade is used to remove a placental tissue block measuring approximately 1 x 2 x 1 cm. This placenta tissue is then minced into approximately 1mm 3 pieces. These pieces are collected into a 50ml Falcon tube and digested with collagenase IA (2mg/ml, Sigma) for 30 minutes, followed by trypsin-EDTA (0.25%, GIBCO BRL) for 10 minutes, at 37°C in water bath.
  • collagenase IA (2mg/ml, Sigma) for 30 minutes
  • trypsin-EDTA 0.25%, GIBCO BRL
  • the resulting solution is centrifuged at 400g for 10 minutes at room temperature, and the digestion solution is removed.
  • the pellet is resuspended to approximately 10 volumes with PBS (for example, a 5 ml pellet is resuspended with 45 ml PBS), and the tubes are centrifuged at 400g for 10 minutes at room temperature.
  • the tissue/cell pellet is resuspended in 130 mL culture medium, and the cells are seeded at 13ml per fibronectin-coated T-75 flask. Cells are incubated at 37°C with a humidified atmosphere with 5% C0 2 . Placental Stem Cells are optionally cryopreserved at this stage.
  • Cryopreserved cells can be quickly thawed in a 37°C water bath. Placental stem cells are immediately removed from the cryovial with 10ml warm medium and transferred to a 15ml sterile tube. The cells are centrifuged at 400g for 10 minutes at room temperature. The cells are gently resuspended in 10ml of warm culture medium by pipetting, and viable cell counts are determined by Trypan blue exclusion. Cells are then seeded at about 6000-7000 cells per cm 2 onto FN-coated flasks, prepared as above (approximately 5xl0 5 cells per T-75 flask).
  • the cells are incubated at 37°C, 5% C0 2 and 90% humidity. When the cells reached 75-85% confluency, all of the spent media is aseptically removed from the flasks and discarded. 3ml of 0.25% trypsin/EDTA (w/v) solution is added to cover the cell layer, and the cells are incubated at 37°C, 5% C0 2 and 90%> humidity for 5 minutes. The flask is tapped once or twice to expedite cell detachment. Once >95%> of the cells are rounded and detached, 7ml of warm culture medium is added to each T-75 flask, and the solution is dispersed by pipetting over the cell layer surface several times.
  • the cells After counting the cells and determining viability as above, the cells are centrifuged at 1000 RPM for 5 minutes at room temperature. Cells are passaged by gently resuspending the cell pellet from one T-75 flask with culture medium, and evenly plating the cells onto two FN-coated T-75 flasks.
  • populations of adherent placental stem cells are produced that express markers CD105, CD33, CD73, CD29, CD44, CD10, CD90 and CD133. This population of cells did not express CD34 or CD45. Some, but not all cultures of these placental stem cells express HLA-ABC and/or HLA-DR. See, e.g., U.S. Patent No. 8,202,703 (especially Examples 2 and 3, at columns 54-60), which is incorporated herein by reference in its entirety.
  • This Example demonstrates an exemplary cellular marker profile of placental stem cells.
  • Placental stem cells or umbilical cord stem cells were obtained by enzymatic digestion as described above. Cells in culture medium were washed once by adding 2 mL 2% FBS-PBS and centrifuging at 400g for 5 minutes. The supernatant was decanted, and the pellet was resuspended in 100-200 2% FBS-PBS. 4 tubes were prepared with BDTM CompBeads (Cat# 552843) by adding 100 ⁇ of 2% FBS-PBS to each tube, adding 1 full drop (approximately 60 ⁇ ) of the BDTM CompBeads Negative Control and 1 drop of the BDTM CompBeads Anti- Mouse beads to each tube, and vortexing. To the 4 tubes of BDTM CompBeads, the following antibodies were added:
  • control and sample tubes were incubated in the dark at room temperature for
  • Matched placental stem cells from amniotic membrane and umbilical cord stem cells were analyzed using fluorescently-labeled antibodies and flow cytometry to identify cell surface markers that were present or absent. Markers analyzed included CD 105 (proliferation related endothelial specific marker); CD200 (marker associated with regulatory function); CD34 (expressed on endothelial cells and on hematopoietic stem cells); CD 10 (stem cell/precursor cell marker); cytokeratin K (epithelial marker); CD44 (cell migration, lymphocyte homing, hematopoeisis); CD45 (lineage marker); CD 133 (marker for hematopoietic progenitor cells); CD117 (stem cell factor (c-Kit)); CD90 (expressed on primitive hematopoietic stem cells in normal bone marrow, cord blood and fetal liver cells); HLA ABC (pan MHC I, antigen presentation, immunogenicity); ⁇ -2 -microglobulin (a)
  • the phenotype CD200 + , CD105 + , CD10 + , CD34 appeared to be consistent over numerous such analyses. This phenotype is additionally positive for CD90, CD44, HLA ABC, ⁇ -2 -microglobulin, and cytokeratin K, and negative for HLA DR,DQ,DP, CD117, CD133, and CD45.
  • BM bone marrow-derived mesenchymal stem cells
  • DF dermal fibroblasts
  • a set of genes was identified that are up-regulated in AC and UC, and either down-regulated or absent in BM and DF, and that are expressed independent of passage number.
  • This set of placental stem cell- or umbilical cord stem cell-specific genes encodes a number of cytoskeleton and cell-to-cell adhesion proteins associated with epithelial cells and an
  • CD200 immunoglobulin-like surface protein, implicated in maternal-fetal immune tolerance. Placental stem cells and umbilical cord stem cells are referred to collectively hereinafter in this Example as AC/UC stem cells.
  • BM (Cat# PT-2501) and DF (Cat# CC-2511) were purchased from Cambrex.
  • AC and UC originated from passage 0 tissue culture flasks. AC and UC in the flasks were obtained by digestion from a donor placenta designated 2063919. T-75 culture flasks were seeded at 6000 cells/cm 2 and cells were passaged when they became confluent. Population doublings were estimated from trypan blue cell counts. Cultures were assayed for gene expression after 3, 11- 14, and 24-38 population doublings.
  • RNA integrity and concentrations were determined with an Agilent 2100
  • RNA samples Ten micrograms of total RNA from each culture were hybridized on an Affymetrix GENECHIP ® platform. Total RNA was converted to labeled cRNAs and hybridized to oligonucleotide Human Genome U133A 2.0 arrays according to the manufacture's methods. Image files were processed with the Affymetrix MAS 5.0 software, and normalized and analyzed with Agilent GeneSpring 7.3 software. 6.2.4.3 Selection of BM-MSC, AC/UC Stem Cell and DF Culture Time- Points for Microarray Analyses
  • the purchased BM and DF cells were expanded many times prior to gene analysis, and cannot be considered early-stage.
  • BM grown for three doublings (BM-03) are deemed a short-term culture.
  • BM-11 is operationally referred to as an intermediate length culture, but because senescence occurred at 14 doublings, BM-11 is most likely a long-term culture biologically.
  • Microarray analysis identifies patterns of gene expression, and hierarchical clustering (HC) attempts to find similarities in the context of two dimensions - genes in the first dimension and different conditions (different RNA samples) in the second.
  • the GeneChips used in this experiment contained over 22,000 probe sets (referred to as the "all genes list"), but many of these sets interrogate genes that are not expressed in any condition.
  • genes not expressed or expressed at low levels (raw values below 250) in all samples were eliminated to yield a list of 8,215 genes.
  • Gene expression patterns of the 8,215 genes were displayed using the line graph view in GeneSpring (data not shown).
  • the x-axis shows the twelve experimental conditions and the y-axis shows the normalized probe set expression values on a log scale.
  • the y-axis covers a 10,000-fold range, and genes that are not expressed or expressed at very low levels are set to a value of 0.01. By default the normalized value is set to 1.
  • Each line represents a single gene and runs across all twelve conditions as a single color. Colors depict relative expression levels, as described for the heatmaps, but the coloring pattern is determined by selecting one condition.
  • Genes up-regulated relative to the normalized value are displayed by the software as red, and those that are down-regulated, are displayed as blue.
  • BM and DF are considered AC/UC stem cell-specific.
  • Two filtering methods were combined to create a list of 58 AC/UC stem cell-specific genes, as shown in the following table of 58 placental stem cell or umbilical cord stem cell-specific genes:
  • GATA6 GATA binding protein 6 transcription factor muscle development
  • ICAM1 intercellular adhesion molecule cell-cell adhesion, cell adhesion,
  • IGFBP7 insulin-like growth factor negative regulation of cell proliferation, binding protein 7 overexpressed in senescent epithelial cells
  • ILIA interleukin 1 interleukin 1 , alpha immune response, signal transduction, cytokine activity, cell proliferation, differentiation, apoptosis
  • IL1B interleukin 1, beta immune response, signal transduction, cytokine activity, cell proliferation, differentiation, apoptosis
  • interleukin 6 interferon, beta 2 cell surface receptor linked signal
  • NFE2L3 nuclear factor erythroid- transcription co-factor, highly expressed in derived 2)-like 3 primary placental cytotrophoblasts but not in placental fibroblasts
  • NUAK1 NUAK family SNFl-like protein amino acid phosphorylation
  • PCDH7 BH-protocadherin (brain-heart) cell-cell adhesion and recognition
  • desmosomes found in epithelia, binds cadherins and intermediate filament
  • RTN1 reticulon 1 signal transduction ; neuron differentiation, neuroendocrine secretion, membrane trafficking in neuroendocrine cells
  • ST3GAL6 sialyltransferase 10 amino sugar metabolism, protein amino acid glycosylation, glycolipid metabolism, protein-lipoylation
  • VTN vitronectin serum spreading immune response, cell adhesion, secreted factor, somatomedin B, protein, binds ECM
  • ZC3H12A zinc finger CCCM-type MCP-I treatment-induced protein, nucleic containing 12A acid binding, hypothetical zinc finger
  • the experimental design compared cells cultured for short, medium, and long periods of time in culture.
  • each culture period has a characteristic set of differentially expressed genes.
  • AC-03 and UC-03 two hundred up-regulated genes regress to the mean after eight population doublings.
  • this early stage gene expression pattern resembles the expression profile of AC and UC while in the natural placental environment. In the placenta these cells are not actively dividing, they are metabolizing nutrients, signaling between themselves, and securing their location by remodeling the extracellular surroundings.
  • BM-03 appears biologically to be a mid-term culture. In this middle stage cell type-specific gene expression is overshadowed by cellular proliferation. In addition, almost every gene over expressed in the short-term AC or UC cultures is down-regulated in the middle and later stage conditions. 143 genes were up-regulated > five-fold during this highly proliferative phase, constituting approximately 1.7% of the expressed genes.
  • the long-term cultures represent the final or senescent phase.
  • cells have exhausted their ability to divide, and, especially for AC and UC, the absolute number of differentially expressed genes is noticeably reduced. This may be the result of cells being fully adapted to their culture environment and a consequently reduced burden to biosynthesize.
  • This subset of genes of 46 genes constitutes a set of molecular biomarkers that distinguishes AC/UC stem cells from bone marrow-derived mesenchymal stem cells or fibroblasts.
  • Adherent placental stem cells were differentiated into several different cell lineages. Adherent placental stem cells were isolated from the placenta by physical disruption of placental tissue, and umbilical cord stem cells were obtained by physical disruption of umbilical cord tissue.
  • Placental stem cells and umbilical cord stem cells were established in a medium containing low concentrations of fetal calf serum and limited growth factors. Flow cytometry analysis showed that placental stem cells typically exhibited a CD200 + CD105 + CD73 + CD34 CD45 phenotype at percentages of >70%. Placental stem cells were found to differentiate down the adipocyte, chondrocyte and osteocyte lineages.
  • placental stem cells In an induction medium containing IBMX, insulin, dexamethasone and indomethacin, placental stem cells turned into fat laden adipocytes in 3 to 5 weeks. Under osteogenic induction culture conditions, placental stem cells were found to form bone nodules and have calcium depositions in their extracellular matrix. Chondrogenic differentiation of placental stem cells was performed in micropellets and was confirmed by formation of glycosaminoglycan in the tissue aggregates. 6.4 EXAMPLE 4: IMMUNOMODULATION USING PLACENTAL STEM CELLS
  • Placental stem cells possess an immunomodulatory effect, including suppression of the proliferation of T cells and natural killer cells.
  • the following experiments demonstrate that placental stem cells have the ability to modulate the response of T cells to stimulation in two assays, the mixed lymphocyte reaction assay and the regression assay.
  • the MLR measures the reaction of an effector population against a target population.
  • the effectors can be lymphocytes or purified subpopulations, such as CD8 + T cells or NK cells.
  • the target population is either allogeneic irradiated PBMCs, or as in the present studies, mature DCs.
  • the responder population consists of allo-specific cells, estimated at 20% of total T cells.
  • the modified placental stem cell MLR uses placental stem cells in the reaction.
  • Placental stem cells were plated in 96 well plate wells, and the effector population was added. Placental stem cells and 5(6)-carboxyfluorescein diacetate N-succinimidyl ester (CFSE) stained effectors were preincubated for 24 hours before targets, mature DCs, were added. After six days, supematants and non-adherent cells were harvested. Supematants were analyzed by Luminex bead analysis, and the cells were analyzed by flow cytometry.
  • CFSE 5(6)-carboxyfluorescein diacetate N-succinimidyl ester
  • CD4 + T cell compartment This response is a na ' ive T cell response, as two allogeneic donors have never encountered each other before. Both CD4 + T cells and CD8 + T cells proliferated vigorously in the standard MLR. When placental stem cells were added to the MLR , the CD4 and CD8 T cell proliferation, as measured by the percentage of CFSE Low responder cells, was dampened.
  • Placental stem cells when added to an MLR, clearly suppressed T cell proliferation. Suppresion of T cell proliferation was similar whether only CD4 + or CD8 + T cells were used individually, or whether equal amounts of CD4 + T cells and CD8 + T cells were used together. Placental stem cells obtained from the amnion-chorion or umbilical cord stroma suppressed the MLR to similar extents, and no difference in suppression was seen between CD4 + T cells and CD8 + T cells. This was also true for the bulk T cell reactions.
  • a separate MLR was performed using CD4 + T cells, CD8 + T cells, or both CD4 + and CD8 + T cells, and allogeneic dendritic cells (DC). Placental stem cells were added to the MLR, and the degree of proliferation of the T cells was assessed, using an MLR without placental stem cells as a control.
  • DC allogeneic dendritic cells
  • CD4 + and CD8 + T cells, and CD14 + monocytes were isolated from buffy coats using Miltenyi MACS columns and beads, used according to manufacturer instructions.
  • Dendritic cells were obtained by a six-day culture of monocytes in RPMI 1640 supplemented with 1% donor plasma, IL-4, and GM-CSF, and a two-day culture in RPMI 1640 supplemented with IL- ⁇ , TNF-a, and IL-6. Allogeneic T cells and DC in the ratio T:DC of 10:1 were incubated to produce a classic 6 day MLR. T cell proliferation was assessed by staining T cells with CFSE (Carboxy-fluorescein diacetate, succinimidyl ester) before being added to the assay. CSFE is used to assess the degree of proliferation by measurement of dilution of the stain among daughter cell populations.
  • CFSE Carboxy-fluorescein diacetate, succinimidyl ester
  • PSCs placental stem cells
  • the reaction was set up in a 96-well plate in a final volume of 200 ⁇ RPMI 1640 supplemented with 5% pooled human serum (R5). After six days, non-adherent cells were briefly resuspended and transferred to a 5 mL tube washed with RPMI, and stained with CD4 and CD8 antibody. Proliferation of the CD4 and CD8 compartment was assessed on a BD FACS Calibur.
  • Placental stem cells Placental stem cells were obtained as described in
  • Placental stem cells were obtained from the following placental tissues: amnion (AM), or amnion/chorion (AC). Placental stem cells from umbilical cord were obtained from digestion of umbilical cord (UC). Fibroblasts (FB) and bone marrow-derived mesenchymal stem cells (MSCs) were added as controls.
  • AM amnion
  • AC amnion/chorion
  • UC umbilical cord
  • UC umbilical cord
  • FB Fibroblasts
  • MSCs bone marrow-derived mesenchymal stem cells
  • Placental stem cells also suppressed the activity of Natural Killer (NK) cells in the
  • Placental stem cells were shown in a regression assay to suppress a T cell response to a B cell line expressing Epstein-Barr virus (EBV) antigens.
  • the regression assay is a recall assay that measures effector T cell mechanisms brought about by presentation of EBV antigen peptides on MHC Class I and II of EBV-transformed B cells.
  • the assay is performed by mixing T cells with an artificially created transformed B cell line, the lymphoblastoid cell line (LCL) from the same donor.
  • the LCL expresses nine Epstein-Barr virus antigens that elicit between them a range of adaptive T and B cell responses, although in the classic regression assay, only T cell effector mechanisms are measured.
  • the regression assay offers a convenient way of measuring cytotoxicity to targets infected with a naturally occurring pathogen, in that the LCL expresses the activated B cell marker CD23. Therefore, the cell count of CD23 -expressing cells is a measure of the number of LCL surviving in the assay.
  • T cells and dendritic cells were obtained from laboratory donors.
  • Epstein-Barr virus-transformed B cells lines, LCLs were obtained by incubating peripheral blood mononuclear cells (PBMCs) with supernatant from a lytic EBV line, B95.8, and cyclosporin A for two weeks.
  • PBMCs peripheral blood mononuclear cells
  • the LCL expressed 9 EBV antigens.
  • the outgrowing LCL line is maintained in RPMI 1640 supplemented with 10% fetal calf serum.
  • the regression assay was performed by mixing CD4 + or CD8 + T cells with autologous LCL at a ratio T:LCL of 10: 1.
  • the assay was performed in a 96-well plate in 200 ⁇ RPMI 1640 supplemented with 5% pooled human serum (R5). To this assay, placental stem cells are added in a ratio T:LCL:PSC of 10: 1 :2. The assay was run for 6, 10, or 17 days.
  • a six-day regression assay was performed using CSFE-labeled T cells.
  • Placental stem cells from placenta 65450 suppressed T cell proliferation in the regression assay by about 65% to about 97%, a result that corresponds to the results for these placental stem cells in the MLR.
  • NK cells when the MLR or regression assay was run including 50 U/ml IL-2, the suppressive effect was about 45% (range about 40% to about 65%, SEM 5%).
  • Placental stem cells are not immunogenic. In no instance was more than 5% background T cell proliferation observed against placental stem cells from any donor or any placental anatomical site.
  • a separate assay confirmed that immunosuppression of T cells by placental stem cells appears to at least partially involve a soluble factor.
  • transwell assays were performed in which placental stem cells were placed in an insert at the bottom of which a membrane allowed passage only of soluble factors.
  • the MLR or T cells were the MLR or T cells alone.
  • the stem cells were added at different relative densities to T cells and DCs.
  • placental stem cells When placental stem cells were used at densities as above, the MLR suppression was abrogated 75% for CD4 + T cells, and 85% for CD8 T cells. The suppressive effect was still at 66% when just a quarter dose of placental stem cells were used (UC OP 25), and dropped to background levels when 12,500 UC placental stem cells were added. No change in suppression with separation using an insert was observed. At 25,000 placental stem cells, despite the still vigorous suppressive effect, the smallest relative drop in suppression on introduction of the insert was observed.
  • Kainic acid induces cognitive deficits that are consistent with the etiology of schizophrenia, Alzheimer's disease, and Huntington's disease. See, e.g., Marcotte et al, 2001, Animal models of schizophrenia: A critical review, Journal of Psychiatry and Neuroscience 26:395-410; and Coyle & Schwarcz, 1976, Lesion of striatal neurones with kainic acid provides a model for Huntington's chorea, Nature 263:244-246, each of which is incorporated herein by reference in its entirety.
  • kainic acid is understood to alter the rat brain's anatomy and neurochemistry in a manner similar to what is observed in schizophrenia patients, causing for example brain lesions and disturbances in sensory information processing that are one of the major symptoms of schizophrenia.
  • Stevens et al, 1998 Kainic acid lesions in adult rats as a model of schizophrenia: changes in auditory information processing, Neuroscience 82:701-708; and Howland et al, 2004, Delayed onset of prepulse inhibition deficits following kainic acid treatment on postnatal day 7 in rats, European Journal of Neuroscience 20:2639- 2648, each of which is incorporated herein by reference in its entirety.
  • behavioral models such as the Morris water maze and the elevated plus maze are considered models for central nervous system (CNS) function and dysfunction (such as schizophrenia and Alzheimer's disease) and are used for testing efficacy of CNS drugs, such as anti-psychotic agents. Improvement in the Morris water maze and the elevated plus maze indicate improvement in, respectively, cognition and anxiety.
  • CNS central nervous system
  • KA solution was formulated at 7.5 mg/ml (for IP administration) as follows: 60 mg of KA was added into 8 ml 0.9%> saline, followed by adjustment of the pH to 7.2 using NaHC0 3 .
  • KA injections The day of KA injection was defined as "Day 0." In cycle 1, each rat was injected IP with a KA dose of 15 mg/kg (0.2 ml/lOOg). Animals without Status Epilepticus (SE) symptoms within half an hour following administration were injected again with KA 7.5 mg/kg IP (0.1 ml/lOOg). Animals in Status Epilepticus received Diazepam 3 hours after initiation of status to reduce the convulsions. Animals were divided into 6 treatment groups so that each treatment group contained equal numbers of rats from one of the three following outcomes: A (Rats developing SE after first injection), B (Rats developing SE after second injection), or C (Rats that did not develop SE during 3 hours after second injection).
  • Cognitive follow-up Morris water maze (MWM). On day -1 the rats were acclimated for one minute to swimming in the MWM. Once a week, following KA administration, animals were tested in the MWM, filled with water at RT and connected to an imaging system. The testing was conducted during two consecutive days (on days 7-8, 14-15, 21-22 and 28-29 following KA administration). Each session included four consecutive trials starting at different starting points. The time required to reach the platform was recorded.
  • rats were subjected to an additional one-day of Reversal Learning, which was tested as follows: (i) probe trial without platform, in which the rat is started from the contralateral side to where the platform used to be (this test assesses retention); (ii) the platform is set on the contralateral side to its previous place and the reversal learning test is performed in four trials per rat (here, "working memory” is the main function tested); and (iii) another probe trial is administered at least two hours following the Reversal Learning to test for memory plasticity and retention.
  • RAM testing is conducted following completion of the MWM test.
  • Food restriction approximately 5 g food per 100 g body weight
  • Each rat is weighed daily throughout the training and testing period.
  • the rats are familiarized to experimental food pellets, one day in their cages and two days in the RAM.
  • food rewards are placed at the end of each arm. The rat is placed on the central platform and allowed a chance to collect all eight pellets or to make 16 arm choices, or until 10 minutes have elapsed. The correct and incorrect trials are recorded.
  • Body weight was monitored prior to KA administration, prior to
  • MWM Probe-Test trial On study day 30 the animals were given two probe trials, in which the platform was removed from the pool to measure spatial bias. The maze was divided into 4 quadrants. One quadrant was the quadrant of the old platform location. The other quadrant was the quadrant of the new location of the platform. Together these two quadrants were assigned later the notation "targeted quadrants.” The other two quadrants were assigned later the notation "non-targeted quadrants.”
  • compositions and methods disclosed herein are not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the compositions and methods in addition to those described will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Reproductive Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des méthodes de traitement d'un individu atteint de schizophrénie ou d'un trouble de forme schizophrène, de la maladie d'Alzheimer ou d'une démence du type maladie d'Alzheimer ou de la maladie de Huntington, à l'aide de cellules souches isolées du placenta, comprenant l'administration à l'individu d'une quantité thérapeutiquement efficace de cellules souches du placenta, par exemple des cellules souches placentaires adhérentes à une matière plastique de culture cellulaire (PDAC).
PCT/US2012/067276 2011-11-30 2012-11-30 Traitement à l'aide de cellules souches du placenta WO2013082417A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161565394P 2011-11-30 2011-11-30
US61/565,394 2011-11-30

Publications (1)

Publication Number Publication Date
WO2013082417A1 true WO2013082417A1 (fr) 2013-06-06

Family

ID=48536096

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/067276 WO2013082417A1 (fr) 2011-11-30 2012-11-30 Traitement à l'aide de cellules souches du placenta

Country Status (1)

Country Link
WO (1) WO2013082417A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3140417A4 (fr) * 2014-05-09 2018-05-23 Reelabs Private Limited Polymix foetal de cellules souches mésenchymateuses placé dans des conditions hypoxiques en vue du traitement d'affections cliniques
EP4173631A4 (fr) * 2020-06-30 2024-07-24 Univ Nat Corp Kochi Univ Agent thérapeutique de neuropathie crânienne contenant un surnageant de culture pour des cellules monocytiques du sang de cordon ombilical

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020028510A1 (en) * 2000-03-09 2002-03-07 Paul Sanberg Human cord blood as a source of neural tissue for repair of the brain and spinal cord
WO2008036374A2 (fr) * 2006-09-21 2008-03-27 Medistem Laboratories, Inc. Allogreffes de cellules souches chez des receveurs non conditionnes
US20080206343A1 (en) * 2007-02-12 2008-08-28 Edinger James W Hepatocytes and Chondrocytes from Adherent Placental StemCells; And CD34+ ,CD45- Placental Stem Cell-Enriched Cell Populations
US20110034565A1 (en) * 2008-04-18 2011-02-10 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
WO2011064669A2 (fr) * 2009-11-30 2011-06-03 Pluristem Ltd. Cellules adhérentes du placenta et leur utilisation dans le traitement de pathologies
US20110250182A1 (en) * 2010-04-07 2011-10-13 Anthrogenesis Corporation Angiogenesis using placental stem cells

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020028510A1 (en) * 2000-03-09 2002-03-07 Paul Sanberg Human cord blood as a source of neural tissue for repair of the brain and spinal cord
WO2008036374A2 (fr) * 2006-09-21 2008-03-27 Medistem Laboratories, Inc. Allogreffes de cellules souches chez des receveurs non conditionnes
US20080206343A1 (en) * 2007-02-12 2008-08-28 Edinger James W Hepatocytes and Chondrocytes from Adherent Placental StemCells; And CD34+ ,CD45- Placental Stem Cell-Enriched Cell Populations
US20110034565A1 (en) * 2008-04-18 2011-02-10 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
WO2011064669A2 (fr) * 2009-11-30 2011-06-03 Pluristem Ltd. Cellules adhérentes du placenta et leur utilisation dans le traitement de pathologies
US20110250182A1 (en) * 2010-04-07 2011-10-13 Anthrogenesis Corporation Angiogenesis using placental stem cells

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3140417A4 (fr) * 2014-05-09 2018-05-23 Reelabs Private Limited Polymix foetal de cellules souches mésenchymateuses placé dans des conditions hypoxiques en vue du traitement d'affections cliniques
US11072776B2 (en) 2014-05-09 2021-07-27 Reelabs Private Limited, a Company Incorporated Under Provisions of The Companies Act 1956 Foetal polymix of mesenchymal stem cells under hypoxic conditions for the treatment of clinical disorders and diseases
EP4173631A4 (fr) * 2020-06-30 2024-07-24 Univ Nat Corp Kochi Univ Agent thérapeutique de neuropathie crânienne contenant un surnageant de culture pour des cellules monocytiques du sang de cordon ombilical

Similar Documents

Publication Publication Date Title
US11090339B2 (en) Treatment of pain using placental stem cells
US11723930B2 (en) Treatment of inflammatory diseases using placental stem cells
US9539288B2 (en) Immunomodulation using placental stem cells
EP2368973A1 (fr) Production d'oligodendrocytes a partir de cellules souches derivees du placenta
US9925221B2 (en) Treatment of amyotrophic lateral sclerosis using placental stem cells
WO2013082417A1 (fr) Traitement à l'aide de cellules souches du placenta
AU2014203165B2 (en) Treatment of inflammatory diseases using placental stem cells
AU2020200467A1 (en) Immunomodulation using placental stem cells
AU2018232953A1 (en) Treatment of inflammatory diseases using placental stem cells

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12852974

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12852974

Country of ref document: EP

Kind code of ref document: A1